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Asthma was already recognized in ancient times as a pathological condition and
described by Hippocrates and Mai'monides. The involvement of inflammation in
the pathogenesis of asthma was suggested in 1892 by Osier [1]. In 1922, this hy-
pothesis was confirmed by the demonstration of airway inflammation in lungs of
asthmatic patients [2]. Despite the introduction of powerful anti-inflammatory
drugs in the treatment of asthma, asthma still represents a major cause for respira-
tory health care occupation and economical health care consumption [3,4].
Asthma is still responsible for a great number of deaths, occurring within the
group of patients with chronic pulmonary disease, despite the tremendous in-
crease in knowledge, concerning pathophysiology and treatment of asthma [5].
At the present time, the working definition of asthma discerns three major charac-
teristics in asthma /'.<?. 1:) the presence of variable airway obstruction, 2:) the pres-
ence of bronchial hyperreactivity, and 3:) the presence of bronchial inflammation
[5,6,7]. Variable airflow-obstruction may be recognized by a pattern of one or
more characteristic symptoms, including wheezing, chest tightness, cough and
dyspnea. However, the diagnosis of asthma should be further supported by the ob-
servation of variable or reversible airflow-obstruction [8]. Bronchial hyperrespon-
siveness (BHR), defined as an increased reponsiveness of airways to a variety of
specific and non-specific stimuli [9], is generally present in asthma, but an overlap
with the normal population exists [ 10,11 ]. In general, levels of BHR correlate with
the seriousness of asthmatic disease [12].
With the development of invasive techniques, insight grew that asthma repre-
sented an inflammatory disease. Studies observed that asthma is not solely a
smooth muscle disease, but involves the presence of local injury, followed by in-
flammatory cell influx in bronchial tissue. In asthma, characteristic inflammatory
changes are detectable in the bronchial epithelium and lamina propria, as has been
observed in bronchial biopsies [13,14,15,16]. Characteristical changes include
epithelial shedding, increased thickness of the basement membrane and increased
numbers of activated mast cells [17], eosinophils [18,19,20], lymphocytes
[20,21], macrophages [20,22,23] and epithelial cells [24, 25]. Vignola rt«*/.[26]
observed that, even in patients with intermittent asthma, increased epithelial shed-
ding and thickening of the basement membrane is present. Several studies have
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observed correlations between levels of bronchial inflammation and respectively
bronchial hyperresponsiveness [20,21,24,27,28,29] and asthma severity [18,20].
1.2 Asthma: general concepts regarding pathogenesis
Asthma and atopy are closely related; the presence of atopy increases the risk of de-
veloping asthma during life by a factor 10-20 in comparison to non-atopic indi-
viduals. Human gene linkage studies have identified several genes, that may be as-
sociated with both atopic disease and asthma [30,31,32]. Positive linkages have
been reported for genes, located on chromosome 5, and encoding for cytokines,
which activate mast cells, basophils and eosinophils; recently, it was reported that,
also on chromosome 5, a gene, which governs bronchial hyperresponsiveness is lo-
cated near a gene that regulates IgE levels [33]. On chromosome 6, linkages have
been detected for genes encoding for HLA, which are involved in antigen presen-
tation, and for genes, encoding for TNFa, a proinflammatory cytokine, which is
implicated in the pathogenesis of asthma. Atopic disease is characterized by the
presence of allergen-specific IgE in serum and a set of cytokines, derived from
T(h2)-lymphocytes (11-4,11-10 and IL-13), is pivotal in mediating IgE production
and the development of immediate hypersensitivity [34]. Interestingly, Th2 de-
rived cytokines are also involved in the pathogenesis of asthma (see paragraph
1.3)[35]. The designation of T-lymphocyte subsets as Thl or Th2 is based on ob-
servations in murine T cell clones, which were divided on the basis of expression of
messenger RNA and cytokine release [36]; Thl cells produce IL-2, IFN-y, and
lymphotoxin (TNF P) and are involved in cell-mediated immune responses f.£.
delayed type-hypersensitivity. Th2 cells produce IL-4,-5,-6,-9,-10 and -13, and
are involved in the humoral response to, for instance, parasitic infections [37].
Both Thl and Th2-type lymphocytes produce IL-3, GM-CSF and TNFa [37].
In recent years, it became clear that, besides hereditary traits, environmental fac-
tors are involved in the further development towards asthmatic disease. Already at
birth, peripheral blood T-lymphocytes of babies, born of atopic mothers, respond
to aeroallergens [38]. Further allergen-exposure in early infancy may provide the
stimulus for sensitization of the lower airways [39], directing T-lymphocyte re-
sponse towards a Th2-type response. This is especially critical, since peripheral
blood mononuclear cells in infants, who develop atopic disease, have been shown
to be deficient in the production of IFN-y [40,41], which inhibits the Th2 re-
sponse. In contrast, recurrent respiratory tract infections, like measles and whoop-
ing cough, may switch the Th-response towards the Thl-type response, including
release of IL-12, IFN-yand TNFa [42]; in Japanese school children, a strong in-
verse relationship was observed between delayed type hypersensitivity (DTH) to
Mycobacterium Tuberculosis as observed after immunization with BCG (bacillus
Calmette-Gue'rin) and atopy [43]; children with higher levels of DTH had a re-
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duced incidence in atopy and asthma and demonstrated a Thl-like cytokine-
profile in peripheral blood. However, the idea of asthma as a Th2-mediated dis-
ease seems too simple; in BAL, no differences were observed in IFN-y expression
in cells of asthmatic patients and healthy volunteers [35], and in severe asthma it
was shown that airway T-lymphocytes have an enhanced capacity to generate both
IL-4 and IFN-y [44,45]. Therefore, the description of asthma as a pure Th2-
response should be reconsidered, since the observed cytokine profile may be the
result of exogenous regulators, which stimulate the expression of individual cyto-
kines [46,47].
1.3 Development of airway inflammation
Dendritic cells are considered to represent the first step in the development of the
asdimatic inflammation, since they capture, process and present allergens to T-
lymphocytes [48]. 11-4 and TNFa can upregulate both the high- and low-affinity
IgE receptors on dendritic cells, which increases their capturing and processing ca-
pacity [49]. The processed antigens are, together with MHC class II molecules,
presented to T-lymphocytes in the regional lymph-nodes. Presentation of the an-
tigen to CD4 T-lymphocytes leads, in susceptible individuals, to the development
of Th2-type lymphocytes, capable of the production and secretion of specific cyto-
kines (see paragraph 1.2). The local balance of cytokines determines the direction
of the T(hO) response; antigen-presenting cells may release IL-12 or IFN-y, which
promote a Thl response, whereas 11-4 and IL-10 promote a Th2 cell proliferation
[50]. 11-4 (and IL-13) is also responsible for the B-cell isotype switching to IgE
production [51]. T-cell released cytokines (IL-3,11-4, IL-5 and GM-CSF) activate
mast cells and eosinophils, leading to the release of preformed and newly formed
mediators. Also, antigen-induced crosslinking of cell-bound IgE on the surface of
mast cells, may result in a direct activation with subsequent release of histamine,
prostaglandins and leukotrienes. Moreover, mast cells release a diversity of pre-
formed and newly generated mediators, including IL-4,-5,-6,-8,-13, GM-CSF
and TNFa [52,53]. Release of histamine and cytokines (especially TNFa) leads
to an increased expression of adhesion molecules (ICAM-1, E-selectin-1,
VCAM-1) on the cell surface of epithelial [54] and endothelial cells, resulting in
an influx of inflammatory cells (T-lymphocytes, monocytes and eosinophils) in
the bronchial mucosa [55]. The local presence of IL-3, IL-5, GM-CSF and TNFa
leads to the subsequent differentiation, growth and activation of eosinophils
[56,57,58], resulting in the release of eosinophil activation products (ECP, EPX,
major basic protein). The importance and clinical relevance of the monitoring of
these eosinophilic products will be discussed later on. Activated eosinophils also
generate new mediators, like leukotriene C,, prostaglandins (PGE, and PGE,),
platelet activating factor and oxygen derived radicals, which may induce consider-
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able tissue damage [56]. The main target for mast cells and eosinophils for induc-
ing tissue damage is the bronchial epithelium [59,60], which becomes fragile and
looses its protective function, thus exposing underlying structures to inhaled sub-
stances and perpetuating the inflammatory reaction with subsequent generation
of bronchial hyperresponsiveness [28]. The cascade of interacting and amplifying
mediators ultimately leads to the chronic airway inflammation, characteristic for
asthma.
1.4 The role of the monocyte/macrophage in the pathogenesis of asthma
In the lung, four subpopulations of macrophages are present: the alveolar macro-
phage, the interstitial and the intravascular macrophage and the various accessory
cells, such as dendritic cells or Langerhans' cells [61]. Two mechanisms are in-
volved in maintaining the population of alveolar and interstitial macrophages z>.
chemotactic attraction of monocytes from the peripheral blood and local replica-
tion within the lung. Bone marrow derived monocytes migrate into the alveoli
both during steady-state conditions, as well as during acute inflammatory events
[62,63,64]. In addition, inflammatory events induce an increased proliferation of
interstitial macrophages [65].
Since alveolar macrophages are easily accessible by bronchoalveolar lavage, most
data in clinical studies reflect observations in alveolar macrophages. Macrophages
possess complement receptors, receptors for IgG and low-affinity receptors for IgE
[66]. In addition, receptors for macrophage-activating cytokines like IL-1, TNFa
and IFN-yhave been described, as well as receptors for macrophage-deactivating
cytokines, like IL-4 and IL-10 [67,68]. Since TNFa and IFN-y are secreted by
macrophages, they activate, in an autocrine fashion, the same cell population.
Upon activation, macrophages produce arachidonic acid metabolites (both pros-
taglandins and leukotrienes) and generate reactive oxygen species (ROS), which
play an important role in the intra- and extracellular defence mechanisms against
micro-organisms. Following activation with bacterial lipopolysaccharides or vi-
ruses, alveolar macrophages produce cytokines (IL-1,-6,-8 and TNFa), growth
factors (TGF-(3, fibroblast growth factors, platelet-derived growth factor) and
colony-stimulating factors [61,69,70]. Because of these inflammatory and
immuno-regulatory properties, macrophages and their precursor cells, monocytes,
are considered to represent pivotal cells, involved in the pathophysiology of in-
flammatory lung disease.
Several studies have demonstrated an important role of mononuclear phagocytes
in the pathophysiology of the asthmatic inflammation. In asthma, the number of
alveolar macrophages, that express the low affinity receptor for IgE (FceRII), is in-
creased [71,72]; in normal conditions, 5-10% of the macrophages express the
IgE-receptor, whereas in asthma this number is increased to 20%. Increased num-
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bers of (activated) macrophages have been observed in BAL fluid in the late asth-
matic response [72,73] as well as in bronchial mucosa of asthmatic patients; many
of these macrophages display phenotypic characteristics of blood monocytes [72].
Alveolar macrophages of patients with allergic disease are activated in comparison
to nonallergic patients [26,70,74], and inhibitory effects on cytokine-release, as
induced by IL-4, are decreased [68]. However, macrophages play a dual role in the
asthmatic inflammation. Macrophages present antigens to T-lymphocytes and
initiate lymphocyte response by release of IL-1, which stimulates 11-2 receptor
(CD25) expression on T-lymphocytes. In turn, 11-2 stimulates T-lymphocyte dif-
ferentiation and induces the release of IL-4, which enhances the Th2 response.
However, activated macrophages from allergic patients also produce a T-
lymphocyte suppressing mediator [75], suggesting, that alveolar macrophages
may also serve to limit proliferative responses in the lower respiratory tract [76].
In peripheral blood, monocytes from asthmatic patients demonstrated an in-
creased expression of the complement receptor, both in stable asthma [77], as well
as after allergen bronchoprovocation [78,79]. Also monocytes of asthmatic pa-
tients released more GM-CSF, both in steady state as well as after stimulation
[70]. In addition, studies have shown that in occupational asthma, peripheral
blood monocytes are also activated [80].
Of further importance is the fact, diat several mediators (TNF, TGF-P, fi-
bronectin) released by macrophages, possess fibrogenic activity [61,72] and may
contribute to the observed airway remodelling in asthma. Also, the increased re-
lease of reactive oxygen species, as observed in peripheral blood monocytes [81,82]
and alveolar macrophages [83], contribute to the observed airway hyperrespon-
siveness and airway remodelling in asthma [84].
1.5 Monitoring of asthma activity
Assessment of the intensity of airway inflammation in the individual asthmatic pa-
tient may serve a number of purposes: to optimize medical treatment, to prevent
or to detect in an early stage an imminent exacerbation of asthma and, if possible,
to detect ongoing inflammation, which may result in the development of an irre-
versible stage of airway remodelling in the long run [85]. To date, there exists no
"gold standard", which adequately reflects asthma severity and which may guide
therapeutic interventions. Up till now, assessment of asthma severity was mainly
performed by analysing the recent history of complaints (asthma-symptom score),
the degree of airway obstruction and the amount of drugs used, with emphasis
placed on the use of relievers (z>. inhaled P,-adrenoceptor agonists). Recently, sev-
eral guidelines have been published regarding therapeutic strategies in asthma-
treatment; however, treatment diagrams are all guided by clinical parameters, such
as symptom-scores and lung-function parameters (like spirometry, peak flow re-
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cordings) [5,7], whereas the underlying hypothesis is centered on the concept of
the reversal and control of asthmatic airway inflammation [5,7,86]. In this sec-
tion, a review will be provided regarding the techniques, which are currently avail-
able for the assessment of asthmatic airway inflammation and their (potential) role
in the clinical management of asthma will be discussed.
1.5.1 Bronchial biopsies
Several studies have evaluated airway inflammation by performing bronchial bi-
opsies and the intensity of inflammation was compared with asthma severity (as-
sessed according to the Aas-score [87]) [18,20,26,54]. The studies demonstrated
that the total number of eosinophils in peripheral blood, in BAL and within the
epithelium of asthmatic patients correlated with asthma severity [18]. Also, the ac-
tivation status of T-lymphocytes and eosinophils in bronchial mucosa of asth-
matic patients was shown to correlate with both Aas asthma symptom score and
bronchial hyperresponsiveness [20]. Recently, consensus was reached regarding a
new classification of asthma, ranging from intermittent to severe chronic asthma
[5]. Vignola «a/. [26] observed a correlation between activated eosinophils and
T-lymphocytes and asthma-severity in patients with intermittent and chronic
asthma, according to the new classification. Although these studies may suggest
that bronchial biopsies can be used to monitor the treatment of asthmatic patients,
so far, bronchial biopsies are not recommended for routine use [88], since they
represent an invasive technique and little is known of their role in the clinical as-
sessment of the individual asthmatic patient. Several studies have shown the use-
fulness of bronchial biopsies in the monitoring of effects of pharmaceutical inter-
ventions in groups of asthmatic patients. Treatment with inhaled corticosteroids
has been shown to decrease both the number of inflammatory cells as well as their
activation status [13,89-94]. However, these studies all evaluated relatively short
term effects of inhaled corticosteroids. In contrast, a recent study, evaluating bron-
chial inflammation in patients treated for a mean duration of 21 months with in-
haled corticosteroids, observed a dissociation between levels of bronchial inflam-
mation and asthma symptoms [95]. Although a relationship still existed between
levels of inflammation and bronchial hyperresponsiveness, no correlation could be
observed between asthma symptoms and the number of inflammatory cells in the
bronchial mucosa. This would imply that clinical scores of asthma do not accu-
rately reflect bronchial inflammation in patients, treated with corticosteroids.
1.5.2 Bronchoalveolar lavage
Bronchoalveolar lavage is also used for the assessment of inflammation in the air-
ways. Since this technique is also performed by bronchoscopy, it represents an in-
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vasive technique. So far, no consensus exists as to the exact procedure. Differences
concern the required volume of instilled fluid, the dwell time within the lung and
standardization of the procedure required to analyse the BALF, since the cellular
composition of the returned fluid can vary with the aliquot size [96]. Because of
the large dilution effects of the instilled fluid in BAL samples, often concentration
of BAL fluid is necessary before measurements of various inflammatory mediators
can be performed. Moreover, for investigational purposes, a control group should
be available, which should have undergone the same procedure in order to make
comparisons. In asthma, BAL-studies have shown that increased numbers of eosi-
nophils are present [18,35,97], which are activated, as has been shown by in-
creased levels of ECP in BAL [18,97]; both were demonstrated to correlate with
asthma-severity. Also, lymphocytes may be increased in BAL of asthmatic patients
[98]; however, this does not represent a common finding [99]. Studies clearly
show, that although total cell numbers in BAL may not be very different, BAL
lymphocytes and leucocytes are clearly activated, even in mild stable asthma
[45,100,101,102]. In addition, BAL has also been used to study the mechanism,
involved in the pathogenesis of the late asthmatic response [103,104,105,106].
BAL has also been used to evaluate the effects of pharmaceutical interventions in
groups of asthmatic patients; treatment with inhaled corticosteroids resulted in
the reduction in the number of eosinophils and ECP-levels in BAL of asthmatic
patients [107,108]. Also, inhaled corticosteroids reduced the number of activated
CD25* CD4* T-lymphocytes [109], as well as cytokine levels in BAL of stable
asthmatic patients [110]. In general, observations in BAL parallel the changes ob-
served in bronchial biopsies in asthma [111, 112].
1.5.3 Sputum induction
Due to their invasive character and since, up till now, bronchoscopic techniques
(/.*. bronchial biopsies and BAL) have not been demonstrated to provide informa-
tion necessary for the treatment of the individual patient with asthma, these tech-
niques are not recommended for monitoring of asthma. However, the recently de-
veloped technique of sputum induction represents a non-invasive technique for
the assessment of airway inflammation. So far, this technique has been used almost
exclusively in a clinical research setting, and whether this technique is also useful
for the monitoring of inflammation in the individual patient still needs to be
evaluated. The technique consists of the inhalation of hypertonic aerosol through
an ultrasonic nebulizer. Safety procedures are necessary, because hypertonic saline
can cause severe airway obstruction in asthmatic patients, which can be dimin-
ished by pretreatment with inhaled (3,-agonists. Analysis of cellular compounds of
the sputum can be performed in the whole sample or in the viscid portion of the
sputum sample [113], whereas various soluble mediators can be measured in the
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supernatant. Of importance is, that the added liquefier (dithiothreitol 0.1%) does
not interfere with the assays. Clinical studies so far have shown that sputum induc-
tion is relatively safe in mild or controlled asthma. The validity and repeatability of
differential cell counts within patients have been reported to be good in the hands
of skilled investigators [114,115,116].In addition to the evaluation of the cellular
components [117,118], in supernatant measurements can be performed regarding
mediators such as ECP [119,120,121], histamine, tryptase, neutrophil-activation
products [122] and several cytokines, <•.£. TNFaand IL-5 [123,124]. In compari-
son to BAL, induced sputum contains more neutrophils and eosinophils than
BAL [111,125,126], whereas numbers of macrophages and lymphocytes are lower
in induced sputum. A good correlation was observed between the number of eosi-
nophils in induced sputum and BAL [111,112,127], whereas the correlation with
the number of eosinophils in bronchial mucosa is less clear [111,112]. Studies, us-
ing allergen challenge, have shown that changes in induced sputum parallel
changes in BAL ;>. a rise in the percentage of eosinophils [128], ECP and hista-
mine [129]. Treatment with inhaled or oral corticosteroids has been shown to re-
duce the number of eosinophils [121,130] and to reduce levels of ECP in induced
sputum [121,130].
However, despite these observations, the clinical accuracy of induced sputum as a
marker of asthmatic inflammation remains to be established, as well as whether
subtle changes in pharmaceutical treatment are reflected by changes in constitu-
ents of induced sputum. So far, no gold standard exists for the performance and
analysis of induced sputum. Moreover, reference values regarding the normal
range remain to be established as well as further optimization of the technique. In
regard to the option of using induced sputum analysis in the serial assessment of
airway inflammation in individual patients, it is of importance to consider obser-
vations from recent studies, which have shown that sputum induction in itself in-
duces changes in airway inflammation within a time-period of 24 hours after spu-
tum induction [131,132].
1.5.4 NO-analysis in exhaled air
Nitric oxide (NO) is produced by a variety of cells both in the upper as well as the
lower airways. Constitutive nitric oxide synthase (cNOS), which is expressed in
endothelial cells (eNOS) and neural cells (nNOS), gives rise to NO, which acts lo-
cally either as a vasodilator or neurotransmitter. Inducible NOS (iNOS) is synthe-
sized <& wow? in macrophages and epithelial cells due to gene activation following
inflammation and can induce large quantities of NO [133,134]. Studies suggest
that iNOS is present in epithelial cells in asthmatic airways, whereas it is not ex-
pressed in epithelial cells from healthy individuals [135]. iNOS can be induced by
endotoxins [136] and by inflammatory cytokines like TNFa [135], IL-iPandin-
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terferon-y and the resulting product NO can be detected in exhaled air in humans
[137,138]. Several studies have observed a marked increase in NO in exhaled air of
asthmatic patients in comparison to controls [139,140,141]. Also, increased con-
centrations of NO were observed in the late asthmatic reaction after allergen chal-
lenge, whereby levels of NO reflected the size of the late response [142]. However,
so far, there exists no certainty regarding the cellular origin of the measured NO
and the pathophysiological consequences of increased concentrations of NO are
still not clear. NO induces bronchodilation [133,134], but, on the other hand,
also increases blood flow in the lung with the possible consequence of increased
plasma exudation in the asthmatic airways. NO may further have detrimental ef-
fects, since high concentrations of NO have been shown to inhibit Thl lympho-
cytes and inhibit production of interferon-y [143]. Although measurements of
NO in exhaled air contain significant contributions of NO, originating from the
nose and pharynx, several procedures have been developed in order to increase the
reproducibility of the measurements of NO, originating from the lower airways
[134]. Nitric oxide analysis in exhaled air has also been demonstrated to be of use
in the assessment of asthma in children [144,145]. Up till now, studies have not
evaluated response of exhaled NO during long-term treatment of asthma with
corticosteroids. Recently, corticosteroids have been shown to inhibit iNOS activ-
ity [146] and one study observed that asthmatic patients, using inhaled corticos-
teroids, showed NO levels in exhaled air comparable to levels in healthy subjects
[140]. Also in acute episodes of asthma, an increase in NO levels was observed,
that decreased during treatment [147].
In summary, nitric oxide measurement in exhaled air represents a non-invasive
technique, which has the potential to detect inflammatory changes within the hu-
man airways. However, additional studies have to be performed before this tech-
nique can be of use in the evaluation of asthma activity within the individual pa-
tient. Further standardization of the technique [148] and the development of
normal ranges of NO concentrations in exhaled air in normal individuals are nec-
essary, before measurements of NO in exhaled air can be of use in the assessment
of asthma in daily practice.
1.5,5 Peripheral blood analysis
Except for NO measurements in exhaled air, the methods mentioned above all
represent more or less invasive techniques with potential hazards to the patient.
For clinical purposes, it is important to monitor asthmatic patients by means of
relatively simple and reproducible techniques. The methods used so far in the
clinical asessment of patients, all depended on individual cooperation. Diaries and
peak flow rate determination have been shown to be useful in asthma management
diagrams [5,7], but do not reflect directly levels of airway inflammation [95] or
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predict relapses [149]. Therefore, detection of biomarkers in peripheral blood,
which are directly related to the asthmatic inflammation and can be measured in a
reproducible, standardized way, should be of interest in the clinical assessment of
asthmatic patients. Ideally, biomarkers should be specific for and primarily in-
volved in the pathogenesis of asthmatic disease, should not be related to other dis-
eases and should have been demonstrated to reflect asthma activity in clinical stud-
ies. In previous years, several biomarkers have been presented, which have been
reported to reflect asthmatic inflammation, but could not live up to all the criteria
described above. To date, efforts are still in progress to find an easy to handle bio-
marker of asthmatic inflammation, which can be used in daily clinical practice. In
this section, a review will be given regarding the mediators, currently in use for the
evaluation of asthma activity, although most of them are still only used in experi-
mental or investigational settings.
Eosinophils and eosinophil derived mediators
Eosinophils are among the first cells described to be involved in the asthmatic pro-
cess and increased numbers of eosinophils have been observed in peripheral blood
of asthmatic patients [18,150,151]. In groups of asthmatic patients, blood eosino-
philia correlated with disease severity [18,152], and in individual patients periph-
eral blood eosinophils have been shown to fluctuate according to disease activity.
After allergen challenge, numbers of peripheral blood eosinophils were shown to
decrease at first [153,154] and increase later on [155], whereas in BAL a signifi-
cant rise in (activated) eosinophils is observed during the late allergic reaction
[156,157,158]. In addition, an inverse correlation was observed between the
number of peripheral blood eosinophils and bronchial hyperreactivity [152,155].
Peripheral blood eosinophils of asthmatic patients have been shown to be acti-
vated [159, 160]. Upon activation, eosinophils release preformed mediators [56],
like eosinophil cationic protein (ECP), major basic protein, eosinophil protein X
(EPX) and eosinophil peroxidase (EPO). Treatment with corticosteroids has been
shown to decrease both total number of blood eosinophils as well as their activa-
tion status [161,162,163].
Eosinophilic cationic protein (ECP)
Serum levels of ECP are increased in asthmatic patients in comparison to healthy
controls [164,165,166,167] and serum ECP was shown to be increased after anti-
gen challenge [164,168]. ECP levels in serum are considered to reflect clinical
asthma activity [169,170] and were shown to correlate with the number of acti-
vated eosinophils in the bronchial mucosa of asthmatic patients [171]. So far, es-
pecially in children, serum ECP is considered to be of diagnostic value for the di-
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agnosis of asthma [172,173,174]. Moreover, several authors have reported
beneficial results in asthma treatment in children, using serum ECP as an addi-
tional marker of eosinophil activation [175]. In asthmatic patients, treated with
corticosteroids, ECP levels decreased in BAL, sputum and in serum [176,177], al-
though response parameters showed a better correlation with sputum ECP than
with serum ECP [177]. One study, adjusting inhaled corticosteroid treatment ac-
cording to serum ECP levels, observed an improvement in pulmonary function in
combination with lower levels of ECP, although no changes were observed in
bronchial hyperresponsiveness [178]. However, ECP is not specific for the asth-
matic inflammation; increased levels of ECP have been observed in eczema, atopy
[179], allergic rhinitis [180], respiratory syncytial virus infections [181] and para-
sitic infections [182]. Therefore, although it is generally accepted that levels of
ECP reflect the activation status of eosinophils, the usefulness of serum ECP in the
treatment of asthmatic patients in combination with allergic disease, /'.<•. allergic
rhinitis, still remains to be investigated. Also, additional studies are needed to
evaluate the usefulness of serum ECP as a single marker in the monitoring and
treatment of asthmatic inflammation, especially since correlations of ECP with
levels of bronchial hyperresponsiveness are low [167,183]. Similar conclusions can
be drawn with regard to the determination of eosinophil protein X, both in serum
as well as in urine.
Cytokines
In asthma, T-lymphocytes, monocytes and eosinophils in peripheral blood have
been shown to be activated and release, either spontaneously or after stimulation,
increased amounts of cytokines and express activation markers on their cell surface
[45,184,185], which can be detected in blood. Also mediators, produced within
the pulmonary compartment, may leak into the peripheral circulation and can be
detected [106]. Although several studies have shown, that differences exist be-
tween levels of cell activation between blood and the pulmonary compartment
[101,186], studies have evaluated the usefulness of these markers in the monitor-
ing of asthmatic inflammation, although for detection of these inflammatory me-
diators sensitive assays are required. Up till now, the relationship between levels of
diese mediators and functional abnormalities, observed in asthma, is ill-defined.
Levels of mediators, measured in the general circulation, only partially reflect local
concentrations in the pulmonary compartment, and allows only prudent interpre-
tation, regarding the concentration of mediators on tissue level.
21CHAPTER 1
T-lymphocyte activation markers and T-lymphocyte associated cytokines
In asthma, "["-lymphocytes are activated, not only within the lung [187], but also
in the general circulation [184,188]. In acute asthma, the expression of the IL-2
receptor (IL-2R), HLA-DRand VLA-1 on T-lymphocytes is increased [184,189]
and correlates with asthma activity [190]. In stable asthma, peripheral blood T-
lymphocytes were shown to be activated, as was shown by the upregulation of the
receptor for IL-2 (CD25), which can be detected in soluble form (sIL-2R)
[191,192]. Moreover, sIL-2R levels are increased in unstable asthma and decrease
following treatment [188,193]. Treatment of severe asthma with cyclosporin was
shown to result in a clinical improvement, that was associated with a decrease in
serum concentrations of sIL-2R [194].
Several other cytokines have been measured in blood of asthmatic patients. Serum
IL-4 has been shown to be increased in asthmatic patients versus healthy subjects
[195,196]; especially in atopic children, increased levels of IL-4 have been ob-
served, which correspond with an increased tendency of peripheral blood cells to
produce IL-4 [197]. 11-4 was shown to be increased in adult patients with asthma,
who also demonstrated enhanced levels of sIL-2R and soluble low affinity receptor
for IgE (sCD23) [192]. In parallel, several studies, especially in children have
evaluated the role of the low affinity receptor of IgE (sCD23) in the pathogenesis
of asthma and also observed increased levels in young asthmatic patients [198], of-
ten in combination with enhanced levels of IL-4 [196]. sCD23 was shown be asso-
ciated with atopy and showed an age-dependent change [ 199].
IL-5 is a T-cell derived mediator, which was shown to induce both eosinophilia in
BAL and increase bronchial hyperresponsiveness, when inhaled by asthmatic pa-
tients [200]. 11-5 has been shown to be increased in peripheral blood of asthmatic
patients [166], although studies in children were only able to detect serum IL-5 in
acute asthma [181]. In adult asthmatic patients, 11-5 was detected in serum of pa-
tients with severe chronic asthma [201], and following corticosteroid treatment,
both serum IL-5 and the number of activated T-lymphocytes in peripheral blood
decreased [202].
GM-CSF represents a cytokine, which is involved in eosinophil activation [97]
and is released in increased quantities by peripheral blood monocytes and macro-
phages in asthmatic patients [70]. So far, only one study reported increased levels
of GM-CSF in peripheral blood of asthmatic patients [97], whereas an inverse
trend was reported in children [195].
IFN -y, aThl cytokine, has been shown to be involved in the asthmatic inflamma-
tion [35, 44,45,47]. Although studies in stimulated peripheral blood cells suggest
a decreased interferon-gamma production [197,203,204], serum interferon-
gamma levels in patients with stable asthma were comparable witii levels of
healthy controls [205].
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Pro-inflammatory cytokines • -
Although proinflammatory cytokines are implicated in the pathogenesis of asthma
[73,70,104,188], measurement of proinflammatory mediators in peripheral
blood of asthmatic patients so far has not been proven to be useful. TNFoc, a pro-
inflammatory cytokine, which is released early in the acute inflammatory response
[206], is implicated in the asthmatic airway inflammation [55,207,208,209] and
development of bronchial hyperresponsiveness [124,210,211]. TNFcx is also im-
plicated in the upregulation of adhesion molecules on the cell surface of epithelial
[212] and endothelial cells [206,210]. So far, few studies were able to detect
TNFot in the circulation, and when present, TNFa was only detected in acute ex-
acerbations of asthma [213,214], whereas, in stable disease, no TNFa could be
detected [188]. Part of these observations can be explained by the very short half-
life of TNFa [215]. Similar observations have been made regarding serum IL-6
levels; serum IL-6 was significantly elevated in acute exacerbations of asthma, and,
in stable asthma, IL-6 levels were found to be comparable with levels in healthy
subjects [216]. Recently, the soluble receptor of IL-6 (sIL-6R) was detected in the
circulation. In contrast to observations with IL-6, sIL-6R levels were elevated in
stable asthmatic patients in comparison with healthy subjects and a further in-
crease was observed in acute asthma and after allergen challenge [217].
Although IL-8 is also implicated in the asthmatic airway inflammation [70,218],
no data exist regarding serum levels of IL-8 in asthma.
Soluble TNF-receptors
TNF-receptors are involved in mediating the effects of TNFa and, following acti-
vation, can be shed from the cellular surface [219]. TNF-receptors are present on
nearly all cells and two types of TNF-receptors (sTNF-R55 and sTNF-R75) can
be detected in healthy subjects [220]. Each TNF-receptor is considered to have a
differential role in the regulation ofTNFa-mediated effects [221,222,223]. Since
TNFa is involved in the asthmatic airway inflammation [73,104,124,210],
evaluation of soluble TNF-receptor levels may be of interest in the treatment of
asthma. So far, two studies evaluated the presence of sTNF-receptors in asthma
[224,225]; one study observed increased levels of sTNF-receptors during acute
asthma, whereas, following treatment, levels of sTNF-receptor decreased [224].
However, sTNF-receptors are not specific for asthmatic inflammation, since en-




Adhesion molecules are involved in the regulation of leucocyte-trafficking
[230,231] and several studies have observed an increased expression of adhesion-
molecules in the bronchial mucosa of asthmatic patients [54,232,233,234].
Analogous to TNF-receptors, adhesion-molecules can be shed from the cell sur-
face and have been detected in body fluids of asthmatic patients and healthy sub-
jects [106,118,235]. After allergen challenge, increased levels of soluble Intercellu-
lar Adhesion Molecule-1 (sICAM-1) were detected in the general circulation
[106,236,237] and were considered to reflect the upregulation of adhesion mole-
cules within the asthmatic airways. Increased levels of soluble adhesion molecules
(sICAM-1, soluble E-selectin-1) have also been observed in acute asthma
[214,238,239]. Although studies reported enhanced levels of sICAM-1 and E-
selectin in stable asthma [236,239], others could not confirm these observations
[238]. Also, conflicting data exist regarding the role and involvement of soluble
Vascular Cell Adhesion Molecule-1 (sVCAM-l)in acute asthma [213,238].
Treatment with corticosteroids decreased soluble adhesion molecule levels in
some studies [239], although not in all [238]. It should be noted that sICAM-1
and sE-selectin-1 are not specific for the asthmatic inflammation, since they are
also involved in other inflammatory and allergic diseases [225, 227, 228, 229,
240, 241]
Markers for oxidative stress
In asthma, alveolar macrophages, peripheral blood monocytes and polymorpho-
nuclear leucocytes have all been shown to generate increased amounts of reactive
oxygen species (ROS), which can be measured by chemiluminescence
[81,83,242,243,244]. The amount of ROS released was observed to correlate with
both asthma severity [83] and bronchial hyperreactivity [84,245], and was signifi-
cantly increased in comparison to healthy subjects [82]. Increased ROS genera-
tion is observed after segmental allergen challenge [246,247] and ROS generation
in peripheral blood cells is increased even more in unstable asthma [82]. Recently,
measurement of whole blood chemiluminescence was demonstrated to represent a
systemic parameter, which reflects asthmatic inflammation [248]; whole blood
chemiluminescence was shown to correlate with airway obstruction, whereas it
was also shown that patients with stable asthma had levels comparable with
healthy subjects. More promising for clinical use, is the recent demonstration of
increased hydrogen peroxide and thiobarbituric acid-reactive products in expired
breath condensate of asthmatic patients [249,250].
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1.5.6 Markers in urine
So far, leukotriene E,, (LTE^) is the soluble marker in urine studied most exten-
sively [251]. LTE^ levels in urine have generally been acccepted as a suitable
marker of endogenous formation of cysteinyl-leukotrienes within the body, in-
cluding the lung. Increases in urine LTE_ have been detected after allergen chal-
lenge in asthmatic patients, whereas no changes in urinary LTE^ levels were ob-
served after exercise-induced bronchoconstriction [252]. Determination of
urinary EPX, an eosinophil-derived mediator, may represent a new marker for
asthmatic inflammation: preliminary data suggest a potential usefulness of urinary
EPX in the monitoring of asthma, both in adults [253] and children [254]. In
asthmatic children, it was shown that urine levels of EPX correlated both with the
number of eosinophils [254] and with asthma activity and pulmonary function
[255]. In addition, measurement of urinary 9(X,1 lp-PGF, was presented recently
as a method to measure mast cell activation in exercise-induced asthma [256,257].
However, before the usefulness of these markers in clinical practice can be deter-
mined, it is necessary to extend basic information (?.£. the definition of normal
values and the effect of different manipulations on these urinary markers). When
such studies have been performed, urinary markers may become useful in clinical
management of asthmatic patients.
In conclusion, although several techniques are currently available for assessment of
asthmatic inflammation, it has not been established yet, which marker or set of
markers may be the best reflection of the asthmatic inflammation. Ultimate goal
in the treatment of asthmatic patients is to restore the quality of life, control the
asthmatic inflammation and to prevent structural changes within the airways. In
order to achieve this, the clinician should have access to a sensitive and specific set
of markers, which enables him to treat the individual patient with asthma in the
best possible way.
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Aim and design of the thesis
The previous two decades have shown a tremendous increase in the knowledge of
asthma. Cytokines were shown to be involved in the pathophysiology of asthma
and several cytokines, like f.g. tumor necrosis factor a, IL-1 to IL-6, IL-10 and
GM-CSF have been implicated in the pathogenesis of asthma, although their pre-
cise role still remains to be established. Tumor necrosis factor a is one of the first
cytokines generated in the inflammatory reaction. Ample studies have demon-
strated a role of TNFcc in the pathophysiology of asthma: an increased expression
of tumor necrosis factor a has been observed in bronchial biopsies, BAL-fluid and
induced sputum; increased levels of TNFa have been observed in sputum after
specific allergen inhalation in asthmatic patients and IgE-receptor activation in
mast cells and macrophages resulted in an increased generation of TNFa. In addi-
tion, inhalation of TNFa was shown to induce airway hyperresponsiveness in hu-
mans. Almost every cell type, involved in the asthmatic inflammation, has been
shown to generate TNFa. Therefore, TNFa is involved in two important charac-
teristics of asthma: inflammation and bronchial hyperresponsiveness (BHR).
In chapter three, we investigated whether TNFa, as a pro-inflammatory cytokine,
is able to induce bronchial hyperresponsiveness directly. We therefore investigated
the effect of TNFa on the isotonic contraction of tracheal smooth muscle of
guinea-pigs /« wVro and additionally analysed whether secondary mediators are in-
volved in the actions of TNFa.
In chapters four and five, we investigated whether drugs, commonly used for their
bronchodilatory effects in asthma, might also influence asthmatic inflammation.
The drugs studied (theophylline (chapter four), salmeterol and salbutamol (chap-
ter five)) all induce the generation of cAMP, which is involved in immunomodu-
lation. In these /« w'm? studies, emphasis was placed on the effect of drugs on
TNFa release in peripheral blood monocytes, as well as on adhesion molecule ex-
pression on endothelial cells, which plays an important role in leucocyte traffick-
ing. We also evaluated the influence of these drugs on the release of IL-10, since
IL-10 has anti-inflammatory effects and has been shown to inhibit TNFa release.
We were especially interested in the effects of salmeterol, since, due to its long du-
ration of action, anti-inflammatory effects may be amplified /» wVo. Since release
of cytokines is influenced by gene-transcription activity, both studies also evalu-
ated the effect of drugs on mRNA levels in activated monocytes.
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Next, we evaluated changes in markers of asthmatic inflammation in patients with
mild, stable asthma, who were treated with inhaled corticosteroids. We studied
patients, who, according to the new guidelines for classification of asthma, should
be classified as having intermittent asthma. Studies have demonstrated that, even
in this group of patients with mild disease, airway inflammation and airway wall
remodelling is present. Therefore, we simultaneously monitored the response of
patients to corticosteroids with regard to airway hyperresponsiveness (chapter six)
and with regard to changes in peripheral blood markers, involved in asthmatic in-
flammation (chapters seven and eight).
In chapter six, we used both conventional pulmonary function measurements and
the forced oscillation technique to assess changes in bronchial responsiveness to
inhaled cold air, because, especially in this group of mild asthmatic patients, the
inspiratory manoeuvre, which precedes conventional lung function testing, may
influence bronchoconstriction. Forced oscillation measurements may reflect
bronchial tone more adequately, since this technique can be performed during
quiet breathing.
In chapter seven, we monitored changes in levels of soluble TNF-receptors and
soluble adhesion molecules (sICAM-1 and sE-selectin-1) in peripheral blood in
order to assess changes in bronchial inflammation, induced by inhaled corticoster-
oids. Since the half-life of proinflammatory cytokines, especially of TNFoc, is very
short, levels are often not detectable and can not be used as biomarkers. Several
studies have demonstrated increased levels of these inflammatory markers in pe-
ripheral blood, both in unstable asthma and after allergen challenge. So far, the ef-
fect of inhaled corticosteroids on levels of these inflammatory markers in stable
asthmatic patients is not known.
In chapter eight, we used erythrocyte antioxidant levels as marker of the asthmatic
inflammation. Reactive oxygen species are involved in the development of bron-
chial hyperresponsiveness and studies have shown that erythrocyte antioxidant
levels reflect long-term exposure to reactive oxygen species in chronic lung disease.
In asthma, reactive oxygen generation is increased and, in addition, studies also
observed decreased antioxidant defenses, leading to an oxidant-antioxidant imbal-
ance, even in stable asthmatic patients. By monitoring changes in erythrocyte anti-
oxidant levels, we tried to measure changes in bronchial inflammation induced by
inhaled corticosteroids.
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ABSTRACT
Recent studies have implicated a role for tumor necosis factor-a (TNFa) in the
development of the asthmatic reaction. In this study, we examined the influence
of TNFa on isotonic contraction of tracheal smooth muscle of the guinea-pig /'»
wfro in response to methacholine.
Tracheal rings were incubated with recombinant human tumor necrosis factor-a
(rhTNFa) (3.10""M) for 30 min, and concentration-response curves to
methacholine before and after incubation with rhTNFa were compared with the
control.
The present study demonstrates that rhTNFa increases maximal isotonic contrac-
tion of tracheal smooth muscle to methacholine (mean ± SEM 169.6 ± 4.3 %, p<
0.005). This effect was observed only after a thirty-minute delay between incuba-
tion and methacholine challenge testing. Experiments with 10'^ -10"'° M
rhTNF-a yielded similar results at all concentrations used. The effects of rhTNFa
(10" M) on tracheal hyperreactivity could be completely inhibited by coincuba-
tion with dimeric rTNF-receptor-p80-construct (10"'" M) (p< 0.01). In order to
analyse secondary mediator release, experiments using coincubation with
indomethacin (10^ M) and WEB 2086 (10^ M), a specific platelet activating fac-
tor (PAF) antagonist, demonstrated that the effect of rhTNFa on tracheal rings
was mediated by PAF, since WEB 2086 completely inhibited rhTNFa-induced
hyperreactivity (p< 0.05).
In conclusion, this study demonstrates that rhTNFa induces hyperreactivity in
tracheal smooth muscle /'« wVro, which was shown to be mediated by PAF. Our
study emphasizes the role of TNFa in the pathophysiology of bronchial hyperre-
sponsiveness.
INTRODUCTION
Bronchial hyperresponsiveness (BHR) is regarded as an important characteristic
of asthma and correlates with the severity of the disease [1]. BHR can be induced
after allergen-inhalation in allergic asthmatics, after viral respiratory tract infec-
tions, industrial chemical inhalation and endotoxin-inhalation [2]. In asthmatic
patients, endotoxin (LPS) primarily induces a fall in FEV, and secondarily an in-
crease in BHR. However, it is not certain that LPS itself is primarily responsible
for inducing BHR. Tumor necrosis factor-a (TNFa) has been found to represent
an important mediator of LPS-induced effects [3]. In animal models, TNF-a lev-
els were elevated in bronchoalveolar lavage fluid after LPS-inhalation and, as was
shown in a rat-model, TNFa inhalation induces BHR [4]. In asthmatic patients,
TNFa levels were elevated in both BAL-fluid [5] and sputum [6] in the late astJi-
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matic reaction and in both BAL and bronchial mucosa in symptomatic asthmatic
patients [7,8]. In occupational asthma, increased expression of TNFa was ob-
served in the bronchial submucosa of workers with toluene diisocyanate induced
asthma [9]. Recently, TNFa inhalation was shown to induce BHR in healthy hu-
man volunteers, supporting a primary role for TNFa in the development of BHR
[10].
TNFa can be released by various cell-types involved in the inflammatory re-
sponse, like monocytes, alveolar macrophages, mast cells, neutrophils and T-
lymphocytes, depending upon the stimulus used [11]. In stable asthmatics, in-
creased release of TNFa was observed in alveolar macrophages, both spontane-
ously and after stimulation [ 12]. In allergic asthmatics, mast cells have been shown
to be a source for TNFa [8] and mast- cell activation initiated by IgE-receptor
crosslinking is considered to be a source for TNFa release [13]. Furthermore,
Th2-lymphocytes play an important role in the development of asthma and pro-
duce a wide array of cytokines like Interleukin (IL)-4, IL-5, GM-CSF and TNFa
[14]. In order to investigate whether TNFa affects the constrictor response of
bronchial smooth muscle directly, we investigated the influence of TNFa on
smooth muscle response to methacholine in guinea-pig tracheal strips. We addi-
tionally investigated whether secondary mediator release is involved in
TNFa-induced effects. This study demonstrates the ability of TNFa to induce
hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro and provides




Acetyl-|3-methylcholine chloride (methacholine chloride) was obtained from
Sigma Chemical Co (St. Louis, Mo, USA). Indomethacin was obtained from
OPG-pharma (Utrecht.The Netherlands) and diluted in dimethyl-sulphoxide.
Recombinant human TNFa was a gift from Knoll/BASF (Ludwigshafen, Ger-
many). Recombinant human TNF-Receptor-p80:Fc (a soluble human TNF-
receptor (p80) linked to the Fc-portion of human IgGl) was kindly provided by
Immunex (Seattle, WA, USA) [15]. WEB 2086 (3-[4-(clorphenyl)-9-methyl-
-6Hthieno(3,20(l,2,4)triazolo(4,3,a)(l,4)diazepine-2-yl]-l-[-4-morpholinyl]-l-
-propanone), a specific PAF-antagonist [16], was a gift from Dr. H. Heuer, Boe-
hringer Mannheim GmbH (Mannheim, Germany). rhTNFa, rTNFR-p80:Fc
and WEB 2086 were dissolved in sterile PBS. All solutions were freshly prepared.
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Tracheal preparation
Dunkin-Hartley guinea-pigs (300-400 g), (Harlan CPB. Zeist, The Netherlands)
were sacrificed by cervical dislocation. Tracheas were rapidly dissected free from
surrounding tissue, excised and opened in longitudinal direction opposite to the
muscle layer by cutting through the cartilage. Tracheal strips (each containing one
cartilage ring) were placed in a 20 mL organ bath containing Krebs buffer solution
of 37 "C (as described previously) [17] and continuously gassed with 95% O, and
5% CO, (pH 7.4).
Experimental design
Tracheal smooth muscle response was measured isotonically with a passive weight
of 0.5 g in all experiments. After an equilibration period of 60 min with four inter-
mediate changes of buffer solution, cumulative doses of methacholine were added
to the organ bath solution to obtain a rapid concentration-response curve (these
data were not used). After a thirty-minute washing period (with six intermediate
changes of buffer solution to remove methacholine), the first concentration-
response curve with methacholine was performed (indicated as the control curve).
Next, the tracheal rings were washed again and incubated with different concen-
trations of rhTNFa or buffer control for 30 min. Thereafter, the tracheal rings
were subjected to a second concentration-response curve with methacholine, ei-
ther directly (designated the direct curve) or after another thirty minute washing
period (designated the delayed curve). During the direct- or delayed-type experi-
ments with TNFa, a buffer control curve was also obtained (designated blank-
curve).
In order to evaluate the dose-response effects, rhTNFa was administered to the
tracheal strips in concentrations ranging from 10'' to 10"'° M. Dose-response ef-
fects were assessed in the delayed-type models (i.e. 30 min of washing after incu-
bation with rhTNFa). Thereafter, in order to assess the specificity of the effect in-
duced by rhTNFa, tracheal rings were simultaneously incubated with 10"" M
rhTNFa and 10'" M rh-soluble TNF-receptor-p80. This concentration of
rhTNF-receptor-p80 was shown previously to inactivate the bioactivity of TNFa
completely, as assessed by the WEHI-assay [15]. All experiments were performed
pairwise in tissues from the same animals.
Since TNFa has been reported to enhance the activity of phospholipase-A,
(PL-A,) [18] with subsequent synthesis of prostaglandins and PAF, in the next set
of experiments, tracheal strips were preincubated for 10 min with 10"^ M
indomethacin or 10''M WEB 2086, followed by 30 min of incubation with 10"
M rhTNFa. These concentrations of indomethacin and WEB 2086 were consid-
ered to block endogenous prostaglandin and PAF effects completely [19]. The sec-
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ond concentration-response curve for methacholine was also performed after
washing for 30 min, during which indomethacin and WEB 2086 were continu-
ously present in the washing solution. As before, experiments were performed
pairwise in tissues from the same animals.
STATISTICAL ANALYSIS •-
Data are presented as mean ± standard error of the mean (SEM) of at least eight in-
dependent experiments. For methacholine concentration-response curves, the
contraction obtained following incubation with buffer control or TNF(X was ex-
pressed as percentage of the initial response (control curve). The results were statis-
tically evaluated using Student's t-test for paired data (two-sided test). A p-value <
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Figure 1. Concentration-response curves of methacholine chloride on
isotonic contraction of tracheal strips of the guinea-pig, without (•-•
control; •-• blank) and after incubation with 3x10 " M rhTNFct for 30
min (Q-Q delayed; O-O direct). The response is displayed as percenta-
ge of contraction in comparison with the control curve. The curves are
the mean ± SEM of at least eight independent experiments. Experi-
ments were performed pairwise. * p< 0.005 delayed versus control,
blank and direct-type incubation with rhTNFo.
45CHAPTER 3
RESULTS
Effect of TNFoc on methacholine induced bronchoconstriction
Incubation of tracheal smooth muscle with 3x10" M rhTNFa significantly in-
creased the maximum response to methacholine (Figure 1). This enhanced re-
sponse was, however, only observed in the delayed model (169.6 ± 4.3 %, p< 0.005
in comparison with the control, blank and direct model). The blank curves (second
methacholine concentration-response curve with buffer control) were not statisti-
cally different from the first concentration-response-curves, indicating that inter-
mediate changes of buffer or prolonged presence in the organ bath did not influ-
ence the contractility of the tracheal strips within the duration of our experiments.
During incubation with TNFa, the baseline tone of tracheal strips did not
change. The -log concentration of drug needed to obtain half maximum response
(pD,) values of the different curves, both with and without rhTNFa, were not sta-
tistically different from those of the control curves (Table 1).
In the second set of experiments, the dose-response effects of different concentra-
tions of rhTNFa (10-'-' to 10'" M rhTNFa (1.7-1700 pg.mL')) on
methacholine-induced contraction of tracheal smooth muscle were evaluated.










































pD,-values of tracheal smooth muscle response to methacholine did not change significantly in all
experiments performed.
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Figure 2. Maximal isotonic contraction to methacholine of tracheal rings of the guinea-pigs wit-
hout ( control, blank) and with different concentrations of rhTNFa ( 10" M, 10 " M, 3.10 " M,
10" M, 3.10 "M, 10'°M). The curves were obtained after a 30 min washing period after incuba-
tion with TNFoc (30 min). Curves are the mean ± SEM of at least eight independent experiments.
*p< 0.02 for all concentrations of rhTNFa versus the control and blank.
Considering the results above, in this and the next set of experiments, only the de-
layed model was used. Our experiments demonstrate that for all concentrations
used, rhTNFa increased the maximum response to a similar extent (Figure 2).
Experiments with selective inhibition of TNFoc with soluble TNF-receptor
construct
In order to ascertain the specificity of action of rhTNFa on tracheal smooth
muscle, in the next set of experiments, simultaneous incubation of 10'"M
rhTNFa and 10'°M recombinant soluble TNFR-p80:Fc-construct was used
(Figure 3). rTNFR-p80:Fc was shown to inhibit the effect of TNFa on trachea!
hyperreactivity completely.
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Figure 3. Specific TNFa-inhibitor abrogates TNFa-induced bronchial
hyperreactivity. Concentration-response curves (mean ± SEM) of
methacholine chloride on (at least eight) tracheal strips of the gui-
nea-pig without (O-O blank), with 10" M rhTNFoc (•-•) or simulta-
neous incubation of 10" M rhTNFa and 10° M sTNF-Receptor-
p80:Fc-construct (A-A). Curves were obtained 30 min after incuba-
tion with TNFa or buffer control. Experiments were performed pair-
wise. *p< 0.01 rhTNFa versus blank and simultaneous incubation of
rhTNFa and sTNF-receptor-p80:Fc.
Experiments evaluating involvement of prostaglandins and PAF in TNFa-induced
bronchial hyperresponsiveness.
Since TNFa increases PL-A^-activity, tracheal rings were incubated with
indomethacin to block endogenous prostaglandin release and with WEB 2086 to
inhibit PAF effects. As observed before, incubation of tracheal rings with
indomethacin alone did induce an increase in contractility, probably induced by
shifts occurring within prostaglandin synthesis. Coincubation of tracheal rings
with indomethacin (10"'' M) and rhTNFa did not influence induction of bron-
chial hyperreactivity by rhTNFa (Figure 4a), indicating that prostaglandin syn-
thesis does not play a direct role in TNFa-induced hyperreactivity.
Treatment with WEB 2086 (10'^ M) alone did not influence reactivity of tracheal
strips, whereas coincubation of WEB 2086 with TNFa completely abrogated
TNFa-induced hyperreactivity of tracheal smooth muscle (Figure 4b), demon-
strating an involvement of PAF in the induction of tracheal hyperreactivity.
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Figure 4 a-b. Effect of: a) Indomethacin and b) WEB 2086 on rhTNFa-induced tracheal hyperreac-
tivity. Concentration-response curve (mean ± SEM) of methacholine on tracheal smooth muscle
contraction with buffer control (O-O blank), blank + indomethacin (10 * M) or WEB 2086 (10' M)
(A-A), 10 " M rhTNFa (•-•) or preincubation with either indomethacin (10'* M) or WEB 2086 (10*
M) followed by incubation with rhTNFa (10 " M, •-•). In a) at least 8 experiments were perfor-
med pairwise. * p< 0.01 rhTNFa, blank with indomethacin and * p< 0.03 preincubation with in-
domethacin and rhTNFa versus buffer control. No significant changes were observed between the
curves of rhTNFa 10" M and the curve of rhTNFa 10" M, preincubated with indomethacin 10'
M. In b) WEB 2086 itself did not influence contractility, whereas preincubation with WEB 2086
completely inhibited TNFa-induced tracheal hyperreactivity (* p< 0.005 rhTNFa versus buffer con-
trol and p< 0.05 rhTNFa (10 " M) versus rhTNFa (10 " M) preincubated with WEB 2086.
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DISCUSSION
The present study demonstrates that rhTNFa induces bronchial hyperreactivity
in isolated tracheal rings of the guinea-pig. The specificity of the effect was ascer-
tained by a specific TNFa-antagonist that completely inhibited the induction of
bronchial hyperreactivity. Additionally, we demonstrated that PAF is involved in
the induction of hyperreactivity by TNFa.
TNFa has been shown to be involved in the development of BHR, both in animal
models [4] as well as in humans [10]. However, these studies did not show
whether TNFa affects bronchial smooth muscle directly or whether TNFa initi-
ates mediator release from other cells within the pulmonary compartment, which
secondarily induce BHR. In the present study, rhTNFa induced BHR in isolated
tracheal rings of the guinea-pig. The effects of TNFa were observed at concentra-
tions comparable with the levels found in bronchoalveolar lavage fluid of asth-
matic patients (10"'- M)[5].
So far, few studies have evaluated the effects of TNFa on bronchial contractility z'w
f/Vro. The limited data available are difficult to interpret due to different experi-
mental designs. Prolonged incubation (18 h) with TNFa (100 ng.mL') of iso-
lated tracheas of sensitized guinea-pigs did not affect carbamylcholine-induced
maximum contraction [20]. More recently, the effect of rhTNFa on isometric
contractility of human bronchial rings was evaluated [21 ]. In this study, TNFa in-
creased the maximum response to 113%. In accordance with the present study,
the investigators also observed a time delay before the onset of the effect, with the
first response starting between 8 and 16 min after incubation. Concentrations
above 10"'' M rhTNFa induced an increased response, and in agreement with our
observations, no clear dose-response effect with regard to TNFa-induced hyper-
contractility was observed.
TNFa has been shown to enhance phospholipase-A, activity in various cells, lead-
ing to synthesis of PAF [18,22]. Our experiments demonstrated that PAF is in-
volved in the TNFa-induced hypercontractility of tracheal rings /'» wVro. PAF has
a wide range of target cells, including smooth muscle cells. Moreover, PAF has
been shown to induce BHR to histamine and methacholine in guinea-pigs
[23,24]. This study did not clarify the cellular source of PAF synthesis in tracheal
rings after stimulation with TNFa. TNFa has been shown to induce PAF synthe-
sis within cells present in tracheal rings, such as endothelial and bronchial epithe-
lial cells and also in macrophages, monocytes and neutrophils [22,25,26]. Studies
with activated rat macrophages have shown that after TNFa-activation, at least 1
h is needed to detect PAF in supernatant, whereas endothelial cells release PAF not
before 2 h [22]. In the previous experiments, PAF was shown to be largely retained
within the cell in the first few hours following stimulation. Considering the time
delay in our experiment after TNFa stimulation, the present study suggests that
50Tumor Necrosis factor-a induces hyperreactivity in tracheal smooth muscle of the guinea pig in vitro
either smooth muscle cells in tracheal rings interact with cells expressing PAF at
their surface or synthesize PAF themselves [27]. The present experiment does not
permit us to specify the cellular source of PAF synthesis.
TNFa was also shown to influence intracellular [Ca^*] in smooth muscle cells of
guinea-pigs [28]. TNFa (10 ng.mL') induced large increases in cytosolic free
[Ca-*] after bradykinin stimulation. Since PAF synthesis is associated with cal-
cium mobilisation, PAF synthesis may also be involved in these experiments.
The present study did observe a steep dose-response effect for TNFa-induced
hypercontractility. This observation concurs with studies in human bronchial
rings [21]. A steep dose-response effect for TNFa-induced PAF synthesis was ob-
served in macrophages and endothelial cells [22], whereas monocytes did not
demonstrate a dose-response effect [26]. In these experiments, TNFa concentra-
tions as low as 1 ng.mL' were shown to induce PAF synthesis, whereas PAF has
been shown to possess an median effective concentration (EC^) value of 10 pM in
isolated ileal smooth muscle cells of guinea-pigs [29]. Therefore, the absence of a
clear dose-response effect of TNFa in the present study may be explained by as-
suming a threshold for TNFa effects.
In humans, both TNFa and PAF have been implicated in the inflammatory pro-
cess of asthma [1,6]. So far, studies with PAF antagonists in asthma have yielded
disappointing results. However, recently a new, very efficient PAF antagonist was
shown to reduce BHR in stable asthmatic patients [30]. The importance of PAF in
asthma was further emphasized by the demonstration of a deficiency in PAF-
acetylhydrolase activity in a subgroup of asthmatic patients [31]. If TNFa /'« two
leads to PAF production, selective inhibition of TNFa itself or its release may
prove more efficient in asthma treatment than PAF antagonists. In this context, it
should be mentioned that a potent inhibitory TNF-receptor construct was re-
cently shown to reduce both BHR and inflammatory cell influx in the late asth-
matic response in guinea-pigs [32].
In conclusion, our study shows that TNFa induces hyperreactivity in tracheal
rings and that this hyperreactivity is PAF-mediated. TNFa represents a common
pathway for different stimuli to generate bronchial hyperresponsiveness in respira-
tory disease, like allergic inflammatory lung disease, viral and bacterial infections
and in occupational asthma. Considering the central and pro-inflammatory role
of TNFa in the pathogenesis of asthma, early inhibition of events leading to BHR
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ABSTRACT
Recently, theophylline has been shown to possess immunomodulatory capacities
besides inducing bronchodilation. Aim of the present study was to evaluate the ef-
fect of theophylline on different cell populations within human lung tissue, in-
volved in the pathogenesis of asthma.
Human peripheral blood monocytes, alveolar macrophages and cultured endothe-
lial cells were stimulated with LPS or TNF-a in the presence of theophylline
(5-100 Hg/ml). Release of TNF-a, IL-6, IL-8, IL-10, sTNFR,, and sTNFR., was
measured in supernatant of cell-cultures and expression of adhesion molecules on
endothelial cells was evaluated.
In monocytes, theophylline significantly inhibited release of TNF-a and to a
lesser extent of IL-6 (p=0.04). Theophylline inhibited TNF-a release in a dose-
dependent way. Northern blot analysis in monocytes demonstrated that theophyl-
line (20 Hg/ml) inhibited production of TNF-a mRNA (inhibition of 59 ± 8%
(mean ± SEM)) and IL-6 mRNA (inhibition of 49 ± 8% (mean ± SEM)) in com-
parison to LPS alone. In monocytes, theophylline was also shown to increase
TNFR,^ shedding for low concentrations of LPS, whereas for high concentrations
of LPS theophylline was shown to decrease TNFR.^ shedding (p=0.04). In human
endothelial cells, theophylline was shown to attenuate VCAM-1 expression in
TNF-a stimulated cells (p=0.03). Theophylline did not influence release of me-
diators in alveolar macrophages, although a trend towards enhancement of IL-8
release was observed.
In conclusion, our study demonstrated anti-inflammatory properties of theophyl-
line, especially in concentrations clinically used. It supports evidence for an immu-
nomodulatory role of theophylline in the treatment of asthmatic patients.
INTRODUCTION
Theophylline is one of the most widely prescribed drugs for asthma-treatment in
the world. In the past, the primary goal for its use was considered relaxation of
bronchial smooth muscle. Theophylline is a non-selective phosphodiesterase in-
hibitor and relaxation of airway smooth muscle is widely held to be induced by the
elevation of intracellular cAMP and cGMP. However, in recent years several clini-
cal studies have implicated additional effects of theophylline in asthma treatment
besides bronchodilation. Clinical studies have shown inhibitory effects of theo-
phylline on the late asthmatic response (LAR), a response which is considered to
be associated with airway inflammation [1,2,3]. In addition, theophylline induced
in asthmatic patients changes in T-cell subsets in peripheral blood both in stable
condition [4] and after antigen-challenge [1]. Also, the observation that theophyl-
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line reduces both total and relative numbers of activated eosinophils in the bron-
chial mucosa in LAR further supports its anti-inflammatory effect [5]. With-
drawal of theophylline in stable asthmatic patients leads to deterioration of asthma
clinically and accumulation of T-lymphocytes in airway epithelium [6]. In addi-
tion to the observed effects in vivo, theophylline has immunomodulatory effects
in vitro which have recently been reviewed [7]. Theophylline shares anti-
inflammatory properties with a wider range of phosphodiesterase inhibitors like
pentoxifylline [8,9,10] and HWA 138 [11]. These compounds have been shown
to be effective in in vivo models of endotoxin induced cytokine release [8,11,12]
and a common observation is inhibition of TNF-a release. In asthma, TNF-a and
IL-6 release have been reported to be elevated in BAL-fluid after allergen challenge
[13] and in stimulated BAL-leucocytes [14]. Also, TNF-a has been shown in
healthy human volunteers to induce bronchial hyperresponsiveness [15]. TNF-a
is a very potent stimulator of adhesion molecule expression and therefore may play
an important role in upregulating adhesion-molecule expression in bronchial mu-
cosa, an important characteristic in asthma [16,17,18].
So far, few reports have extensively investigated the immunomodulatory role of
theophylline in regard to cytokine release and adhesion molecule expression in the
various cell types present within the human airways. In this study, we have investi-
gated the influence of theophylline on the response of human monocytes, alveolar
macrophages and endothelial cells to cytokines and LPS.
MATERIAL AND METHODS
Reagents
Recombinant human (rh) TNF-a was kindly provided by BASF/Knoll (Lud-
wigshafen, FRG). Fibronectin was kindly provided by Dr. van Mourik (CLB,
Amsterdam, The Netherlands). LPS (from Escherichia Coli, Serotype O55:LB5),
heparin, and L-isoproterenol, were purchased from Sigma (St. Louis, MO), theo-
phylline from OPG-farma (Utrecht, The Netherlands) and endothelial cell
growth supplement from Collaborative Research Incorporated (Bedford, MA).
RPMI-1640, was obtained from Gibco Europe (Paisley, Scotland) and DMEM
and RAM's F12 from ICN Biomedic Inc. (Costa Mesa, CA). Bovine calf serum
(BCS) was purchased from HyClone (Logan, UT) and foetal calf serum (FCS)
from Boehringer Mannheim (Mannheim, Germany). Human serum (HS), ob-
tained from healthy donors at the Red Cross blood bank Zuid Limburg (Maas-
tricht, The Netherlands) after informed consent for research was given, was
pooled and sterilized by 0.2 |im filter. The sera, which were heated at 56°C for 30
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minutes before storage at 4°C, contained < 5 pg/ml endotoxin, as determined in
the Limulus-assay (Coatest, KabiVitrum, Stockholm, Sweden).
GTC-solution consisted of 4 mM guanidinium isothiocyanate, 25 mM sodium
acetate, 118 mM 2-mercaptoethanol, 18 mM N-lauroylsarcosine; CsCl-solution
consisted of 5.7 M caesiumchloride, 4 Mm tetrasodiumsalt-dihydrat pH 8.0;
HES solution: 10 mM HEPES pH 7.4, 5 mM tetrasodiumsaltdihydrat pH 7.5,
0.1% sodium dodecyl sulfate; 10*MPS: 200 mM 3-morpholinopropane sulfonic
acid, 80 mM sodium acetate and 10 mM tetrasodiumsaltdihydrat; 20*SSC: 3 M
sodium chloride, 0.33 M sodium citrate.
Probes: IL-6 probe: 0.3 kb HIII-EcoRI fragment in bluescribe Ml3, kindly pro-
vided by Dr. L. Aarden, CLB, Amsterdam, The Netherlands; TNFa-probe: 0.615
kd EcoRI-Cla fragment in plasmid pMGl99, kindly provided by M. Robinson,
Celltech, Slough, UK, and the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) probe: 1.007 kb EcoRI-BamHI fragment in plasmid PSKII+, kindly
provided by Dr. R.G. Crystal, National Institute of Health, Bethesda, MA.
CELLS
Monocytes were obtained from blood kindly provided by the Red Cross Blood
Bank Zuid Limburg, donated by volunteers, which gave informed consent for re-
search. Monocytes were isolated as described previously [19]. In short, mononu-
clear cells obtained after Lymphoprep (Nycomed, Oslo, Norway) centrifugation
were allowed to clump by low speed centrifugation at 4°C. Cell clumps were sepa-
rated from the rest of the cells by sedimentation through ice-cold BCS. The ob-
tained cell suspensions consisted for 80 to 95% of monocytes.
Alveolar macrophages (AM) were recovered from the lung by bronchoalveolar
lavage (BAL) obtained during fiberoptic bronchoscopy of volunteers without un-
derlying pulmonary pathology, after informed consent had been obtained. The
lavage was performed in the following way: 200 mL of NaCl 0.9 %, prewarmed at
37 °C, was instilled into a bronchial segment, in four aliquots. Each aliquot was as-
pirated immediately after inspiration. The first aliquot was discarded, whereas the
second, third and fourth aliquot were pooled and filtered through a sterile nylon
gauze. Total cell content, which consisted for >90% of AM, were used for stimula-
tion experiments.
Human umbilical vein endothelial cells (HUVEC) were obtained by collagenase
treatment of the human umbilical vein, as described previously [20]. The cells
were cultured in fibronectin coated tissue culture flasks (Costar, Cambridge, MA)
in medium consisting of RPMI-1640, 10% HS, 10% BCS, 50 Hg/ml heparin, 30
|ig/ml endothelial cell growth supplement and antibiotics.
58Evaluation of immunomodulatory properties of theophylline
STUDY-DESIGN
Monocytes and AM (5*10^ cells/ml) were cultured in 96-well flat bottom tissue
culture plates (Costar) in standard medium consisting of RPMI-1640, 10% BCS
and antibiotics. Cells were preincubated for 4 hours with different concentrations
of theophylline, followed by a 18 hour incubation period with a concentration
range of LPS. The supematants were harvested and kept at -20°C until determina-
tion of inflammatory mediator levels.
To study the effect of theophylline on LPS-induced monocyte-activation at
mRNA levels, mononuclear leucocyte fraction of blood was used, to prevent loss
of monocytes during the isolation procedure. Contaminating lymphocytes did
not disturb this assay since they do not respond to LPS by producing TNFa or
IL-6. Cells (30 ml a 3*10''/ml), incubated in tissue flasks, were 45 minutes prein-
cubated with theophylline (20 |ig/ml). After 3 hours stimulation with LPS (1
|ig/ml), cells were treated as indicated below for analysis of mRNA content.
HUVEC of passage 3 were seeded at 10* cells/well in fibronectin-coated 96-well
flat-bottom tissue culture plates in culture medium as decribed above, one or two
days prior to stimulation. When HUVEC monolayers were confluent, cells were
rinsed once with RPMI-3% BCS, and cells were stimulated in standard medium.
After 4 hours preincubation with theophylline, cells were stimulated with LPS or
TNFa. For analysis of cell surface expression of E-selectin, cells were stimulated
for 5 hours whereas for detection of ICAM-1 and VCAM-1 expression, and for re-
lease of IL-6 and IL-8 in culture supernatant, cells were stimulated during 18
hours. Supernatant was harvested and stored at -20°C, until analysis, whereas cells
were fixed for detection of adhesion molecule expression, as described below.
Assays for inflammatory mediators in supernatant
TNF-a, IL-6, IL-8, IL-10, soluble TNF-Receptor-55 (sTNFRJ and sTNFR_,
(sTNFR^)-levels in the culture supematants were determined using sandwich-
ELISA's as described previously [21,22,23,24]. In short, for measurement of
TNFa mAb 61E71 was used as catching reagent, whereas specific polyclonal rab-
bit anti-human TNFa Ab was used for detection. rhTNFa was used as standard,
and the detection limit of the assay was 10 pg/ml. For measurement of IL-6, mAb
5E1 was used as catching reagent and specific polyclonal rabbit anti-human IL-6
Ab for detection. The standard rhIL-6 was kindly provided by prof W. Sebald,
Physiologisch-Chemisches Institut der Universitat, Wiirzburg, Germany, and the
detection limit of the assay was 10 pg/ml. mAb HM.5 was used for catching of
IL-8, whereas IL-8 was detected by biotin labeled polyclonal rabbit anti-human
IL-8 IgG. rhIL-8 used as standard was kindly provided by dr. Lindley, Sandoz
Forschungsinstitute. IL-8 could be detected with a lower detection limit of 10
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pg/ml. For IL-10 measurement, mAB HB11677 (rat-anti-human IL-10) was used
as catching antibody, whereas biotinylated mAB HB11677 was used for detection
of IL-10. Both HB11677 and rh-ILlO were kindly provided by dr. van de Waal
Malefyt (DNAX, Palo Alto, CA). The detection limit for the IL-10 assay was 20
pg/ml. For measurement of sTNFR^ and sTNFR,,, mAb MR1-1 and MR2-2
were used as catching reagent respectively. Specific biotin labeled polyclonal rab-
bit anti-human sTNFR IgG were used as detector reagents. The standards used
were rh-sTNFR^ and rh-sTNFR^, kindly provided by M. Bodmer (Celltech,
Slough, UK). The detection limit of both assays was 100 pg/ml.
96-Well immuno maxisorp plates (Nunc, Roskilde, Denmark) were used for the
ELISA assay. Biotinylated samples were analyzed with peroxidase labeled strepta-
vidine (Dako, Glostrup, Denmark), whereas non-labeled rabbit anti-human Ab
were detected by peroxidase conjugated goat anti-rabbit IgG (Jackson, Westgrove,
PA). Peroxidase activity was determined by addition of TMB (3,3',5,5-
tetramethylbenzidine) substrate (Kirkegaard &: Perry Lab., Gaithersburg, MD)
and photospectrometry (450 nm) was performed using a micro-ELISA
autoreader.
Adhesion molecule expression
For detection of adhesion molecule expression, HUVEC were washed with
phosphate-bufifered saline (PBS) supplemented with 4 mM Ca++ and 2.5 mM
Mg++, and fixed with 0.025% glutaraldehyde for 10 min at room temperature
(RT). Cell-surface expression of E-selectin, ICAM-1 and VCAM-1 was detected
by incubation for 2 h at RT with mAbs ENA-1 (anti-E-selectin) [25], RR-1 (anti-
ICAM-1, a kind gift of Dr. R. Rothlein, Boehringer Ingelheim Pharmaceuticals,
Inc., Ridgefield, CT) and 1G11 (anti-VCAM-1, a kind gift of Dr. D.O. Haskard,
Hammersmith Hospital, Department of Rheumatology, London, U.K. [26]) re-
spectively, followed by incubation with peroxidase-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch, West Grove, PA) for 1 h. Peroxidase activity was
determined as described above.
mRNA analysis
RNA was isolated from cells as described by Davis ««/. [27], using a 4M GTC-
solution. The ultracentrifugation, northern blot analysis, hybridization (including
GAPDH as control probe) and semiquantitative analysis was performed as de-
scribed before [28]. mRNA expression of TNFa and IL-6 was determined rela-
tively to the expression of the control gene GAPDH. The hybridization signals
were analyzed semiquantitatively with a phosphor-imaging system (Molecular
Dynamics, Sunnyvale, CA).
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STATISTICAL ANALYSIS
The results shown are expressed as mean ± SEM of independent experiments, un-
less otherwise specified. Cytokine release in each individual experiment represents
the mean of four replicates. Differences within groups were analyzed using two-
tailed Wilcoxon signed-rank test for paired data. In order to evaluate dose-
response effects for theophylline in the experiments with monocytes and alveolar
macrophages, the slope of cytokine-release for different concentrations of theo-
phylline was calculated in individual experiments for each concentration of LPS.
The slope was defined by the formula (-3Y,-Y,+Y,+3Y,)/10 [29], wherein Y,, Y,, Y,
and Y, stand for cytokine-release respectively at concentrations 0, 5, 20 and 80
|ig/ml of theophylline. In each experiment the calculated slope was tested by Wil-
coxon signed-rank test against the hypothesis that the slope equalled 0 (= no dose-
response effect). A p-value < 0.05 was considered statistically significant.
RESULTS
Effect of theophylline on monocytes
Stimulation of monocytes with a concentration-range of LPS for 18 hours resulted
in a dose-dependent increase in release of TNF-a, IL-6, IL-8 and shedding of
TNF-FL,, (Fig. 1). No significant spontaneous release was observed for TNFa,
whereas we detected spontaneous release for IL-6, IL-8 and TNF-R.,. Theophyl-
line (concentrations 5-80 (ig/ml) exhibited a significant inhibition of LPS-
induced TNFa-release, maximum inhibition observed amounted 79 ± 6% SEM
(p=0.04). Dose-dependent inhibition of TNFa release by theophylline was dem-
onstrated for 10 and 1000 ng/ml LPS, as demonstrated by statistically significant
slopes for the concentrations of theophylline used (p=0.02). IL-6 release was mod-
erately inhibited by theophylline (Fig. lb). In most experiments, a small decrease
in IL-6 release was observed for all concentrations of theophylline used, however
statistical significance was only achieved with LPS 10 ng/ml and theophylline 5
and 20 (ig/ml (p= 0.04). In contrast to the effect upon LPS induced TNF-a and
IL-6 release, theophylline did not affect IL-8 release (Fig. lc). Theophylline influ-
enced release of TNF-FL< in two different ways: at a low concentration of LPS
(100 pg/ml), theophylline induced a dose-related increase in sTNF-R., (p=0.04),
whereas at 1000 ng/ml LPS theophylline significantly decreased sTNF-R,, in a
dose-dependent way (p=0.04) (Fig. Id).
Experiments, evaluating the involvement of IL-10 release in theophylline induced
inhibition of TNFa and IL-6 release, demonstrated that LPS induced a dose-


















Figure 1. Effects of theophylline on a:) TNF-a-, b:) IL-6-, c:) IL-8- and d:) sTNFR.< release in peri-
pheral blood monocytes. Monocytes (5.10* cells/ml), preincubated for 4 hours with different con-
centrations of theophylline (open bars: control medium; hatched bars: 5 ng/ml; double-hatched
bars: 20 ng/ml; solid bars: 80 ng/ml), were incubated overnight with a concentration range of LPS.
Data are expressed as mean ± SEM of five experiments. Theophylline inhibits TNF-a release and in-
duces a moderate inhibition of IL-6 release in LPS-stimulated monocytes (*p= 0.04 in comparison
to control), whereas theophylline did not modulate IL-8 release. Theophylline induces an inhibi-
tion of STNF-R75 release in monocytes in the higher concentration range of LPS, whereas in the lo-
wer concentration of LPS theophylline induces an increase in TNF-R75 shedding (* p= 0.04 in
comparison to control).
shown to inhibit cytokine release at LPS concentrations of 10 and 1000 ng/ml, no
significant changes were observed in IL-10 release within the duration of the ex-
periments. Moreover, a trend towards inhibition of IL-10 release was observed for
monocytes, coincubated with theophylline and LPS (100 ng/ml and 1
Hg/ml)(p=0.07).








Figure 2. Theophylline does not influence IL-10 release in LPS-stimulated
monocytes. Monocytes (5.10/" cells/ml), preincubated for 4 hours with dif-
ferent concentrations of theophylline (open bars: control medium; hat-
ched bars: 5 ng/ml; double-hatched bars: 20 ng/ml), were incubated over-
night with a concentration range of LPS. Data are expressed as mean ±
SEM of four experiments. A trend towards a reduction of IL-10 release
was observed (p=0.07).
Effect of theophylline on alveolar macrophages
As expected, stimulation of alveolar macrophages with LPS during 18 hours in-
duced a dose-dependent increase in TNF-a, IL-6 and IL-8 release (Fig. 3a-c). Al-
veolar macrophages produced greater quantities of TNF-a and IL-8 in compari-
son to peripheral blood monocytes. LPS induced dose-dependent shedding of
TNF-R_^ in alveolar macrophages comparable to results obtained in peripheral
blood monocytes (Fig. 3d). In contrast to monocytes, alveolar macrophages did
also shed TNF-R^, however quantities were small and no dose-response relation
to LPS was observed (data not shown). Theophylline did not affect TNF-a, IL-6,
sTNF-R^ or sTNF-R_^ release by alveolar macrophages, in contrast to results ob-
tained in monocytes. Moreover, theophylline appeared to induce a dose-












Figure 3. Effect of theophylline on a:) TNF-a-, b:) IL-6-, c) IL-8-and d:) sTNF-R^ release in alveolar
macrophages. Alveolar macrophages (5.10' cells/ml) were isolated from BAL-fluid, preincubated
for 4 hours with different concentrations of theophylline (open bars: control medium; hatched
bars: 5 ng/ml; double-hatched bars: 20 ng/ml; solid bars: 80 (ig/ml) and thereafter incubated
overnight with a concentration range of LPS. Data are expressed as mean ± SEM of four experi-
ments. Theophylline did not modulate TNF-a nor IL-6 release, whereas a moderate enhancement
of IL-8 release by theophylline was observed. In contrast to monocytes, theophylline did not influ-
ence sTNFR,; release in alveolar macrophages.
Effect of theophylline on endothelial (HUVEC) cells
Both LPS and TNF-a stimulated endothelial cells showed a dose-response effect
for expression of E-selectin (after 5 hours) and ICAM-1 and VCAM-1 (after 18
hours) (Fig. 4). TNF-a stimulated expression of adhesion-molecules at lower con-
centrations than LPS. Theophylline (100 |Xg/ml) significantly attenuated
VCAM-1 expression in TNF-a stimulated HUVEC (p=0.03). No effect of theo-
phylline was observed on LPS- or TNF-a stimulated expression of ICAM-1 and
E-selectin.
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Figure 4. Effect of theophylline on expression of a:) VCAM-1, b:) ICAM-1 and c) E-Selectin-1 in
LPS- and TNF-a-stimulated HUVEC. Endothelial cells were isolated, preincubated for 4 hours with
theophylline (open bars: control medium; double-hatched bars: 20 ng/ml; solid bars: 100 jig/ml)
and thereafter stimulated for 5 ( E-selectin) or 18 hours (VCAM-1, ICAM-1) with LPS (0, 10 and
1000 ng/ml) and TNF-a (1, 10, 100 pg/ml). Data are expressed as mean ± SD. The experiment was
repeated at least four times; results of one representive experiment are given. Theophylline in high
concentration (100ng/ml) significantly attenuated TNF-a induced VCAM-1 expression on HUVEC
(*p= 0.03).
LPS and TNF-a also dose-dependently stimulated IL-6 and IL-8 release in
HUVEC. Theophylline did not influence IL-8 release. Although theophylline at-
tenuated IL-6 release in some cultures, this effect was only observed in high con-
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Figure 5. Theophylline inhibits TNF-a and IL-6-mRNA accumulation in LPS stimu-
lated peripheral blood mononuclear cells. Cells (30 ml, concentration 3.107ml)
were preincubated for 45 minutes with theophylline (20 ng/ml) or medium and
subsequently stimulated with LPS (lug/ml) for 3 hours. The experiment was re-
peated three times. The upper panel shows representive Northern blot autora-
diographs for TNF-a-, IL-6 and GAPDH mRNA. The left lane represents culture
medium, the medium lane culture medium with LPS (1 ng/ml) and the right lane
represents cells, preincubated with theophylline (20 ug/ml) and stimulated with
LPS (1 ug/ml). The lower panel represents phosphor-densitometry, wherein the-
ophylline was shown to reduce TNF-a mRNA by 59 % and IL-6 mRNA by 49% in
comparison to stimulation with LPS alone.
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Effect of theophylline on the transcription of TNF-oc and IL-6 in LPS-stimulated
peripheral blood mononuclear cells.
After isolation of peripheral blood mononuclear cells (PBMC) and culturing in
regular medium, only very small amounts of mRNA for TNF-a and IL-6 were de-
tectable. Incubation of PBMC with LPS resulted in a distinct increase in TNF-a-
and IL-6-mRNA. In all three experiments performed, the same pattern was ob-
served; theophylline (20 |ig/ml) inhibited LPS-induced TNF-a mRNA accumu-
lation 59 ± 8% (mean ± SEM of three experiments) in comparison to LPS and in-
hibited LPS-induced IL-6 mRNA accumulation 49 ± 8% (mean ± SEM) in
comparison to LPS (Fig. 5).
DISCUSSION
In our study, theophylline inhibited LPS-induced TNF-a release in peripheral
blood monocytes dose-dependently. Theophylline also decreased LPS-induced
TNF-a mRNA accumulation. Also for IL-6, both in supernatant and on mRNA-
level, theophylline was shown to inhibit IL-6 production. Our study confirmed
observations from previous studies, demonstrating that theophylline [30] and
odier xanthines [9,10,31] inhibit TNF-a production in monocytic cells. Re-
cently, specific type IV and III/IV phosphodiesterase (PDE)-inhibitors were also
found to inhibit LPS-induced TNF-a release in mouse peritoneal macrophages
[32,33]. Data from studies with PGE, [34,35,36], PDE-inhibitors and cAMP-
elevating agents [9,33] relate the observed inhibition of TNF-a to the increase in
intracellular cAMP. However, a discrepancy remains between the observed inhibi-
tion of TNFa release and accumulation of cAMP, as was shown with pentoxifyl-
line (250 |iM), that induced only minor increases in intracellular cAMP, whereas
evident inhibition of TNF-a was observed [37]. Therefore, additional pathways
may be involved in the inhibitory effect of theophylline on TNFa release.
An explanation may be provided by studies with PGE,, implying involvement of
IL-10 in modulation ofcytokine release [38]. PGE, enhanced IL-10 production in
LPS-stimulated murine peritoneal macrophages and IL-10 was shown to be in-
volved in the inhibition of TNFa and IL-6 release. Therefore, the mechanism of
theophylline or other PDE-inhibitors might also involve IL-10. The present study
showed that theophylline did not enhance levels of IL-10, whereas a clear inhibi-
tion of TNFa was observed. These observations do not fit in with observations
from a previous study with specific type IV PDE-inhibitors, that decreased TNFa
release, while at the same time enhanced levels of IL-10 were observed [33]. These
specific type-IV PDE-inhibitors were shown to inhibit TNFa release at much
lower concentrations than theophylline in the present study. Although higher
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concentrations of theophylline might enhance IL-10 release, these concentrations
are toxic in patients. The observed trend towards a decrease in IL-10 release, ob-
served with different concentrations of theophylline in the present study, may be
explained by TNFa. Since TNFa is able to enhance IL-10 release in monocytes
[39], decreased levels of TNFa, induced by theophylline, may secondarily lead to
reduced levels of IL-10 in supernatant.
The inhibition of TNFa mRNA accumulation by theophylline in human cells,
observed in the present study, are in line with data from murine macrophages [9].
The present study suggests that theophylline primarily inhibits TNFa-mRNA ac-
cumulation, whereas IL-10 might be involved in the late phase inhibition of
TNFa release, although this was not observed in the present study. cAMP might
be involved in both pathways since cAMP inhibits TNFa gene-transcription [40]
and enhances IL-10 release, since the IL-10 gene contains a cAMP responsive ele-
ment [39].
In the present study, theophylline was also shown to inhibit IL-6 production in
LPS stimulated monocytes, although to a lesser degree than TNF-a. The inhibi-
tion was more prominent on mRNA-level than on protein level, suggesting that
post-transcriptional mechanisms are involved, which compensate for effects of
theophylline on mRNA. This observation is clearly different from observations in
previous studies, that showed no influence of methylxanthines on IL-6 [12,32]. In
contrast, specific type IV phophodiesterase inhibitors, mentioned above, were also
shown to inhibit IL-6 release in peritoneal macrophages [33]. It may be argued
that the downregulation of IL-6 mRNA, observed in the present study, may occur
as a result of the decreased release of TNFa, since it is known that TNF-a stimu-
lates IL-6 release, certainly within the time-span of our experiment [41]. However,
observations of evident downregulation of IL-6 mRNA 3 hours after LPS-
stimulation do not favour the influence of TNF-a, since at that moment TNF-a
release has just started.
We also investigated the influence of theophylline on IL-8 release. IL-8 belongs to
the family of C-X-C-chemokines and represents a powerful neutrophilic chemo-
attractant and activator. Alveolar macrophages were shown to be very potent pro-
ducers of IL-8 in comparison to peripheral blood monocytes. Although IL-8 re-
lease was not influenced by theophylline in monocytes, theophylline appeared to
enhance LPS-induced IL-8 release in alveolar macrophages. In contrast to periph-
eral blood monocytes, theophylline did not influence cytokine release in LPS-
stimulated alveolar macrophages. This observation is in line with previous obser-
vations, wherein 1000-fold higher concentrations of PGE, were needed for similar
inhibition of TNF-a release in human alveolar macrophages in comparison to
PBMC [42]. The different effects of theophylline on alveolar macrophages and
blood monocytes can be explained by differences in PDE-activity or PDE-
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isoenzyme distribution within cell populations [43]. Moreover, differences may
exist within macrophage cell populations, since, in contrast to data presented
above, pentoxifylline induced a 50 % inhibition in TNF-a release in human inter-
stitial pulmonary macrophages [44].
Since adhesion-molecules play an important role in leucocyte-trafficking and
therefore represent a potential target for immunomodulation, the influence of
theophylline on the expression of adhesion-molecules on endothelial cells was
evaluated. Theophylline partially inhibited TNF-a induced VCAM-1 expression,
whereas no influence was observed on E-selectin and ICAM-1 expression.
VCAM-1 is a member of the immunoglobulin superfamily and interacts with the
integrin very late antigen-4 (VLA-4) on circulating lymphocytes and eosinophils
and plays a role in lymphocyte trafficking to sites of inflammation. Our observa-
tions are in line with studies reporting similar inhibitory effects of caffeine (10
mM) on IFN-y stimulated VCAM-1 expression in murine endothelial cells [45]
and the effects of forskolin and isobutylmethylxanthine on VCAM-1 expression
in TNF-a stimulated HUVEC [46]. Furthermore, modulation of VCAM-1 ex-
pression by theophylline could explain accumulation of activated T-lymphocytes
in the bronchial mucosa, observed after withdrawal of theophylline in stable asth-
matic patients [6].
Our study confirmed previous observations, that LPS enhances TNF-receptor
shedding in peripheral blood monocytes [47] and, in addition, showed that LPS
induced TNF-receptor shedding in human alveolar macrophages. Different pat-
terns in TNF-receptor shedding were observed between monocytes and alveolar
macrophages: in monocytes, LPS induced release of sTNF-R.^, whereas in alveolar
macrophages release of both TNF-R.^ and TNF-R^ was observed, both spontane-
ously and after LPS-stimulation. Interestingly, TNF-R.^ shedding was more
influenced by LPS than TNF-R^., in contrast to data from a previous report [48].
In monocytes, a dichotomy was observed in the response to LPS: theophylline in-
creased TNF-R., shedding in low concentrations of LPS, whereas, for high con-
centrations of LPS theophylline decreased shedding of TNF-R.^. The decrease of
TNF-R,,. shedding could be due to a direct effect of theophylline or due to the in-
hibition of TNF-a release, induced by theophylline. Our results concur with in
vivo effects of pentoxifylline and chlorpromazine in LPS-treated mice [8]. Despite
TNF-a reduction by pentoxyfylline and chlorpromazine, only for chlorpromazine
a significant decrease in sTNF-R., was observed. Biological effects of enhanced
TNF-receptor shedding are not clear, however studies have implicated a role for
sTNF-R., in neutralization of TNF-a in vivo [49,50].
Our study demonstrated relatively modest immunomodulatory effects of theo-
phylline /'« p/iro. Animal studies have observed that theophylline inhibited the in-
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flammatory reaction and the development of bronchial hyperresponsiveness after
allergen-exposure [51,52,53,54]. In human studies, the role of theophylline in
asthma management is undisputed, both in low and high concentrations
[1,2,3,5,6,55]. The different magnitudes of effect, observed in «'« w'/ro experi-
ments and effects of theophylline /'« two, can be explained in some ways. Cells,
used in the present study, were obtained from healthy human volunteers, in whom
theophylline in dierapeutic concentrations induces a relatively minor inhibition of
phosphodiesterase activity [56,57]. In atopic disease, theophylline inhibits PDE-
activity more efficiently in cells from atopic individuals than from healthy indi-
viduals, probably due to an increased expression of phosphodiesterase [58]. This
may explain why theophylline induces bronchodilation in asthmatic patients,
whereas it lacks bronchodilatory effects in normal individuals [59]. Therefore, the
immunomodulatory effects of theophylline, observed in the present study, may be
magnified in atopic disease and may explain part of the beneficial effects of theo-
phylline, observed in studies with asthmatic patients [55].
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SUMMARY
Long-acting p,-adrenoceptor agonists improve asthma-control and pulmonary
function. Aim of the present study was to analyse effects of salmeterol and salbuta-
mol, respectively a long- and short-acting P,-adrenoceptor agonist, on the release
of pro-inflammatory cytokines in human monocytes /« w'fro. Pro-inflammatory
cytokines, like TNFa, are involved in both asthmatic inflammation and induc-
tion of bronchial hyperresponsiveness.
Human blood monocytes of healthy volunteers were isolated and incubated with
different concentrations of salbutamol (10''MO'*' M) and salmeterol (10""MCK'
M). After overnight incubation with LPS (0-1 |Ig.mL')> TNFa-, IL-6-, IL8- and
IL-10-release was determined in supernatant by specific ELISA.
The study shows that both salmeterol (n=8) and salbutamol (n=9) significantly
inhibited TNFa release (maximum inhibition respectively (mean ± SEM) 47 ±
8% and 46 ± 5%, p< 0.03), and a trend in inhibition of IL-6 release was observed.
In contrast, salbutamol and salmeterol increased IL-10 release in LPS-stimulated
monocytes (1 (Ig.mL') (n=7). Evidence for the primary involvement of the
P-adrenoreceptor was demonstrated by the complete reversal of the inhibitory
effects of salbutamol and salmeterol (10~^ M) on TNFa release by coincubation
with propranolol (lO"'* M) (n=4). mRNA-analysis showed that both salmeterol
and salbutamol (10'' M) inhibited LPS-induced TNFa-mRNA accumulation
(inhibition respectively (mean ± SEM) 73 ± 5% and 64 ± 2%) and IL-6 mRNA
accumulation (respectively 42 ± 9% and 37 ± 12%).
In conclusion, salmeterol and salbutamol decreased pro-inflammatory cytokine
release and inhibited accumulation of mRNA encoding for TNFa and IL-6 in
LPS-stimulated monocytes /'« f/'m>. Observations from the present study may ex-
plain part of the immunomodulatory effects of long-acting p,-adrenoceptor ago-
nists /'» «'i>0.
INTRODUCTION
Long-acting p,-agonists, like salmeterol, provide better asthma control and pul-
monary function improvement than short-acting p,-sympaticomimetic drugs,
like salbutamol [ 1 ]. Besides bronchodilatory effects, salmeterol has been demon-
strated to have antiinflammatory effects [2], although in some respects this has
also been observed for short-acting P,-agonists. Salbutamol has been shown to in-
hibit histamine release in human lung mast cells [3] and to reduce the early and
late asthmatic response [4]. Salmeterol, which possesses more than fifteen times
the potency of salbutamol on P,-adrenoceptor activation in airway smooth muscle
[5], inhibits mediator release in mast cells, eosinophils, neutrophils and alveolar
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macrophages z'w i>/m> [5]. Furthermore, salmeterol has been shown to inhibit me-
diator release in both passively sensitized human lung [6] and in segmental aller-
gen challenge [7] and to protect against the allergen-induced late asthmatic re-
sponse (LAR) in patients [8,9]. In asthmatic patients, salmeterol also protected
against non-specific bronchial hyperresponsiveness, as assessed by distilled water
bronchoprovocation, independent of the bronchodilatory effects induced by sal-
meterol [10]. Despite the proven antiinflammatory effects of salmeterol in both »'n
w'fro and acute broncho-provocation experiments, clinical studies evaluating pos-
sible anti-inflammatory effects of salmeterol are less unequivocal in this point. Al-
though long-term use of salmeterol did not result in detectable changes in chronic
asthmatic airway inflammation as evaluated in both bronchial biopsies [11] and
bronchoalveolar lavage (BAL) [12], the addition of long-acting p,-agonists to in-
haled corticosteroid therapy was shown to result in better control of symptoms
and improvement in PEFR in asthmatic patients [13,141. These observations sug-
gest that long-acting (3,-agonists may influence inflammation ;» wVo. This hy-
pothesis is supported by data from studies with other cAMP-elevating drugs (like
theophylline and PGE,), which have been shown to inhibit the release of TNFa IH
w'tro [15,16,17]. TNFa, a pro-inflammatory cytokine, has been shown to play an
important role in asthmatic inflammation. TNFa induces the release of inflam-
matory mediators [18] and enhances the expression of adhesion molecules on en-
dothelial cells, which represents an important step necessary for tissue infiltration
of inflammatory cells. In addition, TNFa has been shown to induce bronchial hy-
perresponsiveness [18,19,20].
Aim of the present study was to evaluate the effect of salmeterol and salbutamol on
the release of proinflammatory cytokines (TNFa, Interleukin (IL)-6 and IL-8)
and on IL-10, an immuno-regulatory cytokine, in lipopolysaccharide (LPS)-stim-
ulated human monocytes /» w'/ro. In the present study, peripheral blood mono-
cytes are used since they can easily be obtained and can be regarded as progenitor
cells of airway macrophages, which are involved in the asthmatic inflammation.
The present study demonstrates that salmeterol and salbutamol inhibited LPS-
induced monocyte-derived TNFa, both at the level of mRNA as well as at protein
levels in supernatant. Salmeterol and salbutamol also decreased LPS-induced IL-6
mRNA accumulation, whereas effects on IL-6 protein levels in supernatant were
smaller. In addition, it was shown that salmeterol and salbutamol increased IL-10




LPS (from Escherichia Coli, serorype 055: LB5) was obtained from Sigma Chemi-
cals, Inc. (St. Louis, Mo). Recombinant human (rh) TNFa was kindly provided
by BASF/Knoll (Ludwigshafen, Germany); rhIL-6 was provided by W. Sebald
(Wiirzburg, Germany); rhIL-8 was provided by I. Lindley (Vienna, Austria);
rhIL-10 and HB11677 were kindly provided by Van de Waal Malefyt (Palo Alto,
CA). RPMI-1640 was obtained from Gibco, Europe (Paisley, Scotland). Bovine
calf serum (BCS), obtained from Hyclone (Logan, UT), was heat-inactivated for
30 min at 56" C and stored at 4° C. Salbutamol and Salmeterol were a kind gift
from Glaxo-Wellcome BV, the Netherlands. Propranolol was obtained from ICI-
pharma.
GTC-solution consisted of 4 mM guanidinium isothiocyanate, 25 mM sodium
acetate, 118 mM 2-mercaptoethanol, 18 mM N-lauroylsarcosine; CsCl-solution
consisted of 5.7 M caesiumchloride, 4 Mm tetrasodiumsalt-dihydrat pH 8.0;
HES solution: 10 mM HEPES pH 7.4, 5 mM tetrasodiumsaltdihydrat, pH 7.5,
0.1% sodium dodecyl sulfate; 10*MPS: 200 mM 3-morpholinopropane sulfonic
acid, 80 mM sodium acetate and 10 mM tetrasodiumsaltdihydrat; 20*SSC: 3 M
sodium chloride, 0.33 M sodium citrate.
Probes: the TNFa-probe, 0.615 kd EcoRl-Cla fragment in plasmid pMG199,
was kindly provided by M. Robinson, Celltech (Slough, UK). 11-6 probe, 0.3 kb
HIII-EcoRl fragment in bluescribe Ml3, was provided by L. Aarden, CLB (Am-
sterdam, The Netherlands).
Preparation of solutions of salbutamol and salmeterol
Salbutamol (C,,H,,NO,, MW 239.4) and salmeterol (C,,H,.NO,, MW 415.6)
were obtained in micronized form. Solutions of salbutamol and salmeterol were
either feshly prepared or diluted from stock solutions (10"-' M). Salbutamol was di-
luted in sterile bidest. Salmeterol, due to its low solubility (0.13% at pH 6.8), was
diluted in phosphate-buffered saline (PBS), acidified with glacial acetic acid, until
a clear solution was obtained.
Cell isolation and stimulation
Buffy coats were kindly provided by the Red Cross Blood Bank Zuid-Limburg,
Maastricht, The Netherlands. Blood was donated by healthy volunteers, after in-
formed consent for research was obtained. Human monocytes were isolated from
buffy coats, essentially according to the method described by Graziano rt
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Briefly, mononuclear cell suspensions obtained after density gradient centrifuga-
tion on Lymphoprep (Nycomed, Oslo, Norway) were allowed to clump at low
speed centrifiigation at 4° C. Cell clumps were separated by sedimentation
through icecold BCS, resulting in cell suspensions consisting of more than 85 %
monocytes. Monocytes were resuspended in RPMI 1640 supplemented with 10%
BCS, 2 mMol L-glutamine, 100 IU/ml penicillin and 100 |J.g/ml streptomycin,
plated on 96-well, flat-bottom tissue culture plates (Costar) at 5. 10^ cells.mL'
(200 ^1 per well) and incubated at 37°C. The cells were preincubated for 15 min
with salbutamol (10''MO'"* M), salmeterol (10"'"-10"'' M) or control medium and,
thereafter, stimulated overnight with different concentrations of LPS (1, 100 and
1000 ng.mL'). Supernatants of cells were harvested (for analysis of TNFct, IL-6,
IL-8 and IL-10) and stored at -70" C until determination. Each experiment was
performed at least in quadriplicate. Interindividual differences were discarded by
comparing the effects of salbutamol and salmeterol in monocytes of the same do-
nor.
Viability of the cells, as measured by trypan blue exclusion, was not affected by any
of the reagents used (viability above 90-95%).
CYTOKINE ASSAYS
Cytokines in supernatant were determined using previously described sandwich
ELISA's for TNFa, IL-6, IL-8 and IL-10 [22,23,24]. In short, 96-well Immuno
Maxisorp plates (Nunc, Roskilde, Denmark) were coated overnight at 4" C with
cytokine specific murinemAb 61E71 (anti-TNFa), 5E1 (anti-IL-6), HM5 (anti-
IL8) and HB11677 (rat anti-hlLlO). Recombinant human TNFa, IL-6, IL-8 and
IL-10 were used as standards. Samples were added and incubated for 1 to 3 h at
room temperature. Therafter, samples were incubated with polyclonal rabbit
anti-human TNFa, biotinylated polyclonal rabbit anti-hIL-6 and anti-hIL-8, and
biotinylated rat-anti-hIL-10 at room temperature for 1 h, followed by 1 h incuba-
tion with peroxidase conjugated goat anti-rabbit IgG (Jackson, West Grove, PA)
for TNFa and with peroxidase labeled streptavidin for IL-6, IL-8 and IL-10. Fi-
nally, 3,3',5,5'-tetramethylbenzidine (Kirkegaard & Perry Laboratories, Inc.,
Gaitersburg, MD) was added as substrate. The reaction was stopped after 15 min
with 1 M H,SO, and photospectrometry was performed at 450 nm. The lower de-




In order to establish the specificity of the results obtained with salbutamol and sal-
meterol, control-experiments with propranolol (C^H,,NO,.HCL, MW 259.3), a
non-specific P-antagonist, were performed. These experiments also served the
purpose of ruling out the possibility that the presence of salbutamol or salmeterol
interfered with the detection of cytokines in the ELISA. Cells were preincubated
for 15 min with propranolol (1(H M), coincubated with salbutamol or salmeterol
(lO'' M) for 15 min, and immediately thereafter stimulated with LPS. Propra-
nolol in 1:100 excess has been shown in a previous study to block P-adrenergic ef-
fects completely [6].
Isolation and determination of TNFa and IL-6 mRNA
RNA was isolated from die mononuclear cell fraction of blood in order to prevent
loss of monocytes during the procedure. Mononuclear cells (30 mL a 3x10''
cells.mL') were preincubated for 15 min with either salbutamol or salmeterol
(10''' M) and, thereafter, stimulated for 3 h with LPS (l(ig.mL"')- Subsequendy,
RNA was isolated from the cells as described by Davis rt <?/. [25], using a 4M
GTC-solution. The ultracentrifugation, northern blot analysis, hybridization (in-
cluding GAPDH as control probe) and semiquantitative analysis was performed
as described before [26]. mRNA expression of TNFa and IL-6 was determined
relatively to the expression of the control gene GAPDH. The hybridization signals
were analyzed semiquantitatively with a phosphor-imaging system (Molecular
Dynamics, Sunnyvale, CA).
STATISTICAL ANALYSIS
All data are presented as mean ± SEM. Cytokine release in each individual experi-
ment represents the mean of at least four replicates. Since cytokine-release did not
show a normal distribution, non-parametric tests were used for analysis. Differ-
ences between medications were analysed by Mann-Whitney U test, whereas for
differences within medication-groups Wilcoxon test for paired data was used. Dif-
ferences were considered statistically significant at p< 0.05 (two-sided). The statis-
tical package SPSS/PC+ (version 6.01 Windows, SPSS Inc., Chicago, IL) was used
for analysis.
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Figure 1. Salbutamol significantly inhibits the release of TNFa and, to a lesser extent, of IL-6 by
LPS-stimulated monocytes. Monocytes were incubated with a concentration range of LPS (1 -1000
ng.mL') in the absence (open bar) or presence of 10''", 10*, 10'' and 10^ M salbutamol. After
overnight incubation, the presence of a) TNFa; b:) IL-6; and c:) IL-8 in supernatant was determined
by specific ELISA. The mean ± SEM of nine independent experiments are shown ( * * p<0.01, * p<
0.03). No changes were observed in IL-8 release.
RESULTS
Overnight stimulation of monocytes with LPS resulted in a dose-dependent in-
crease in TNFa, IL-6 and IL-8 release. Incubation with salmeterol and salbutamol
inhibited TNFa release in LPS-stimulated monocytes (p< 0.03) (Fig.la+2a); al-
though for salbutamol and LPS 1000 ng.mL', significance was not reached
(p=0.07). The experiments show a trend towards inhibition of IL-6 release, how-
ever IL-6 release was only significantly inhibited with salbutamol 1 (K' M and LPS
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Figure 2. Salmeterol significantly inhibits TNFa release by LPS-stimulated monocytes. Monocytes
were incubated with a concentration range of LPS (1-1000 ng.mL') in the absence (open bar) or
presence of 10 °, 10° and 10" M salmeterol. After overnight incubation, a:) TNFa; b:) IL-6; and c:)
IL-8 were determined in supernatant by specific ELISA. The mean ± SEM of eight independent ex-
periments are shown (* p< 0.03). Although salmeterol seems to inhibit IL-6 release, no significant
changes were observed in IL-6 nor IL-8 release.
observed in IL-6 and IL-8 release. In contrast, salmeterol and salbutamol did not
affect LPS-induced IL-8 release (Fig.lc+2c).
When comparing the effects of salmeterol and salbutamol on TNFa release, sal-
meterol (lO* M) inhibited TNFa release to a similar extent as salbutamol (lO'*"
M) (respectively 47 ± 8% and 46 ± 5%) (Fig.3). The overall inhibitory effect of
salbutamol on TNFa release was dose-dependent and maximum inhibition of
TNFa release (57 ± 7% ) was observed with salbutamol 10"* M (Fig.la). In con-
trast, salmeterol seemed to reach already maximum inhibition of TNFa release at
concentrations as low as 10"'" M, although at low LPS levels (1 ng.mL') a dose-




















Figure 3. Comparison of the inhibitory effects of salbutamol and salmeterol on TNFa-release by
LPS stimulated monocytes. Inhibition is defined as ((cytokine-release in medium - cytokine-release
in the presence of drug)/cytokine-release in medium)) x 100%. Salmeterol (B-Wand salbutamol
(A-A) inhibited TNFa release to a similar extent (with the exception of salmeterol 10' M and LPS
100 ng.mL' (* p=0.03)). Whereas for salbutamol a dose-dependent inhibition of TNFa was obser-
ved, salmeterol seemed to reach already maximum inhibition of TNFa at low concentrations,
when stimulated with LPS 100-1000 ng.mL'
dependent inhibition seemed to exist. Generally speaking, inhibitory effects of sal-
meterol and salbutamol were comparable (Fig.3). The maximum inhibitory ef-
fects of both p,-agonists on TNFa release tended to be lower for the highest con-
centration of LPS.
In order to examine whether P-adrenergic receptors were involved in the
cytokine-inhibition, induced by salmeterol and salbutamol, control experiments
with the non-specific P-blocking drug propranolol were performed. Propranolol





Figure 4. Propranolol, a non-selective p-adrenoceptor in-
hhibitor, completely reversed salbutamol- and salmeterol-
induced inhibition of TNFa release. Monocytes were
preincubated for 15 min with propranolol (10" M),
followed by 15 min incubation with salbutamol (n=3)/
salmeterol ( 10" M) (n=4) or control medium (open bar).
Thereafter, cells were stimulated overnight with different
concentrations of LPS. Since similar results were obtained
for salbutamol and salmeterol, data are compiled (** p<
0.01 salbutamol/salmeterol 10' M in comparison with
medium control and in comparison with coincubation of
salbutamol/salmeterol with propranolol 10' M).
LPS-induced TNFa release (Fig.4). This indicates that the observed inhibition of
TNFa release resulted from an interaction with P-adrenoreceptors, and not
merely from a possible interference of the (},-adrenergic drugs with the detection
of TNFa in the ELISA.
Additionally, we analysed pathways involved in the regulation of cytokine-
synthesis. Since cAMP elevating drugs have been shown to inhibit TNFa release
partially through the involvement of IL-10 [15], and since both salbutamol and
salmeterol increase intracellular cAMP, the next set of experiments measured
IL-10 in supernatant together with TNFa (Fig.5). LPS induced a dose-dependent
increase in the release of both IL-10 and TNFa. However, although salbutamol
and salmeterol inhibited TNFa release at all concentrations of LPS tested
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Figure 5 a-b. Changes in IL-10 do not correlate with changes in the release of TNFa, induced by
salbutamol and salmeterol. Presence of a:) TNFa and b:) IL-10 in supernatant of monocytes, incu-
bated with different concentrations of salbutamol or salmeterol (10'°; 10°; 10* M) and stimula-
ted overnight with LPS (1-1000 ng.mL') (n=7). Since for salbutamol and salmeterol similar results
were obtained, data were compiled. Whereas salmeterol and salbutamol significantly inhibited
TNFa release at all concentrations of LPS ( * p<0.02, ** p<0.01), an increased release of IL-10 is
only observed at LPS 1 ng.mL' in the presence of salbutamol/salmeterol (* p<0.03). Data suggest
that IL-10 is not involved in the inhibition of TNFa release at lower concentrations of LPS.
(Fig.5a), IL-10 release was only increased at the highest concentration of LPS.
This observation suggests that at lower concentrations of LPS an IL-10-
independent pathway is involved in the salmeterol- and salbutamol-induced inhi-
bition of TNFa.
Since phosphodiesterase inhibitors, which also increase intracellular cAMP, have
been shown to inhibit LPS induced TNFa-mRNA accumulation in mononuclear
cells [16,17], the present study additionally established the effect ofsalmeterol and
salbutamol on the levels of TNFa- and 11-6 mRNA expression. Analysis for IL-8
mRNA expression was not performed, since no changes were observed for IL-8 in
supernatant.
Both salmeterol and salbutamol were shown to decrease LPS-induced
TNFa-mRNA levels (inhibition (mean ± SEM of 3 individual experiments) re-
spectively 73 ± 5% and 64 ± 2%)(Fig.6). IL-6 mRNA accumulation was also de-
creased, although this effect was less pronounced (with salmeterol 42 ± 9% and
with salbutamol 37 ± 12% (mean ± SEM of 3 individual experiments).
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Figure 6. Northern-blot autoradiographs of TNFa-,
IL-6- and GAPDH-mRNA, induced by stimulating
monocytes with LPS 1 ng.mL' in the presence of ei-
ther medium or salmeterol or salbutamol 10' M.
Monocytes were stimulated for three h in the pre-
sence of LPS and thereafter mRNA was isolated. The
figure shows northern blots of one representive ex-
periment (out of three). Lane 1: medium; lane 2: LPS;
3: LPS + salbutamol; lane 4: medium; lane 5: LPS; la-
ne 6: LPS+salmeterol. Both salmeterol and salbu-
tamol reduced LPS-stimulated TNFa-mRNA accumu-
lation (the inhibitory effect amounting respectively
(mean ± SEM) 73 ± 5% and 64 ± 2%) and IL-6
mRNA (respectively for salmeterol (mean ± SEM ) 42
± 9% and salbutamol 37 ± 12%).
DISCUSSION
The present study shows that salmeterol and salbutamol decrease TNFa release in
LPS-stimulated human monocytes. Involvement of the p,-adreno-receptor in this
immunomodulatory effect was demonstrated by the complete reversal of inhibi-
tion of TNFa release by the non-selective ^-antagonist propranolol. Salmeterol
and salbutamol were also shown to inhibit TNFa and IL-6 mRNA accumulation
in LPS-stimulated monocytes, although inhibitory effects on IL-6 mRNA accu-
mulation were smaller. IL-10 was not involved in the (3,-agonist-induced down-
regulation of TNFa, except for the highest concentrations of LPS.
TNFa, a pro-inflammatory cytokine, has been shown to be involved in the patho-
genesis of asthma [18,19]. Previously, theophylline and other phosphodiesterase-
inhibitors, have been shown to inhibit TNFa release in monocytic cells, although
concentrations necessary for this effect lay well above clinically acceptable levels
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[16,17]. In these studies, increased levels of cAMP were considered to be responsi-
ble for the observed effect on TNFa release. The present study observes that, in
line with data from studies above, salbutamol and salmeterol, which also increase
intracellular cAMP, inhibit TNFa release; however, salbutamol and salmeterol
were found to decrease TNFa levels at pharmaceutical concentrations. Our data
are supported by a previous study, which demonstrated that salmeterol and salbu-
tamol inhibited TNFa release in a monocytic cell line [27]; although
TNFa-release was inhibited more than observed in the present study, differences
in TNFa release between the two studies can be explained by differences in cell ac-
tivation status either due to maturation effects or culture conditions.
Besides interference with TNFa production, cAMP has also been implicated in
LPS-induced IL-10 synthesis [28] and IL-10 gene-activation [29]. Therefore, the
present study also studied the presence of IL-10 in supernatant, since it has been
shown that IL-10 is, at least partially, involved in the effect of cAMP-elevating
agents on TNFa. IL-10 is produced by Th2- and B-lymphocytes, mast cells and
mononuclear phagocytes and has been shown to be involved in the autoregulatory
pathway of cytokine release in monocytic cells [15,30,31,32]. IL-10 inhibits
TNFa-, IL-6- and IL-ip mRNA production both in LPS-stimulated monocytic
cells [30,31] and human alveolar macrophages [32]. In the present study, IL-10
levels were evaluated after 20 h incubation, at which point in time IL-10 levels are
nearly maximum [30,33]. De Waal rtrf/. observed in monocytes that IL-10 inhib-
ited release of TNFa more than IL-6, without affecting IL-8. The present study
showed that IL-10 release was enhanced by salmeterol and salbutamol at maxi-
mum LPS concentrations, which is in accordance with observations with adeno-
sine [34]. The trend of decreasing IL-10 levels by increasing concentrations of sal-
butamol/salmeterol per concentration of LPS may be explained by decreasing
concentration of TNFa in supernatant, since TNFa itself has been shown to
stimulate IL-10 release in monocytes, as part of the autoregulatory cycle of
cytokine-synthesis [35]. The present study also demonstrated that TNFa release
is markedly inhibited, even when IL-10 levels are not increased. These data are in
line with data from studies with adenosine [34], PGE, [15] and Rolipram [36],
which demonstrated that IL-10 is only partially responsible for TNFa inhibition,
since treatment with anti-IL-10 only partially reversed TNFa-inhibition. This
suggests that other pathways are involved in the inhibition of TNFa. Data from
the present study support this hypothesis. Whereas salbutamol was observed to in-
hibit TNFa release dose-dependently, salmeterol seemed to reach already maxi-
mum inhibition at low concentrations. A possible explanation may be that sal-
meterol induces higher levels of cAMP in comparison with salbutamol [37].
However, salmeterol in the present study maximally inhibited TNFa release at
concentrations, which are not considered to be associated with high cAMP levels.
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Interestingly, the inhibitory effects of salmeterol on TNFa release, observed in the
present study, closely resemble inhibitory effects of salmeterol on
sulphopeptidoleukotriene-release in stimulated human lung mast cells [38]. Sal-
meterol was found to be an effective inhibitor in picomolar concentrations,
whereas intracellular cAMP levels were not increased. Observations from the pres-
ent study suggest the existence of cAMP-independent pathways of cytokine-
modulation.
So far, few studies have demonstrated interference of cAMP-elevating drugs on
LPS-induced IL-6 release. Adenosine, a mediator released during ischemia, was
shown to inhibit both TNFa- and 11-6 release in LPS-stimulated monocytes [24].
More recently, a specific type IV phosphodiesterase-inhibitor was also shown to
inhibit both TNFa and IL-6 release in LPS-stimulated macrophages [38]. Both
studies observed that IL-6 release was less affected than TNFa release. Observa-
tions in the present study show that, although salmeterol and salbutamol de-
creased LPS-induced IL-6 mRNA levels, only mild changes were detected in IL-6
protein levels in supernatant. This suggests the presence of post-transcriptional
modulations.
In conclusion, this study demonstrated antiinflammatory effects of salmeterol and
salbutamol, both on LPS-induced TNFa and IL-6 mRNA levels and on TNFa
and IL-6 protein levels in supernatant of human monocytes. IL-10 release was en-
hanced by salmeterol and salbutamol at the highest LPS-concentration and may
have exerted an additional (late) immunoregulatory role. Observations from the
present study may serve to explain part of the inhibitory effects of P,-adrenergic
drugs on the late asthmatic response, which has been shown to involve the release
of TNFa [9,18]. Although salmeterol and salbutamol demonstrated immuno-
modulatory effects at therapeutic concentrations, inhaled corticosteroids still are
the most powerful antiinflammatory drugs currently used. However, since corti-
costeroids and cAMP-elevating agents inhibit cytokine synthesis via separate path-
ways [39], this may explain why clinical studies, using the combination of inhaled
corticosteroids with long-acting P,-adrenoceptor agonists, have observed an im-
proved control of asthmatic disease [13,14]. Modulating pro-inflammatory
cytokine-synthesis may be one of mechanisms through which long-acting P,-ag-
onists may influence asthmatic inflammation.
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Effect of inhaled beclomethasone
dipropionate on isocapnic
hyperventilation with cold air in
asthmatics, measured with forced
oscillation technique
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Isocapnic hyperventilation with cold air (IHCA) is a reliable technique for assess-
ing indirect bronchial hyperresponsiveness in patients with asthma. Impedance
measurement of the respiratory system by the forced pseudo-random noise oscilla-
tion technique is a sensitive technique to assess changes in bronchial tone after
IHCA.
The aim of the study was to evaluate the effect of six weeks of treatment with be-
clomethasone dipropionate (BDP) 1000 |ig.day' on isocapnic hyperventilation
with cold air in asthmatic patients measured with both forced oscillation tech-
nique and flow-volume recordings. Forty patients with mild asthma were included
in this double-blind, placebo-controlled parallel-group study. Stratification on the
basis of sex was performed to overcome differences in airway diameter. At entry
and every 2 weeks during the treatment period, IHCA was performed and
patient-diaries were evaluated. Characteristic changes in forced oscillation pa-
rameters after IHCA were observed in all patients. After 6 weeks of treatment,
BDP-treated patients showed statistically significant differences in impedance
measurements after IHCA, manifested by significant attenuation of resistance at 8
Hz (p< 0.01), slope of the frequency-resistance curve (p< 0.01), reactance at 8 Hz
(p=0.01) and resonant frequency (/„) (p< 0.02). Flow-volume recordings showed
only a statistically significant change in the decrease of IVC (p=0.01). Further-
more, a significant correlation was observed between serum IgE levels and the ef-
fect of BDP on IHCA, measured with forced oscillation technique. In this study,
beclomethasone dipropionate, 1000 |ig.day' for 6 weeks, decreased indirect
bronchial hyperresponsiveness as assessed by cold air bronchoprovocation in asth-
matic patients. The forced oscillation technique proved a more sensitive method
to detect changes in bronchial tone than flow-volume recordings.
INTRODUCTION
Asthma is characterized by an increased responsiveness of the tracheobronchial
tree to a variety of specific and nonspecific stimuli. The degree of bronchial hyper-
responsiveness (BHR), as assessed by methacholine and histamine challenge, is
closely related to the severity of asthma [1]. BHR is considered to occur as a result
of inflammation in the asthmatic airways [2]. Even in very mild asthmatic patients
an inflammatory process is present in the airways [3,4]. Inhaled corticosteroids
improve asthma symptoms, decrease airway inflammation [5] and reduce the level
of BHR [6-9]. However despite distinct improvement of asthma symptoms by in-
haled corticosteroids, only moderate changes in BHR, as assessed with histamine
and methacholine, are observed. Moreover, histamine thresholds in patients with
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asthma show considerable overlap with the general population [10]. Therefore,
besides direct bronchial challenge tests, techniques have been developed which in-
fluence bronchial smooth muscle indirectly in order to better represent natural cir-
cumstances. Isocapnic hyperventilation with cold air (IHCA) represents a reliable
and well standardized method for evaluating indirect bronchial hyperresponsive-
ness [11-13]. In comparison to pharmacological stimuli, bronchoprovocation
with IHCA is better able to distinguish asthmatic patients from the general popu-
lation [11], and from patients with COPD [14,15]. Most broncho-provocation
tests evaluate the response in bronchial tone by measuring the forced expiratory
volume in one second (FEV,). However, the inspiratory manoeuvre which pre-
cedes measurement of FEV, may change bronchial tone and, therefore, influences
the result of bronchoprovocation testing, both in normal and asthmatic subjects
[7,16]. Impedance measurement of the respiratory system by forced oscillation
represents a technique which enables evaluation of bronchial hyperresponsiveness
both with direct [17-19] and indirect stimuli [20-22]. The technique requires lit-
tle co-operation from the patient and allows evaluation of the bronchial response
during quiet breathing.
The aim of this study was to evaluate the effect of inhaled beclomethasone di-
propionate on bronchial provocation with isocapnic hyperventilation with cold
air in stable asthmatic patients. In addition to flow-volume recordings, impedance




Forty patients, equally distributed over both sexes, were included in the study. Pa-
tient characteristics are presented in Table 1. The following inclusion criteria were
met by all patients: a clinical diagnosis of asthma, defined as recurrent attacks of
dyspnea with perceptible wheezing; normal baseline impedance measurements as
defined by a resonant frequency (/„) lower than 16 Hz and the absence of fre-
quency dependence (defined as a negative value for(R,^ -R^,) /20) (Table 2). Pa-
tients entering the study all had evidence of bronchial hyperresponsiveness, as de-
fined by a provocative dose of histamine causing a 20% fall in FEV, (PD,,,) < 8
|Xmol. All patients had positive skin tests for at least one aero-allergen ( number of
positive tests (mean ± SD) 4.4 ± 2.4). Patients were in a clinically stable condition
and showed no evidence of a recent respiratory tract infection. None of the pa-
tients had been treated with inhaled or oral corticosteroids within 3 months prior
to entry into the study. Only p,-sympaticomimetic drugs were allowed for control
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FEV,: forced expiratory volume in one second; IVC: inspiratory vital capacity; PD,,, histamine: pro-
vocative dose of histamine producing a 20% fall in FEV,; M: male; F: female. *p=0.02 between
groups.




















































R8: Resistance at 8 Hz; R28: Resistance at 28 Hz; F.D.: frequency dependence of resistance
((R28-R8V20); X8: Reactance at 8 Hz; /,: resonant frequency. *p<0.01 before and after IHCA
within groups. At entry, no statistically significant differences were observed between groups.
of asthma. Patients were asked to refrain from using p,-sympaticomimetic drugs at
least 8 hours before bronchoprovocation testing. The protocol was approved by
the Ethics Committee of the University Hospital Maastricht and written in-
formed consent was obtained from all patients.
Study design
The study was a double-blind placebo-controlled parallel-group study, in which
subjects were randomly allocated to receive either beclomethasone dipropionate
(BDP) 250 |lg/puff 2 puffs £./'.<^. by metered dose inhaler or placebo for six weeks.
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In order to avoid possible sex-related differences in airway diameter, additional
stratification was performed according to gender. The time schedule consisted of a
run-in period of one week, followed by a treatment period of 6 weeks, with
follow-up visits scheduled every 2 weeks. At every visit, diary-information and
peak flow-registrations were assessed and cold air bronchoprovocation was per-
formed.
Asthma-assessment
During the study period, assessment of asthma severity was made in three ways: 1:)
all patients were given a diary, in which they recorded asthma symptom scores (0=
no complaints to 5= major interference with daily activities, inability to work); 2:)
the use of P,-sympaticomimetic drugs was recorded (patients were instructed to
use these only if needed) and 3:) patients recorded peak expiratory flow rates (3
successive measurements) in the morning and evening using a mini-Wright peak-
flow meter (Airmed, Clement Clarke International Ltd., London, England).
Cold air challenge
Cold air challenges (IHCA) were performed using a heat-exchange system (Jaeger
GmbH, Wiirzburg, FRG), as described previously [21,22]. The patients inhaled
dry air delivered from a cylinder. Temperature of the air leaving the cooling system
was -20° C. The flow of air could be adjusted by a needle valve and was measured
by a rotameter. Patients were instructed to breathe at a predetermined ventilation
rate of 60 % of the predicted indirect maximal breathing capacity (defined as
35xFEV,) by maintaining the size of a guide balloon. To avoid hypocapnia, CO,
was added to the system at a rate of 5% of the predetermined minute ventilation
[12]. Hyperventilation was sustained for 3 minutes, after quiet breathing into the
system for one minute. Prior to cold air bronchoprovocation, three successive
measurements of the respiratory impedance by forced oscillations were performed,
followed by flow-volume measurements using a pneumotachograph (Masterlab,
Jaeger GmbH, Wurzburg, FRG). Three minutes after cold air bronchoprovoca-
tion, measurements were repeated in the same order.
Forced oscillation technique
The technique used in our study is similar to the method developed by Landse'r <rr
#/[24] and has been published previously [18,21,22]. In short, a complex pseudo-
random noise oscillation signal, containing various harmonics in steps of 4 Hz
ranging from 4-52 Hz, was applied at the mouth during spontaneous quiet
breathing. Cheeks and mouth floor were supported by the hands of the patient.
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Mouth pressure and flow rate were recorded by transducers (MP45®, Validyne,
Northridge, CA, USA), and the recorded signals were fed directly into a Fourier
analysing system, calculating impedance values for each frequency applied. The
impedance value can be divided into a resistance (R) and a reactance (X). The total
resistance of the respiratory system (RJ is the sum of resistance of central airways,
peripheral airways, lung parenchyma and chest wall. In normal individuals, the re-
sistance increases with increasing frequency of the signal applied [18,20]. The
slope of the curve is defined by (R,^,-R^)/ 20 and is called the frequency depend-
ence of resistance (FD) [18,21,22].
The reactance value depends on the elastic and the inertial properties of the sys-
tem. The frequency at which the sum of elastic and inertial properties equals zero
is called the resonant frequency (/„). For this study, resistance was measured at 8
Hz (R8), at 28 Hz (R28) and frequency dependence of resistance (FD). The reac-
tance of the impedance was characterized by reactance at 8Hz (X8) and the reso-
nant frequency (/„). Only impedance values with a coherence function (compara-
ble with a signal-to-noise-ratio) equal to or greater than 0.95 were used for
analysis.
Data analysis
All data described are mean ± SD, unless otherwise specified. Differences between
groups were compared with Mann-Whitney U-test. In order to evaluate differ-
ences between the two treatment regimens, repeated measures analysis of variance
(ANOVA) (BMDP Statistical Software Inc., Los Angeles, USA) was performed;
this statistical method allows comparison of individual responses and compensates
for baseline response differences. The model used in our study assumes a fixed ef-
fect of treatment in time. Differences were considered significant at a p-level less
than 0.05 (two-sided).
RESULTS
Thirty-five of 40 patients completed the study. In the placebo-group, 3 patients
withdrew, one patient at 2 weeks and 2 patients at 4 weeks, because of lack of co-
operation. In the beclomethasone dipropionate-group, 2 patients were excluded
from the study at 6 weeks of treatment; one patient due to inability to attend the
follow-up visit in time. The other patient had to be treated with oral corticosteroids
for generalized eczema, which she had also experienced before the study. All data up
to withdrawal have been included in the analysis.
Patient characteristics of both groups are presented in Table 1. At entry, the
BDP-treated group showed a higher baseline FEV, than the placebo-group (101%
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Figure 1a-d. Changes in R8 (fig. la), frequency dependence (fig. 1b), X8 (fig. 1c) and /„ (fig. Id)
after IHCA for individual patients, both at entry and after 6 weeks follow-up. For legends: see ta-
ble 2. Treatment with beclomethasone dipropionate during 6 weeks resulted in statistically signifi-
cant changes for all parameters shown.
predicted twrar 92%, p< 0.02). Baseline values for forced oscillation parameters
(Table 2) were not statistically different between groups, although a slightly lower
value for R8 was observed in the BDP-group than in the placebo-group (0.314
versus 0.363 kPa.s.L', n.s.). Isocapnic hyperventilation with cold air resulted in
similar changes in both groups. FEV, decreased (mean±SD) 18 ± 15% predicted
from baseline in the BDP-group and 19 ± 14% in the placebo-group. Impedance
measurements after cold air bronchoprovocation yielded a similar change in
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Figure 2a-b. Changes in FEV, (fig. 2a) and IVC (fig. 2b) after IHCA for individual patients. Figures
show data obtained at entry and after 6 weeks follow-up. Treatment with beclomethasone dipro-
pionate resulted in a small change in fall of IVC after IHCA. No statistical significant effect was ob-
served for FEV,.
forced oscillation pattern in both groups: a large increase in R8, a small increase in
R28, the occurrence of a negative slope of the resistance-frequency curve, a more
negative value of X8 and an increase in resonant frequency (/o)(Table 2). At entry,
no statistically significant differences in flow-volume and forced oscillation
changes were observed between groups after IHCA.
Baseline impedance and flow-volume measurements did not change significantly
in either treatment groups during 6 weeks of treatment. After 6 weeks of beclo-
methasone dipropionate treatment, statistically significant changes were observed
in forced oscillation response to IHCA (Fig. la-d). Treatment with beclometha-
sone dipropionate resulted in: a diminished increase of R8 after IHCA (at entry
(mean ± SD): 0.336 ± 0.174; after 6 weeks: 0.250 ± 0.160 kPa.s.L' (p=0.006;
-26% baseline)); a decrease in steepness of the slope (FD) of the resistance-curve
after IHCA (at entry: -0.013 ± 0.009, at 6 weeks -0.009 ± 0.006
kPa.s.L-'(p=0.001; -31 % baseline)); a decrease in X8 changes after IHCA (at en-
try: -0.263 ± 0.246, after 6 weeks -0.155 ± 0.105 kPa.s.L'(p=0.012; -41% base-
line)) and a decrease in change of/,, after IHCA (at entry: 19.5 ± 10.1, after 6
weeks 13.3 ± 9 Hz (p=0.015; -32 % baseline).
In contrast, flow-volume measurements only yielded a statistically significant
change in IVC after IHCA (at entry: -6.1 ± 8.0 %pred., after 6 weeks -3.1± 3.4%
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Figure 3. A significant correlation was observed for IgE-levels at entry and
changes in forced oscillation parameters after IHCA after 6 weeks beclo-
methasone dipropionate. The Y-axis indicates the IHCA-induced change in
/„ after 6 weeks BDP in comparison to baseline-response. The figure shows
a significant correlation between IgE-levels and beclomethasone-induced
change in /, (r= -0.88, p<0.001, Spearman rank correlation). Note that IgE
levels are shown on a logarithmic scale.
Levels of total serum IgE in patients were found to be significantly correlated with
the level of response to BDP as measured by forced oscillation technique (Spear-
man rank correlation for changes in R8 after 6 weeks BDP in comparison to entry
(r= -0.80, p< 0.001); for changes in frequency dependence (r= 0.81, p<0.001); for
changes in X8 (r= -0.68, p<0.01); and for changes in /„ (r = -0.88, p<0.001)(Fig
3)). No significant correlations were found for total numbers of eosinophils and
histamine PD,,,-levels and response to inhaled steroids in our patient group.
No clinically significant differences were observed in asthma symptom-score, peak
flow registration and peak flow variability between groups both at entry and after
six weeks.
Adverse effects were reported by 6 patients in the BDP-treated group: complaints
of a sore throat (2 patients); hoarseness (2 patients); dry cough (1 patient) and one
patient was suspected of oral candidiasis. However no smear was made to evaluate
the presence of oral candidiasis. In the placebo group a dry irritant cough was re-
ported by 1 patient and 2 patients complained of a sore throat.
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DISCUSSION
In this study, inhaled beclomethasone dipropionate (BDP) reduced bronchial hy-
perresponsiveness in stable mild asthmatic patients, as assessed by isocapnic hyper-
ventilation with cold air. The forced oscillation technique was more sensitive in
detecting BDP-induced changes in bronchial tone after IHCA in comparison to
conventional flow-volume recordings. Furthermore a high correlation was ob-
served between serum IgE levels and the effect of BDP on IHCA, as measured by
forced oscillation technique.
At the present time, inhaled corticosteroids play an important role in the treat-
ment of asthma. Inhaled corticosteroids reduce BHR to pharmacological stimuli
in a dose- and time-dependent way [7-9,24]. This report is the first to discuss the
influence of inhaled BDP on the bronchial challenge with IHCA in asthmatic pa-
tients assessed both with forced oscillation technique and conventional pulmo-
nary function testing. Impedance measurement of the respiratory system was cho-
sen to overcome modulation in bronchial tone, which may result from a preceding
deep inspiratory manoeuvre [7,16]. In the present study, a characteristic pattern of
changes after IHCA was observed in forced oscillation parameters; an increase of
resistance at lower frequencies, the development of a negative slope of resistance
and an increase in resonant frequency. This pattern of changes is characteristic for
asthmatic patients and these results concur with previous studies [20-22].
The present study showed that BDP 1000|ag.day' for 6 weeks, significantly at-
tenuated the response to IHCA assessed with the technique of forced oscillations,
whereas only small changes in FEV, response to IHCA were observed. From the
literature, one would expect an effect of BDP on change in FEV, after IHCA, but
considering the large variability in FEV, changes after IHCA detected in the pa-
tient population, it is likely that the number of patients in the present study was
not high enough to detect differences in FEV,. No changes were detected in
asthma-symptom scores or PEF-scores in our BDP-treated group, but this is not
surprising considering the fact that all of the patients had mild asthma. Further-
more, it appeared that the patients treated with BDP were the patients with the
better values of FEV,.
So far, no other studies have been published using forced oscillation technique in
response measurement of corticosteroids in IHCA. Several reports have been pub-
lished regarding the influence of long term treatment with inhaled corticosteroids
on exercise induced asthma [25-27] and on eucapnic hyperventilation with room
air [28,29]. Only one study has evaluated the effect of an inhaled corticosteroid on
IHCA [30]. In this study, budenoside 800 flg.day' for four weeks, induced a
small but significant change in FEV, (- 8.5%) after IHCA in asthmatic patients.
Other studies [27,29] have observed larger effects of inhaled corticosteroids in
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exercise-induced asthma, however in these studies baseline FEV, was clearly lower
and BHR more severe than in the present patient group. Apart from the fact that
the response to exercise in asthmatics is correlated with the severity of BHR as as-
sessed by methacholine or histamine [31], the effect of pharmacological interven-
tion also depends upon the basic level of bronchial reactivity.
In the present study, the forced oscillation technique in our study detected
changes in airway bronchial tone that were not detected by conventional flow-
volume recordings. The superiority of forced oscillation technique in detecting
differences in bronchial tone in comparison to conventional flow-volume record-
ings was noted before. Wesseling #<*/. [21] noted differences in forced oscillation
recordings in IHCA at 40% maximum breathing capacity whereas no difference
was observed in FEV,. Van Noord rtd/.[19] described the reciprocal value of the
resistance at 6 Hz as a more sensitive parameter for detection of histamine induced
bronchoconstriction in asthmatics than FEV, measurement in response evalua-
tion. Only measurement of specific airway conductance (sGaw) proved more sen-
sitive in patients with more or less normal lung function.
Furthermore, the present study also observed that the effect of BDP on IHCA, as
assessed by forced oscillation technique, significantly correlated with total serum
IgE. Patients with high levels of IgE showed a greater response to treatment with
BDP than patients with lower levels. These findings concur with a previous study,
wherein response to inhaled corticosteroids in asthmatic patients, measured by
changes in histamine PC,,,, also correlated with total serum IgE levels [32].
Up till now several mechanisms have been proposed to explain airway obstruction
induced by exercise, />. hyperventilation with cold air [33]. Inhaled corticoster-
oids could influence response to cold air challenge by reducing plasma exudation
in asthmatic airways [34] or by modulating secondary mediator release by inflam-
matory cells. Bronchial biopsy studies have shown that even in mild asthmatic pa-
tients inflammatory cells are present in the airways [5]. BDP was shown to reduce
the number of eosinophils and mast cells in bronchial mucosa of asthmatic pa-
tients after 6 weeks of treatment [35]. In the present study, however, no bronchial
biopsies were performed and, therefore, no answer can be provided regarding the
mechanism by which BDP influences BHR in this study.
In conclusion, this study has demonstrated that treatment with beclomethasone
dipropionate, 1000 (ig.day' for 6 weeks, modulated bronchial response to iso-
capnic hyperventilation with cold air in patients with mild stable asthma. We have
also shown that the technique of forced oscillation was more sensitive to changes
in bronchial tone than conventional flow-volume recordings, and represents a sen-
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sitive technique to assess pharmacological modulation of indirect bronchial hyper-
responsiveness.
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Asthma is an inflammatory disease, characterized by the accumulation of inflam-
matory cells in the bronchial mucosa. Upregulation of adhesion molecules, both
on vascular and epithelial cells, plays an important role in initiating the influx of
inflammatory cells in bronchial mucosa. In acute asthma, elevated levels of these
inflammatory mediators have been detected in the general circulation.
Aim of the present study was to compare levels of inflammatory mediators (soluble
E-selectin, soluble Intercellular adhesion molecule-1 (sICAM-1) and TNF-
receptor-55 and -75 (sTNF-R55/sTNF-R75)) in the general circulation both in
stable mild asthmatic patients and healthy controls and to analyse the influence of
6 weeks treatment with inhaled beclomethasone dipropionate (BDP) on levels of
these inflammatory mediators. Study design consisted of a double-blind,
placebo-controlled, parallel-group study, in which effects of 6 weeks treatment
with BDP 500 (J.g b.i.d. were compared to placebo in patients with stable mild
asthma. Effects of treatment on levels of inflammatory mediators, pulmonary
function and asthma-symptom scores were evaluated. Results show that at base-
line no differences were observed in levels of inflammatory mediators between pa-
tients with stable asthma and healthy controls. Treatment with BDP significantly
decreased levels of sTNF-R55 after 2 to 6 weeks (p<0.02) and sICAM-1 after 6
weeks (p<0.05). Decreases of sTNF-R55 and sICAM-1 were significantly corre-
lated to levels at baseline (r=-0.56, p<0.02 respectively r=-0.53, p<0.03). BDP also
induced a significant decrease in number of blood eosinophils (p<0.02). In con-
trast, no changes in sTNF-R75 and sE-Selectin were observed. The results of the
present study suggest that BDP-induced changes in levels of circulating inflamma-
tory mediators may reflect attenuation of bronchial inflammation.
INTRODUCTION
Asthma is an inflammatory disease, characterized by an increase of inflammatory
cells in bronchial mucosa [1]. The steroid beclomethasone dipropionate (BDP) is
widely used for treatment of asthma, since it has been demonstrated to achieve
both functional and structural improvement in asthma. BDP has been shown to
induce a decrease in bronchial hyperresponsiveness (BHR) [2,3], which is paral-
lelled by a decrease in inflammatory cell numbers in bronchial mucosa [2]. Corti-
costeroids have been shown to decrease adhesion molecule expression on stimu-
lated endothelial and epithelial cells in vitro and this may explain clinical activity
of corticosteroids in disease [4,5]. Evidence for the involvement of adhesion mole-
cules in the pathophysiology of asthma has been shown in several studies: endo-
thelial leucocyte adhesion molecule-1 (E-selectin) expression was enhanced on en-
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dothelial cells and an increased expression of intercellular adhesion molecule-1
(ICAM-1) was observed on cells, present in asthmatic airways [6,7]. Also in spu-
tum of asthmatic patients enhanced levels of soluble ICAM-1 (sICAM-1) and an
increased ICAM-1 expression on T-lymphocytes have been demonstrated [8]. In
line with these data, allergen exposure by segmental allergen challenge was shown
to increase levels of sICAM-1 in epithelial lining fluid [9]. The expression of
ICAM-1 is regulated by cytokines such as tumor necrosis factor a (TNFa)
[10,11]. TNFa has been shown in several studies to be involved in the patho-
physiology of asthma [12,13]. TNFa levels are enhanced in BAL [14] and in in-
duced sputum [15] following antigen challenge. These data correlate well with
data of enhanced sICAM-1 in BAL after allergen challenge. Interestingly, in-
creased levels of sICAM-1 were also detectable in the general circulation [9]. Next
to cytokine levels, also soluble TNF-receptor levels in the general circulation are
known to reflect inflammatory disease [16]. Enhanced levels of soluble TNF-
receptors have been detected in patients with chronic inflammatory disease
[17,18,19] and in neoplastic disease [20]. In asthma, elevated levels of sICAM-1
and sTNF-receptors have been described in acute exacerbations [21,22,23] and
are considered to reflect the enhanced bronchial inflammation.
Since inhaled corticosteroids modulate the local inflammatory reaction within the
airways, aim of the present study was to evaluate the effect of inhaled beclometha-
sone dipropionate on levels of circulating inflammatory mediators in patients with
stable asthma and to correlate this with clinical parameters.
This study demonstrates that inhaled beclomethasone dipropionate 500 (Xg b.i.d.
reduces levels of sTNF-R55 and sICAM-1 in stable asthmatic patients. We specu-
late that the modulation of sTNF-R55 and sICAM-1 reflects attenuation of bron-
chial inflammation in stable asthmatic patients.
MATERIAL AND METHODS
Study design
This study was performed simultaneously with investigations of the effects of be-
clomethasone dipropionate on isocapnic hyperventilation with cold air, the results
of which are reported elsewhere [3]. 40 Patients with mild stable asthma, equally
distributed over both sexes, were included in the study. Study design consisted of a
double-blind, placebo-controlled, parallel-group study, in which patients were
randomly allocated to receive either beclomethasone dipropionate 250 (ig/puff 2
puffs b.i.d. by metered dose inhaler or placebo for six weeks. Time schedule con-
sisted of a run-in period of 1 week followed by a treatment period of 6 weeks, dur-
ing which control visits were scheduled every 2 weeks. All patients entering the
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study had a documented bronchial hyperresponsiveness (defined by a PD,,, to his-
tamine lower than 8 |imol) and were all atopic, with a mean number of positive
skin tests for aero-allergens 4.4 ± 2.4 (mean± SD).
Patients were all in a clinically stable condition and showed no evidence of recent
respiratory tract infection. None of the patients had been treated with inhaled or
oral corticosteroids within 3 months prior to the study. Only p.,-sympaticom-
imetic drugs were allowed for control of asthma.
During the study patients were evaluated in three ways: recording of asthma-
symptoms, analysis of venous blood for hematology and acute-phase-response and
determination of levels of circulating inflammatory mediators in plasma. Addi-
tionally, levels of circulating inflammatory mediators were also determined in a
group of 32 healthy, nonatopic, nonasthmatic volunteers, ranging in age from
20-40 years.
The study was approved by the local medical ethical committee and written in-
formed consent was obtained from all patients.
Asthma-severity evaluation
Patients recorded disease-severity in three different ways using a diary: all patients
recorded asthma-symptoms (0= no complaints to 5= major interference with daily
activities), the number of (3,-sympaticomimetic drugs used for control of asthma
and peak expiratory flow rates, using mini-Wright peak-flow meters ( Airmed,
Clement Clarke international Ltd., London, England).
Peripheral blood analysis
Venous blood was obtained by venapuncture. At entry, blood was routinely ana-
lysed and at every visit white blood cell count, both total numbers and differentia-
tion, total number of eosinophils, C-reactive protein (CRP) and pre-albumin were
determined. Both CRP and pre-albumin were determined in order to evaluate the
occurrence of acute-phase reactions during the study. CRP was evaluated using
turbimetry; lower detection limit of the assay was 5 mg/1. Pre-albumin was ana-
lysed using standard immunochemical methods, normal values ranging between
0.15-0.40 g/1.
Plasma-samples
For measurement of inflammatory mediators venous blood (10 ml) was collected
in EDTA-coated blood tubes (Sherwood Medical, Balleymoney, N-Ireland).
Plasma was separated from blood cells by centrifugation at 1,000 G for 5 minutes
within 1 hour after collection. Plasma samples were stored at -70" C until analysis.
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All samples were evaluated in duplo and mean value of each pair of results was used
for analysis. For each inflammatory mediator, samples of one patient were ana-
lysed in a single analytical set.
Measurement of inflammatory mediators
Inflammatory mediators were measured using sandwich enzyme-linked immuno-
sorbent assay (ELISA), as described before [11,24,25]. In short, for detection of
soluble TNF-Receptor-55 and-75, monoclonal antibodies (mAb) MR1-1 respec-
tively MR2-2 were used for coating. Specific biotin-labeled polyclonal rabbit-
anti-sTNF-R immunoglobulin-G's were used as detector reagents. After washing
procedure, peroxidase labeled Streptavidine (Dako, Glostrup, Denmark) was
added, followed by the addition of 3,3',5,5'-tetramethylbenzidine (TMB) sub-
strate (Kirkegaard and Perry Laboratory, Gaitersburg, MD). Photospectrometry
(450 nm) was used to analyse the samples. Standards used were rh-sTNF-R55 and
rh-sTNF-R75. The lower detection limits of both assays was 100 pg/ml. Intra-test
variability was <10 %. For soluble E-selectin detection, as catching mAb ENA-1
was used, followed by biotin-labeled ENA-2 as second catching antibody. In this
assay 4 mmol/L calcium and 2.5 mmol/L magnesium was added to the buffers,
since binding of mAb ENA-1 and ENA-2 to sE-selectin is calcium-dependent.
rh-E-Selectin was used as standard. Lower detection limit of the ELISA is 1 ng/ml.
Intratest-variability amounts < 10%. Soluble ICAM-1 was analysed using mAb
HM.2 as catching antibody, followed by biotinylated mAb HM.l as second anti-
body. rh-sICAM-1 was used as standard. Sensitivity ofthisELISA was determined
at 400 pg/ml. Intra-assay variability ranged from 2.8-12.2% with a mean variance
of 6.2%.
STATISTICAL ANALYSIS
Effect of treatment on inflammatory mediators was expressed as changes from
baseline in order to correct for the observed differences in baseline levels of inflam-
matory mediators. Since levels of inflammatory mediators were not normally dis-
tributed, for analysis non-parametric tests were performed. Differences within
treatment groups were analysed using Friedman's test, whereas differences be-
tween treatment-groups were analysed using Mann-Whitney U-test for unpaired
data, two sided test. A p-value < 0.05 was considered statistically significant. The
effect of BDP on levels of sICAM-1 was additionally analysed by calculating the
slope of the curve (indicating mean decrease during time), as characterized by cal-
culating linear contrast [26], and comparing the slope between the two treatment
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Baseline demographic parameters did not show significant differences between the two groups
of asthmatic patients, except for FEV., which was at baseline significantly higher in the BDP-group
(* p= 0.02).
groups. Correlations between different parameters were evaluated using Spearman
rank correlation coefficient.
RESULTS
Thirty five patients completed the study; three patients in the placebo-group with-
drew after two (one patient) and four weeks (two patients) because of lack of co-
operation; in the BDP-group after six weeks of treatment one patient was excluded
from the study because of treatment with oral corticosteroids for generalized ec-
zema and one patient failed to attend the follow-up visit in time.
At baseline, asthmatic groups (placebo and BDP-treated group) were comparable
in demographic variables (Table 1). Unfortunately, FEV, in the placebo group
was significantly lower than in the BDP-treated group. No differences were ob-
served between groups in white blood cell count, number of eosinophils, CRP and
prealbumin, which were all within normal range.
Levels of inflammatory mediators in asthmatic patients did not show differences
when compared with levels of healthy volunteers (Table 2). These data confirm
observations from previous studies. It has to be noted that all patients in the pres-
ent study had stable, mild asthma.
Treatment with BDP resulted in a statistically significant, although small, de-
crease in sTNF-R55 (at entry (mean ± SEM) 0.45 ± 0.04 ng/ml versus 0.39 ± 0.03
ng/ml after two weeks treatment (p<0.01 in comparison to placebo))(Fig. 1),
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Baseline inflammatory mediators were not statistically different between healthy, age-matched
controls and patients with asthma, nor were there any differences between the two different
treatment-groups in asthmatic patients at baseline.
which remained statistically different between groups during the six weeks treat-
ment period (Fig. 2). Analysis within the placebo-group did not show changes in
sTNF-R55 levels. In contrast, BDP induced no changes in levels of sTNF-R75,
which is intriguing since sTNF-R55 and sTNF-R75 were closely correlated in our
study (r=0.6l, p<0.001) (data not shown).
We also evaluated the influence of BDP on sICAM-1 and observed that BDP in-
duced a significant decrease in levels of sICAM-1 after 6 weeks of treatment (at en-
try (mean ± SEM) 341 ±24 ng/ml, 311 ± 23 ng/ml after 6 weeks (p<0.05 in com-
parison to placebo)) (Fig. 3)). Additionally, we evaluated the effect in time of BDP
on sICAM-1 levels by linear contrast analysis, and observed a significant difference
between the two groups (for BDP (mean ± SEM) -17 ± 6 ng/ml/2 weeks versus
placebo -2 ± 5 ng/ml/2 weeks, p<0.03). Levels of sE-Selectin-1 did not show sig-
nificant changes during treatment with BDP (data not shown).
Further analysis of the present data showed that BDP induced a statistically sig-
nificant decrease in the number of circulating eosinophils (p< 0.02 in comparison
with placebo), whereas no changes were observed within the placebo-treated
group (Fig. 4). BDP decreased the number of eosinophils already after 2 weeks of
treatment (data not shown) and the number of eosinophils remained well below
baseline levels during the rest of the study-period.
As reported before, asthma-symptom-scores, pulmonary function and peak-flow
measurements did not change significantly between groups during treatment with
BDP, which is not unexpected considering the normal baseline pulmonary func-
tion of the BDP-treated group.
Since clinical studies have shown correlations between levels of inflammatory me-
diators and disease severity, we correlated inflammatory mediators with indices of
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Figure 1. Beclomethasone dipropionate reduces
levels of STNF-R55 in patients with stable asthma;
individual responses are shown after 2 weeks of
treatment, horizontal bars represent the mean of






Figure 2. Time-response effect (mean ± SEM) of
treatment with beclomethasone dipropionate on
sTNF-R55 in patients with stable asthma; already
after 2 weeks a significant decrease from baseline
is observed (** p< 0.01, * p< 0.02). Open bars:
levels at entry; hatched bars: after 2 weeks;
crosshatched bars: after 4 weeks; solid bars: after
6 weeks treatment.
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Figure 3. Beclomethasone dipropionate redu-
ces levels of slCAM-1 after 6 weeks of treat-
ment in patients with stable asthma. Horizon-
tal bars represent the mean of the observed























entry 6 wk entry 6 wk
Figure 4. Beclomethasone dipropionate redu-
ces the number of peripheral blood eosinop-
hils in patients with stable asthma. Individual
responses are shown after 6 weeks of treat-
ment. Horizontal bars indicate the mean of the
observed response (* p< 0.02 versus placebo).
number of eosinophils and IgE). A weak correlation was found for sICAM-1 and
FEV,, although statistical significance was not reached (r=-0.30, p=0.056). No
further significant correlations could be observed between levels of inflammatory
mediators and indicators of asthma severity.
We also investigated the correlation between sTNF-receptors and adhesion mole-
cules, since correlations between sICAM-1 and sTNF-receptors have been re-
ported in inflammatory disease [19,20]. Interestingly, we observed a weak correla-
tion between sTNF-R55 and sICAM-1 (r=0.27, p=O.O25), whereas no correlation
was found for sTNF-R75 and sICAM-1.
Analysis of the effects of BDP on changes in both sTNF-R55 and sICAM-1
showed a significant correlation between BDP-induced changes in sTNF-R55
and levels of sTNF-R55 at entry of the study (r=-0.56, p=0.014, Fig. 5a) and for
sICAM-1 a similar correlation was found (r= -0.53, p=0.025, Fig. 5b). Although
at entry a weak correlation was observed between sICAM-1 and pulmonary func-
tion, effects of BDP on inflammatory mediators were not correlated with levels of
pulmonary function, number of circulating eosinophils, IgE or levels of BHR;
also, changes induced by BDP in number of peripheral blood eosinophils did not
correlate with BDP-induced changes in inflammatory mediators.
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Figure 5a. A close correlation was observed between initials levels of STNF-R55 and change in
STNF-R55, induced by treatment with beclomethasone dipropionate in patients with stable
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Figure 5b. Also, a close correlation was observed between levels of slCAM-1 at entry and change
in sICAM-1 after 6 weeks of treatment with beclomethasone dipropionate in patients with stable
asthma (Spearman rank correlation r= -0.53, p<0.03).
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DISCUSSION
In the present study beclomethasone dipropionate decreased levels of sTNF-R55
and sICAM-1 in clinically stable asthmatic patients. Levels of sTNF-R55 de-
creased after two weeks, whereas changes in sICAM-1 occurred after six weeks of
treatment. BDP-induced changes in sTNF-R55 and sICAM-1 were significantly
correlated with initial levels of sTNF-R55 and sICAM-1.
Cell adhesion molecules and TNF-receptors have been shown to be involved in
the pathogenesis of asthma [7,10,23]. These cell adhesion molecules and TNF-
receptors can be shed from the cellular surface and enhanced levels of these media-
tors have been detected in the general circulation during asthma attacks
[21,22,23,27]. ICAM-1 is involved in the adhesion of neutrophils and eosinophils
to endothelial cells and serves as a receptor for rhinovirus [10]. Cytokines like
IL-1, IL-4, IFN-yand TNFa induce an upregulation of ICAM-1. In asthma, an
increased expression of ICAM-1 has been observed following antigen challenge
[9] but also in patients with stable disease [7]. Soluble forms of ICAM-1 have been
isolated in healthy individuals and elevated levels of sICAM-1 have been observed
in inflammatory disease [18,19]. These soluble forms of ICAM-1 may have a
functional role in inhibiting cell adhesion to for instance endothelial cells. In the
present study no differences were observed in levels of sICAM-1 between stable
asthmatic patients and healthy controls, which is in agreement with previous stud-
ies [21,22]. BDP was shown in the present study to reduce levels of circulating
ICAM-1 in stable asthmatic patients. This decrease was statistically significant af-
ter 6 weeks treatment, which might explain why in a prior study using corticoster-
oids no changes in sICAM-1 were observed during 4 weeks follow-up [21]. Inter-
estingly, the magnitude of change in levels of sICAM-1 in the present study is
comparable to the change in sICAM-1 following segmental allergen challenge [9].
Elevated levels of sICAM-1 have been described in exacerbations of asthma and
levels of sICAM-1 decreased following oral corticosteroid therapy [27]. In the
present study BDP decreased levels of sICAM-1 in stable asthmatic patients,
whereas no changes were observed in sE-selectin. This observation may be ex-
plained by a decreased ICAM-1 expression in bronchial tissue or decreased shed-
ding of ICAM-1 by BDP. Corticosteroids have been shown in vitro to decrease
ICAM-1 expression on bronchial epithelial cells [4], endothelial cells [5], eosino-
phils [28], lymphocytes and macrophages [4]. Since we did not perform bronchial
biopsies in this study, we can not provide a direct answer to BDP-induced changes
in bronchial mucosa of the patients. BDP, in a dosage similar to the present study,
has been shown in several bronchial biopsy studies to reduce bronchial inflamma-
tion in asthma [2,29]. Animal studies have demonstrated a role for ICAM-1 in the
development of BHR in asthma [30,31]. Although in the present study no direct
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correlation was observed between changes in sICAM-1 and BHR, the present data
support the involvement of ICAM-1 in the pathophysiology of asthma.
In the present study BDP also induced a small, but significant change in levels of
sTNF-R55, whereas at baseline levels were not different between asthmatic pa-
tients and healthy volunteers. Soluble TNF-receptors are naturally occurring in-
hibitors of TNFa activity and have been isolated in serum and urine of healthy in-
dividuals [32]. Many of the inflammatory stimuli that induce TNFa production,
also induce shedding of the TNF-receptors. Elevated levels of sTNF-receptors
have been observed in clinical disease and levels decrease following treatment
[17,18,19]. Data on the involvement of TNF-receptors in the pathophysiology of
asthma are rare. Nasal epithelial cells of patients with allergic rhinitis were shown
to express TNF-receptors whereas cells of healthy volunteers did not [33]. Data
from the present study confirm observations in a previous study, which demon-
strated that levels of circulating TNF-receptors in stable asthmatic children were
comparable with healthy subjects [34]. In patients with unstable asthma, levels of
both sTNF-R55 and -75 were elevated by 30-60%, whereas treatment with sys-
temic high dose corticosteroids resulted in normalization [23]. In the present
study, BDP induced changes in levels of sTNF-R55 in patients with stable
asthma, which has not been reported before. BDP reduced levels of sTNF-R55,
whereas no changes occurred in levels of sTNF-R75, which is interesting since at
entry of the study both TNF-receptor levels were closely related in all patients.
The present study therefore suggests that inhaled corticosteroids may differen-
tially influence TNF-receptor expression. Interestingly, in the present study levels
of soluble TNF-R5 5 correlated with levels of sICAM-1 and changes in sTNF-R55
preceded changes in sICAM-1. Similar observations have been made in acute ma-
laria [19], indicating that parallel changes may occur in different kinds of inflam-
matory disease.
BDP-induced changes in circulating inflammatory mediators in the present study
were relatively small, but this may be explained by the stable mild asthmatic pa-
tients studied. It is therefore not surprising that we did not observe changes in
asthma symptom scores and PEF variability. The observation of a decrease in
number of circulating eosinophils in the present study may reflect decreased in-
flammation; however changes in circulating eosinophils did not reflect changes in
BHR in another study [35]. Therefore the observed changes in circulating inflam-
matory mediators in the present study are interesting. We speculate that in accor-
dance with other inflammatory diseases [17,18,19] a decrease of sTNF-R55 and
sICAM-1 in the general circulation may reflect decreased inflammation. The ef-
fect of BDP on circulating inflammatory mediators was more enhanced in pa-
tients with higher levels of inflammatory mediators, although no clear correlation
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could be observed between levels of inflammatory mediators and levels of asthma
severity.
In the present study we can not exclude the possibility that BDP may have influ-
enced levels of sICAM-1 and sTNF-R55 by a systemic effect, although arguments
above favour an attenuation of local inflammation by BDP. BDP 800 fig/day did
not induce changes in urinary cortisol excretion in comparison to placebo [36],
whereas in another study BDP up to 1600 |ig/day did not suppress the hypotha-
lamic pituitary adrenal axis [37]. These data argue against a systemic effect of BDP
in the dose used in the present study.
In conclusion, the present study demonstrated that treatment with BDP resulted
in decreased levels of sICAM-1 and sTNF-R55 in stable asthmatic patients. The
changes induced by BDP were correlated with initial levels of sTNF-R55 and
sICAM-1, indicating that higher levels of inflammation respond more to anti-
inflammatory treatment. The present study suggests that changes in circulating
ICAM-1 and TNF-R55 may reflect possible therapeutic actions of BDP on bron-
chial inflammation. The present data support a clinical role for non-invasive
monitoring of bronchial inflammation in asthma.
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SUMMARY
Reactive oxygen species (ROS) are involved in the pathophysiology of the
asthmatic inflammatory response. In asthmatic patients, antioxidant defense is
decreased, leading to an oxidant-antioxidant imbalance. Although inhaled
corticosteroids decrease asthmatic inflammation and modulate ROS generation,
little is known of their effect on cellular antioxidant levels. Aim of the present
study was to evaluate the effect of 6 weeks treatment with inhaled beclomethasone
dipropionate (BDP) (1000 |Ig.day') on erythrocyte antioxidant levels in stable
asthmatic patients.
40 Patients with stable, mild asthma were treated in a double-blind, placebo-
controlled, parallel-group study with beclomethasone dipropionate 250 |0.g 2
puffs b.i.d. for 6 weeks. At entry and every 2 weeks during treatment erythrocyte
antioxidant levels, hematology parameters, pulmonary function tests and
asthma-symptoms were determined.
Results show that during treatment with BDP erythrocyte catalase levels increased
(at entry (mean ± SEM) 41 ± 4, after 6 weeks 54 ± 4 |imol H,0,.min'.g' Hb,
p=0.05 in comparison with placebo). An inverse correlation existed between
erythrocyte catalase levels at entry of the study and changes in erythrocyte catalase
after BDP treatment. Erythrocyte total glutathione levels significantly decreased
after 6 weeks treatment with BDP (from 7.0 ± 0.4 to 6.6 ± 0.3 (imol.g"' Hb (p=
0.04)). Blood eosinophil counts were higher in patients, responding with an in-
crease in erythrocyte catalase levels during BDP treatment, than in patients, not
responding with an increase in catalase levels during treatment with BDP ((mean
± SEM) 340 ± 39 respectively 153 ± 52 x 10<\L-', p=0.05).
The present study shows that treatment with inhaled BDP results in changes in
antioxidants levels in erythrocytes of patients with stable, mild asthma.
INTRODUCTION
Asthma is characterized by reversible airflow obstruction and the presence of a
chronic inflammation within the airways. Cells involved in the inflammatory pro-
cess in asthma have been shown to generate increased amounts of reactive oxygen
species (ROS) [1,2,3] and levels of ROS generation correlate with asthma severity
[4]. ROS-generation is enhanced in BAL-cells of stable asthmatics [5] and in-
creases after antigen challenge [6]. ROS can influence airway cell function by in-
teracting with DNA, altering protein structures, interfering with signal transduc-
tion mechanisms by oxidative modification (e.g. (3,-adrenergic receptors),
contracting airway smooth muscle, increasing vascular permeability and increas-
ing release of secondary inflammatory mediators (i.e. leukotrienes, platelet-
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activating factor) [7]. Within the lung powerful antioxidant enzymes are present,
both intra- and extracellularly, and levels of these enzymes may increase following
chronic exposure to increased levels of ROS [8,9]. Levels of glutathione have been
shown to be elevated in bronchoalveolar lavage fluid of patients with stable asthma
[ 10]. In asthma, ROS generation is not only increased within the pulmonary com-
partment, but also in peripheral blood cells [1,3]. This observation is in line with
data showing the presence of activated leucocytes in the general circulation after
allergen challenge [11]. In asthma, evidence for a disturbed oxidant-antioxidant
balance has been found in the general circulation. Decreased glutathione peroxi-
dase levels have been reported in serum, platelets and red blood cells (RBC)
[12,13] and levels of selenium, a co-factor for glutathione-peroxidase, are reduced
in asthmatic patients [13]. Decreased levels of catalase in RBC of asthmatic chil-
dren have also been reported [14]. Recently, it was shown that antioxidant capac-
ity is decreased in plasma of asthmatic patients, both in stable and in acute asthma
[15].
Red blood cells can be regarded as circulating antioxidant carriers, reflecting expo-
sition to ROS [9,16]. The importance of RBC antioxidant enzymes in protecting
target cells from ROS has been shown in both /« w'/ro [ 17] and /'« ww> [ 18] studies.
RBC antioxidative enzymes can be determined with a high degree of reproducibil-
ity and studies have shown that wide interindividual variations exist [19]. Since
RBC are more easily accessible than lung tissue, RBC antioxidant levels have been
used in studies evaluating chronic ROS exposure [16,20,21].
Corticosteriods play a dominant role in the treatment of asthma due to their pow-
erful anti-inflammatory effects [22]. So far, few studies have evaluated the effects
of inhaled corticosteroids on antioxidant levels in asthma [23]. Aim of the present
study was to evaluate the influence of inhaled beclomethasone dipropionate
(BDP) on antioxidant levels of RBC in patients with mild, stable asthma. We
chose to study changes in RBC, since they represent a long term index of antioxi-
dant status [16]. The present study shows that treatment with BDP results in an
increase in levels of RBC catalase, whereas for total RBC glutathione a reduction
was observed. The study suggests diat these changes may be explained by effects of




The present study was performed simultaneously with investigations into the ef-
fect of beclomethasone dipropionate on isocapnic hyperventilation with cold air,
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the results of which have been reported elsewhere [24]. 40 Patients with mild sta-
ble asthma, equally distributed over both sexes, were included in the study. Study
design consisted of a double-blind, placebo-controlled, parallel-group study, in
which patients were randomly allocated to receive either beclomethasone dipropi-
onate 250 (lg/puflF2 puffs b.i.d. by metered dose inhaler or placebo for six weeks.
The time schedule consisted of a run-in period of 1 week followed by a treatment
period of 6 weeks, during which control visits were scheduled every 2 weeks. All
patients entering the study had a documented bronchial hyperresponsiveness (de-
fined as a PD^ value to histamine lower than 8 |imol) and were all atopic, with a
mean number of positive skin tests for aero-allergens of 4.4 ± 2.4 (mean± SD).
Patients were all in a clinically stable condition and showed no evidence of recent
respiratory tract infection. None of the patients had been treated with inhaled or
oral corticosteroids within three months prior to the study. Only p,-sympaticom-
imetic drugs were allowed for control of asthma.
During the study, patients recorded in a diary asthma-symptoms (0= no com-
plaints to 5= major interference with daily activities), the number of p,-sympat-
icomimetic drugs used for control of asthma and peak expiratory flow rates
(PEFR), using mini-Wright peak-flow meters (Airmed, Clement Clarke interna-
tional Ltd., London, England). Patients recorded the best of three successive
measurements of PEFR in the morning and the evening. At every visit, the patient
diary was reviewed and pulmonary function was evaluated by flow-volume meas-
urements using a pneumotachograph (Masterlab, Jaeger GmbH, Wiirzburg,
FRG).
The study was approved by the local medical ethical committee and written in-
formed consent was obtained from all patients.
Chemicals
The following chemicals were used: superoxide dismutase (SOD, bovine
erythrocytes), xanthine oxidase (cow milk) and glutathione reductase (yeast),
NADPH and reduced (GSH) and oxidized (GSSG) glutathione (Boehringer
Mannheim, Mannheim, Germany); xanthine, cytochrome C, hemoglobin, sodium
azide and (X-tocopherol (Merck, Darmstadt, Germany); TV-Ethylmaleimide and
0-phthaldialdehyde (Aldrich, Steinheim, Germany); l-chloro-2,4-dinitrobenzene
(CDNB), glutathione reductase (type III)(GR) and reduced (3-nicotinamide
(NADPH) (Sigma, St. Louis, Mo, USA). All other chemicals used were of analytical
quality. Only microfiltrated deionized water was used.
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Venous blood Preparation r
Venous blood (15 ml) was collected in EDTA-coated tubes (Sherwood Medical,
Balleymoney, N-Ireland). White blood cell counts, cell-differentiation as well as
quantification of eosinophils was performed. For antioxidant analysis, blood was
immediately stored at 4" C after collection and processed within 2 hours. Subse-
quently blood was centrifuged for 10 min., 3000 rpm at 4" C. The buffy coat and
plasma was removed and RBC were washed with 10 mL phosphate buffered saline
(PBS), gently swaying the tube and afterwards RBC were centrifuged again for 10
min, 3000 rpm at 4" C. This procedure was repeated three times. After the wash-
ing procedure, samples were frozen in aliquots of 1 mL at -70° C until analysis.
G7«/«fA/'owf-^roxwiu*, ;»^f roxzW? *&wttta#' «»</ frfta/ktt" rfc/z'fiVy were determined
as described previously [20]. Hemoglobin was determined according to the
method of van Kampen and Zijlstra [25]. In short, for glutathione peroxidase 1
mL of hemolysate was mixed with an equal volume of potassium ferricyanide and
KCN containing buffer. 50 (J.L of the mixture was added to the incubation buffer
containing 1 raM GSH, 200(iM NADPH and 1 IU.mL ' GSSG-reductase and
the rate of oxidation of NADPH was followed for 3 min by spectrophotometry at
340 nM. Substrates used were 0.33 raM H,0, for measurement of Se-dependent
GSH-Px. Units of enzyme activity were expressed as (imol NADPH. min'. g ' he-
moglobin using a molar extinction coefficient for NADPH of 6.22
xlO-'.mM'.cm'.
SK/XTO*/^ Z)ww«foWf activity was measured by the method of McCord and Frido-
vich. A standard curve was prepared using commercially available SOD. The en-
zyme activity at 25" C was expressed in units enzyme per mg hemoglobin.
Gzw^f-art/w'fy was measured according to Aebi, as described before. Prior to the
catalase measurement, lysates were diluted to a concentration of 50 mg Hb.mL"'.
At 25° C 4|XL lysate and 1 mL H,0, (30 raM) were added to 2 mL PBS. The rapid
decomposition of H,O, was followed during 15 sec from the decrease in absor-
bance at 240 nm. Enzyme activity was expressed as |imol H,CX.min~'.g"' hemo-
globin using a molar extinction coefficient for H,O, of 0.0394.mM'.cm'.
rofcz/^/tt&z/A/oHf (reduced plus oxidized) and ^/«wfA/o«f S-taZJw/erart- were deter-
mined as described previously [21]. In short, for determination of total glu-
tathione, RBC were treated with an equal volume of 10% (w/v) trichloroacetic
acid. Supematants were diluted 9 fold with 100 mM sodium/potassium buffer
(pH 7.4) and measured using the cyclic oxidation-reduction method essentially as
described by Andersen.
For determination of glutathione S-transferase activity (EC 2.5.1.18) with CDNB
as substrate, full lysis of the thawed cells was induced with 5 volumes of ice-cold




All data described are mean ± SEM, unless otherwise specified. Effect of treatment
was expressed as changes from baseline. Since antioxidant enzyme levels were not
normally distributed, non-parametric tests were used for analysis between treat-
ment groups (Mann-Whitney U test). A p-value lower than 0.05 was considered
statistically significant (two-sided test). Correlations between parameters were
evaluated using Spearman rank correlation coefficient. The statistical package
SPSS/PC+ (version 6.1-Windows, SPSSInc, Chicago, IL, USA) was used for all
calculations.
RESULTS
40 Patients were included in the study. Demographic variables are given in Table
1. As reported previously, patients in the BDP-group demonstrated a significantly
higher FEV, than the placebo group (101 versus 92 % predicted, p= 0.02). 18 Pa-
tients in the BDP-group and 17 patients in the placebo group completed the
study. In the placebo-group the main reason for dropping-out was withdrawal of
consent (3 patients), whereas in the BDP-group exacerbation of eczema, necessi-
tating oral corticosteroid treatment (1 patient) and non-compliance (1 patient)
were the reasons for exclusion from the study.
At baseline, no differences in RBC antioxidant enzymes were observed between
groups (Table 2). In the BDP-group, catalase levels could not be determined for 2
patients due to technical reasons. Smoking patients were equally distributed be-
tween groups (Table 1); no differences in antioxidant levels were observed be-
tween smokers and non-smokers (data not shown). Furthermore, no differences
were observed in hemoglobin, white blood cell count and total number of eosino-
phils between groups (Table 1). At entry, for the whole group a significant correla-
tion was observed between levels of glutathione peroxidase and glutathione S-
transferase (r= 0.51, p=0.001) and also for glutathione peroxidase and SOD (r=
-0.54, p< 0.001). No significant correlations were observed between levels of anti-
oxidant enzymes and baseline pulmonary function, levels of bronchial hyperre-
sponsiveness, IgE or white blood cell parameters.
During treatment with BDP, a gradual increase in RBC catalase activity was ob-
served, which reached statistical significance after 6 weeks (at entry (mean ± SEM)
41 ± 4 |amol H,0,.min '.g' Hb, after 6 weeks 54 ± 4 (imol H,0,.min'.g' Hb,
p=0.05) (Fig. la and 2a). Interestingly, for total RBC glutathione an opposite
change was observed; during BDP treatment, a gradual decrease in total glutathione
levels was observed, which also reached statistical significance after 6 weeks treat-
ment (at entry (mean ± SEM) 7.0 ± 0.4 (Imol.g' Hb, at 6 weeks 6.6 ± 0.3 (Imol.g''
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No significant differences were observed between both groups of asthmatic patients, except for
FEV,, which was at baseline significantly higher in the BDP-group (* p= 0.02).
Table 2. Baseline RBC antioxidant levels in asthmatic patients
BDP Placebo
SOD(U.mg'Hb) 1.14± 0.09 1.28±0.10
GSH-Px(U.mg'Hb) 3.27± 0.38 2.96± 0.28
GST(U.g'Hb) 1.94±0.14 1.85± 0.15
Catalase 41.1 ± 3.7 47.1 ± 3.3
(jimol HjOj.min'.g' Hb)
total Glutathione 7.01 ± 0.35 6.27 ±0.25
(nmol.g' Hb)
At baseline, no significant differences were observed between the two groups of asthmatic pa-
tients. SOD: superoxide dismutase; GSH-Px: glutathione peroxidase; GST: glutathione S- transfe-
rase.
Hb, p=0.04) (Fig. lb and 2b). No correlation was present between changes in
catalase and total glutathione in RBC. However, the increase of RBC catalase-
activity during treatment with BDP showed a weak correlation with the initial
level of RBC catalase activity (r= - 0.51, p=0.04). For changes in total glutathione,
a similar trend was detected, although statistically not significant (r=-0.42,
p=0.08). BDP-induced changes in levels of catalase or glutathione were not corre-
lated with pulmonary function, level of bronchial hyperresponsiveness or IgE.
However, when the BDP-group was divided in responders (increase in catalase at
6 weeks) and non-responders (stable or decreased catalase), a significant difference











































Figure 1. Beclomethasone dipropionate (1000 ng.day') induces a:) a significant rise in RBC cata-
lase levels and b:) a decrease in RBC glutathione levels of stable asthmatic patients after 6 weeks
treatment. Individual responses after 6 weeks treatment are shown for the BDP- and placebo-tre-




BDP PLACEBO BDP PLACEBO
Figure 2. Changes in time in a:) RBC catalase and b:) RBC glutathione in stable asthmatic patients,
treated for 6 weeks with beclomethasone dipropionate 1000|ig.day'. Bars indicate mean ± SEM
of the two treatment groups at entry (open bars), after two weeks (hatched bars), four weeks
(crosshatched bars) and after six weeks (solid bars). After 6 weeks, a significant difference was ob-
served between groups for catalase (*: p=0.05) and for glutathione (*: p=0.04).










Response of catalase to BDP
Figure 3. Boxplots showing that the number of peripheral
blood eosinophils in responders (patients responding with a rise
in RBC catalase after BDP-treatment, n=13) was significantly
higher than in non-responders (i.e. stable or decreased catalase
levels, n=3). Boxes indicate interquartile range, the horizontal
line indicates the median. *: p= 0.05.
(number of eosinophils at entry in non-responders (mean ± SEM) 153 ± 52 x
10<\L' versus responders 340 ± 39 x 10M/', p=0.05, Fig. 3). No differences in
pulmonary function, airway hyperresponsiveness or baseline antioxidant levels
were present between responders and non-responders. For glutathione, no differ-
ences in number of eosinophils could be observed between responders and non-
responders.
Activities of SOD, GSH-Px and GST did not change during treatment with BDP
(data not shown). Also, during treatment with BDP no significant changes were
observed in asthma symptom-scores, use of ^.-rescue medication and pulmonary
function, as reported before [24].
During treatment with BDP, a significant decrease was observed in the total
number of eosinophils in peripheral blood; this decrease was already observed after
2 weeks of treatment (at entry (mean ± SEM) 318 ± 33 x 10<\L '; after 2 weeks
BDP 228 ± 31 x 10<\L'; p< 0.02 between groups) and number of eosinophils re-




Figure 4. Beclomethasone dipropionate induces a significant
decrease in number of circulating eosinophils in stable
asthmatic patients. Bars indicate mean ± SEM of number of
blood eosinophils during treatment with BDP or placebo. Data
are presented for entry of study (open bars), after two weeks
(hatched bars), four weeks (cross-hatched bars) and after six
weeks (solid bars) of treatment. *: p<0.02 for BDP-treated
patients versus placebo.
DISCUSSION
The present study demonstrates that erythrocyte levels of catalase increase and to-
tal glutathione levels decrease in patients with mild stable asthma, treated with be-
clomethasone dipropionate (BDP). Additionally, treatment with BDP resulted in
a significant decrease in the total number of circulating eosinophils.
In asthma, numerous studies have shown that ROS are involved in the inflamma-
tory process [1-7]. Alveolar macrophages of asthmatic patients demonstrated en-
hanced chemiluminescence, which correlated with asthma severity and bronchial
hyperresponsiveness [4,5]. Not only in the pulmonary compartment an increased
oxidative burden has been noted, also peripheral blood cells generate both sponta-
neously and after stimulation higher levels of ROS in comparison to healthy con-
trols. This has been observed for both blood polymorphonuclear neutrophils and
monocytes [1,2], and also for blood eosinophils [3].
Antioxidants levels increase in response to oxidant stress and can ameliorate oxi-
dant induced injury [9]; knowledge of antioxidant defense levels is therefore essen-
tial to predict total outcome of tissue damage. In asthma, it has been shown that
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antioxidant levels are decreased, both in the pulmonary compartment [23,26] as
well as in peripheral blood [1,12]. RBC have been used to monitor long-term al-
terations in antioxidant status in chronic pulmonary disorders [16,20], as well as
in asthma [14].
In the present study, treatment with BDP resulted in an increase in RBC catalase
activity, whereas no changes were observed in levels of GSH-Px, SOD and GST.
RBC express high levels of catalase in contrast to, for instance, bronchial epithelial
cells [9]. Catalase is one of the most important mechanisms by means of which
RBC dispose of H,O, [17] and RBC catalase has been demonstrated to protect
cells from ROS-burden [17]. Therefore, the increase in RBC catalase in the
present study reflects an increased defense against ROS-exposure. The observed
negative correlation of baseline catalase levels with the response of catalase to BDP
treatment, observed in the present study, leads to the assumption that RBC cata-
lase levels may be a marker of the asthmatic inflammation, where lower levels of
catalase reflect enhanced exposure to ROS. Indeed in asthmatic children, catalase
levels have been shown to be decreased in comparison to controls [14].
Several mechanisms may be involved in the effect of BDP on RBC-catalase. Treat-
ment with BDP attenuates the local inflammatory response as is shown in bron-
chial biopsies [27] and BAL [28]. This may lead to a reduction in the local forma-
tion of ROS. Recently, it was shown that monocytes of asthmatic patients, treated
with inhaled steroids, produced less superoxide anions when stimulated with
phorbol myristate-acetate (PMA) in comparison with monocytes of untreated
asthmatic patients [29]. Furthermore, inhaled corticosteroids may decrease levels
of inflammatory mediators, like TGF-fi, which normally inhibit antioxidant gene
activity [26], resulting in increased gene-transcription. Animal studies have shown
that corticosteroids influence catalase gene-transcription. Dexamethasone has
been shown /'« w'm? to increase catalase-mRNA in perinatal rat lung cells [30] and
to enhance SOD and GSH-Px enzyme activity in fetal rat lung [31]. Administra-
tion of corticosteroids /'« W'PO increased catalase and GSH-Px activity in rat perito-
neal macrophages and significantly inhibited ;'» wVro hydrogen peroxide produc-
tion in peritoneal macrophages [32]. Effects of corticosteroids on human cells are
less clear. Although inhaled corticosteroids failed to influence ROS generation in
stimulated alveolar macrophages [28], corticosteroids significantly reduced superox-
ide production in stimulated polymorphonuclear cells [33] and monocytes [29].
The present study observed a reduction in RBC total glutathione during treat-
ment with BDP. Few data exist regarding glutathione levels in RBC of asthmatic
patients [14]. Both animal and human studies have shown that glutathione levels
can increase during oxidant stress. Increased levels of glutathione were demon-
strated in BAL of asthmatic patients [10], in RBC of patients with chronic occupa-
tional lung disorders [8] and in RBC of volunteers, participating in exercise train-
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ing [21]. The decrease in RBC glutathione, observed in the present study, may
therefore reflect decreased oxygen radical exposure. Indeed, animal studies have
observed that corticosteroids decrease oxidative metabolism, followed by a de-
crease in antioxidant enzyme levels [34]. Another explanation for the observed de-
crease of total glutathione in the present study may be that GSSG is transported
out of the RBC; however, this mechanism mainly occurs in heart and liver cells [9]
and is only observed in RBC, when exposed to very high levels of ROS. In addi-
tion, the observation of a decrease in RBC glutathione levels argues against sys-
temic effects of inhaled BDP as an explanation for the observed changes in RBC
antioxidant levels, since, in mice, systemically applied corticosteroids have been
shown to increase hepatic synthesis of glutathione [35], which would raise levels of
circulating glutathione.
The present study demonstrated that patients, responding to BDP with an in-
crease in catalase, had higher eosinophil counts at entry than the patients not re-
sponding. In addition, the present study supports data from a previous study,
which also demonstrated a reduction in peripheral blood eosinophils during treat-
ment with inhaled corticosteroids [36]. Since the number of blood eosinophils
have been shown to correlate with asthma-severity [37], the present study suggests
that patient with higher levels of inflammation show lower levels of RBC catalase
and higher blood eosinophil counts. The fact that the present study did not ob-
serve changes in asthma-severity, may be explained by the relative insensitivity of
these parameters to monitor subtle inflammatory changes in patients with mild,
stable asthma.
In conclusion, the present study demonstrates that, in patients with mild, stable
asthma, treatment with inhaled beclomethasone dipropionate results in an in-
crease in RBC catalase levels and, at the same time, a decrease in RBC glutathione.
Peripheral blood eosinophil counts were higher in patients, who demonstrated an
increase in RBC catalase during treatment with BDP. We speculate that inhaled
BDP decreases ROS-generation within the lung, which leads to a subsequent
change in systemic antioxidant levels. Further studies, simultaneously evaluating
ROS formation within the lung while monitoring antioxidant defenses, will be
needed in order to improve our understanding of the effects of inhaled corticoster-
oids on antioxidant defenses in asthma.
ACKNOWLEDGEMENTS
The authors wish to thank E. Rhijnsburger and A. Knaapen (Department of
Health Risk Analysis and Toxicology) and L. Baars (Department of Pharmacol-
ogy) for their assistance with the analyses.
132Changes in levels of catalase and glutathione in erythrocytes
REFERENCES
1. Vachier I, Damon M, Doucen Le C, Crastes de Paulet A, Chanez P, Michel FB, Godard P.
Increased oxygen species generation in blood monocytes of asthmatic patients. /Am Rev
Resp/rD/5 1992; 146: 1161-1166.
2. Vachier I, Chanez P, Doucen Le C, Damon, Descomps B, Godard P. Enhancement of reactive
oxygen species formation in stable and unstable asthmatic patients. Fur Resp/r 7 1994; 7;
1585-1592.
3. Chanez P, Dent G, Yukawa T, Barnes PJ, Chung KF. Generation of oxygen free radicals from
blood eosinophils from asthma patients after stimulation with PAF or phorbol esther. Fur
Resp/r 7 1990; 3: 1002-1007.
4. Cluzel M, Damon M, Chanez P, Bousquet J, Crastes de Paulet C, Michel FB, Godard P.
Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. 7 /4//ergy C//n
Immuno/1987; 80: 195-201.
5. Kelly C, Ward C, Stenton CS, Bird G, Hendrick DJ, Walters EH. Number and activity of
inflammatory cells in broncho-alveolar lavage fluid in asthma and their relation to airway
responsiveness. 7/iorax 1988; 43: 684-692.
6. Sanders SP, ZweierJL, Harrison J, Trush MA, Rembish SJ, LiuMC. Spontaneous oxygen radical
production at sites of antigen challenge in allergic subjects. /4m 7 Resp/r Cr/f Care Med 1995;
151: 1725-1733.
7. Barnes PJ. Reactive oxygen species and airway inflammation. Free Rad/c B/o/ Med 1990; 9:
235-243.
8. Borm PJA, Bast A, Wouters EFM, Slangen JJ, Swaen GMH, De Boorder TJ. Red blood cell
antioxidant parameters in healthy elderly subjects versus silicosis patients. Free Rad Res
Commun 1987; 3: 117-127.
9. Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. /4m Rev Resp/r D/s 1989;
140: 531-554.
10. Smith U, Houston M, Anderson J. Increased levels of glutathione in broncho-alveolar lavage
fluid from patients with asthma. Am Rev Resp/r D/s 1993; 147: 1461-1464.
11. Durham SR, Carroll M, Walsh GM, Kay AB. Leucocyte activation in allergen-induced
late-phase asthmatic reaction. A/fng/JMed 1984; 311: 1398-1402.
12. Malmgren R, Unge G, Zetterstrom O, Theovell H, de Wahl K. Lowered glutathione peroxidase
activity in asthmatic patients with food and aspirin intolerance. /4//ergy 1986; 41: 43-45.
13. Stone J, Hinks U, Beasley R, Holgate ST, Clayton BE. Reduced selenium status of patients with
asthma. C7/n So 1989; 77: 495-500.
14. Novak Z, Nemeth I, Gyurkovits K, Varga Sz I, Matkovics B. Examination of the role of oxygen
free radicals in bronchial asthma in childhood. C//n C/)/m/ca/4cfa 1991; 201: 247-252.
15. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD
and smokers. Am J Resp/r Cr/f Care Med 1996; 154: 1055-1060.
16. Schins RPF, Keman S, Borm PJA. Blood antioxidant status in coal dust-induced respiratory
disorders: a longitudinal evaluation of multiple biomarkers. B/omar/lrers 1997; 2: 45-50.
17. Agar NS, Sadrsadeh SMH, Hallaway PE, Eaton JW. Erythrocyte catalase; a somatic oxidant
defense? 7 C7/n /nvesr 1986; 77: 319-321.
18. Van Asbeck BS, Hoidal J, Vercelotti GM, Swarts BA, Moldow CF, Jacob HS. Protection against
lethal hyperoxia by tracheal insufflation of erythrocytes; role of red cell glutathione. Sc/ence
1985; 227: 756-759.
19. Andersen HR, Nielssen JB, Nielsen F, Grandjean Ph. Antioxidative enzyme activities in human
erythrocytes. O/n C/iem/sfry 1997; 43: 562-568.
20. Engelen JJM, Borm PJA, van Sprundel M, Leenaerts L. Blood anti-oxidant parameters at
different stages of pneumoconiosis in coal workers. FnvHea/fri Persp 1990; 84: 165-172.
21. Evelo CTA, Palmen NGM, Artur Y, Janssen GME. Changes in blood glutathione
concentrations, and in erythrocyte glutathione reductase and glutathione S-transferase
133CHAPTER 8
activity after running training and after participation in contest, fur./ /4pp/ Phys/'o/1992; 64:
354-358.
22. Barnes PJ. Anti-inflammatory therapy for asthma. /4nnu P,ev Med 1993; 44: 229-242.
23. De Raeve HR, Thunissen FBJM, Kaneko FT, Guo FH, Lewis M, Kavuru MS, Secic M, Thomassen
MJ, Erzurum SC. Decreased Cu,Zn-SOO activity in asthmatic airway epithelium: correction by
inhaled corticosteroid in vivo. /Vn./«7ys/o/1997; 272: L148-L154.
24. Pennings HJ, Wouters EFM. Effect of inhaled beclomethasone dipropionate on isocapnic
hyperventilation with cold air in asthmatics, measured with forced oscillation technique, fur
Resp/rV 1997; 10: 665-671.
25. van Kampen EJ, Zijlstra WG. Determination of hemoglobin and its derivatives. 4oV C//V? C/)em
1965:8; 141-187.
26. Smith U, Shamsuddin M, Sporn PH, Denenberg M, Anderson J. Reduced superoxide
dismutase in lung cells of patients with asthma. Free flad B/o/Med 1997; 7: 1301-1307.
27. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate
ST. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. /Am
Rev Resp/r D/s 1992; 145: 669-674.
28. Duddridge M, Ward C, Hendrick DJ, Walters EH.Changes in bronchoalveolar lavage
inflammatory cells in asthmatic patients treated with high dose inhaled beclomethasone
dipropionate. furResp/r./1993; 6: 489-497.
29. Majori M, Vachier I, Godard P, Farce M, Bousquet J, Chanez P. Superoxide anion production
by monocytes of corticosteroid-treated asthmatic patients. fur/?esp/rj 1998; 11: 133-138.
30. Clerch LB, Iqbal J, Massaro D. Perinatal rat lung catalase gene expression: influence of
corticosteroids and hyperoxia. ,4m 7 Priys/o/1991; 260: L428-L433.
31. Frank L, Lewis PL, Sosenko IRS. Dexamethasone stimulation of fetal rat lung antioxidant
enzyme activity in parallel with surfactant stimulation, flpd/afr/cs 1985; 75: 569-574.
32. Pereira B, Costa Rosa LFBP, Safi SA, Bechara EJH, Curi R. Hormonal regulation of superoxide
dismutase, catalase and glutathione peroxidase activities in rat macrophages. B/ocAiem
Priarmaco/1995; 50: 2093-2098.
33. Goldstein IM, Roos D, Weissman G, Kaplan HB. Influence of corticosteroids on human
polymorphonuclear leucocyte function in vitro. Reduction of lysosomal enzyme release and
superoxide production, /nflammaf/on 1976; 1: 305-315.
34. Weglarz L, Dr6zdz M, Goss M. Effect of anti-inflammatory drugs on the activity of antioxidant
anzymes and /n wVo peroxidation products in the liver and kidney of rat. Comp B/ocr>em
Priys/o/1990; 96C: 83-85.
35. Speck RF, Schranz C, Lauterburg BH. Prednisolone stimulates hepatic glutathione synthesis in
mice. 7 Hepafo/1993; 18: 62-67.
36. Evans PM, O'Connor BJ, Fuller RW, Barnes PJ, Chung KF. Effect of inhaled corticosteroids on
peripheral blood eosinophil counts and density profiles in asthma. 7 ,A//ergy C7/n /mmuno/
1993; 91: 643-650.
37. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstad S,
Simony-Lafontaine J, Godard Ph, Michel FB. Eosinophilic inflammation in asthma. /V Eng/7
Med 1990; 323: 1033-1039.
134CHAPTER 9
Summary and general discussion
9.1 SUMMARY OF THE OBSERVATIONS IN THE THESIS
The first part of the thesis focuses on the effect of TNFa on bronchial hyperre-
sponsiveness /» wVro and evaluates possible immunomodulatory effects of drugs,
used in the treatment of asthma, in /'« wVro models.
TNFa is implicated in the pathogenesis of asthma, as has been shown in several
studies [1,2,3|4]. TNFa release is increased in cells, involved in the asthmatic in-
flammation i?.£. mast cells [5], epithelial cells [6], activated T-lymphocytes [7] and
macrophages [8] and enhanced levels of TNFa may in turn augment the inflam-
matory response [6,9]. Increased levels of TNFa have been observed in the the late
asthmatic reaction (LAR) [10,11,12], as well as after IgE-receptor crosslinking
[13]. Since the LAR is associated with an increase in bronchial hyperresponsive-
ness, we speculated diat TNFa itself may affect the contractile response of bron-
chial smooth muscle directly. In <r/w/>ter3, we investigated the effect of TNFa on
the isotonic contraction of tracheal smooth muscle strips of unsensitized guinea-
pigs in organ baths. Incubation of tracheal strips for 30 min with TNFa
(10"'-'-10'° M), induced an increase in methacholine-induced maximum contrac-
tion by 70%. The specificity of the observed effect was demonstrated by coincu-
bating recombinant human TNFa with a soluble TNF-Receptor construct
(sTNFR-p80-construct), which completely inhibited the increase in contractility.
In contrast to the effects of TNFa on membrane potentials in striated muscle
[14], we observed a very steep dose-response effect in tracheal smooth muscle, sug-
gesting a differential effect of TNFa in the two muscle types. We also observed
that the effect of TNFa was only apparent after a 30 min washing period, whereas
no effect was observed on methacholine-induced contraction, when tracheal strips
were stimulated directly after the incubation-period. Since this may suggest in-
volvement of secondary mediators and, since TNFa induces activation of phos-
pholipase A, [8,15], we coincubated tracheal rings with indomethacin (10"') (to
block prostaglandin synthesis) and with a platelet activating factor antagonist
(WEB 2086 (10-6 M)), to inhibit PAF effects. We observed that, although
indomethacin did induce changes in contractility itself, no effect was observed on
TNFa-induced effects. In contrast, the PAF-antagonist completely inhibited
TNFa-induced hypercontractility, demonstrating the involvement of PAF. Con-
sidering the observed time-delay and the biological availability of PAF, we specu-
late that either TNFa induces PAF-synthesis within airway smooth muscle cells or
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that smooth muscle cells interact with cells, expressing PAF at their surface. The
present study therefore extends observations from previous studies in humans
[16,17], demonstrating that TNFa can affect bronchial smooth muscle cells di-
rectly.
After the demonstration of a direct effect of TNFa on smooth muscle contractility,
we analysed in r/w/>fcr 4 the effects of theophylline on the release of proinflamma-
tory mediators (TNFa, IL-6, IL-8) and soluble TNF-receptors in peripheral blood
monocytes and alveolar macrophages. Theophylline induced a dose-dependent
inhibition of TNFa release in lipopolysaccharide (LPS) stimulated monocytes /'«
v/'fro; theophylline partially inhibited TNFa release at a concentration of 20
Hg/ml, however maximum inhibition was observed at concentrations of 80 Hg/ml,
well above clinically acceptable levels. Additional analysis showed that theophyl-
line (20 Hg/ml) induced a 59% inhibition of LPS-induced TNFa mRNA accu-
mulation and also inhibited LPS-induced IL-6 mRNA accumulation by 49%.
However, IL-6 was only mildly decreased on protein level, suggesting that post-
transcriptional adaptive mechanisms exist, which compensate for the reduced
IL-6 mRNA synthesis, induced by theophylline. We also showed hat the observed
decrease in TNFa synthesis was not induced by enhanced levels of IL-10, in con-
trast to other studies [18,19]. Theophylline induced, parallel to a decrease in
TNF, a decreased release of IL-10, probably secondary to a decreased TNFa re-
lease [20]. In line with observations with PGE, [21], theophylline did not affect
cytokine release in alveolar macrophages, probably due to differences in the level
of maturation between alveolar macrophages and peripheral blood monocytes.
This difference in maturation might also explain the observation that levels of
LPS-induced TNFa release were much higher in alveolar macrophages than in
monocytes. In addition, theophylline induced changes in the shedding of sTNF-
Receptor-75 in monocytes, whereas no effect was observed in alveolar macro-
phages. The importance of this effect is not clear yet.
In human endothelial cells, theophylline (100 (Jg/ml) inhibited the expression of
VCAM-1 in TNFa-stimulated cells, whereas no effect was observed on LPS-
stimulated cells. Theophylline did not affect cytokine (IL-6 and IL-8) release of
endothelial cells, nor influence the expression of ICAM-1 and E-selectin on endo-
thelial cells. Since the ligand of VCAM-1, VLA-4 (very late antigen-4) is expressed
on eosinophils and T-lymphocytes, observations from our study provide a mecha-
nism for the observed inhibition of T-lymphocyte and eosinophil influx in bron-
chial mucosa by theophylline [22]. This may also explain why withdrawal of theo-
phyllline in patients with asthma resulted in an increase in T-lymphocytes,
infiltrating the airways [23]. In conclusion, the present study shows that theophyl-
line has immunomodulatory effects «'» wVro, which may explain part of the benefi-
cial effects of theophylline in the treatment of asthma »w two [24].
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In accordance with observations on theophylline, addition of long-acting
p,-agonists to treatment regimens in asthma show an advantageous effect, which
could involve immunomodulatory effects of p,-agonists [25,26]. In f/w/>f<rr 5 ef-
fects of salmeterol and salbutamol were investigated on the release of proinflam-
matory cytokines (TNFoc, IL-6 and IL-8) in LPS-stimulated monocytes of heal thy
volunteers /'« w'fro. Both salmeterol (10'MO'' M) and salbutamol (10"M0"*M) in-
hibited TNFa release (maximum inhibition ± 50%), whereas a trend in inhibition
of IL-6 release was observed. The specificity of the observed response was shown
by coincubation of salmeterol and salbutamol with propranolol, a non-selective
(^-antagonist, that completely reversed the inhibition of TNFa release. Additional
analysis showed that, in contrast to theophylline, IL-10 may be involved in the ob-
served immunomodulatory effects, since salmeterol and salbutamol induced en-
hanced IL-10 release in the presence of LPS (l(ig/ml). However, since TNFa re-
lease was also inhibited in experiments without IL-10 induction, effects of
salmeterol and salbutamol on LPS-induced gene-transcription for TNFa and
IL-6 were analysed. Both drugs inhibited TNFa mRNA accumulation and to a
minor extent IL-6 mRNA. Comparison of the inhibitory effects of salmeterol and
salbutamol on TNFa release demonstrated that salbutamol dose-dependently in-
hibited TNFa release, whereas salmeterol appeared to reach already maximum in-
hibition at much lower concentrations.
The second part of the thesis evaluates the effect of inhaled beclomethasone di-
propionate in patients with mild, stable asthma with regard to asthma-symptoms
and bronchial hyperresponsiveness, as assessed with cold air bronchoprovocation.
In addition, the effect of beclomethasone on biomarkers in peripheral blood of
asthmatic patients was evaluated.
In c/uzpter 6, we evaluated the effect of treatment with inhaled beclomethasone di-
propionate(1000|ig.day' for six weeks) on asthma symptoms, peak-flow, pulmo-
nary function and bronchial hyperresponsiveness. Forty (steroid-naive) patients
with mild, stable asthma were included in a double-blind, placebo-controlled
parallel-group study. Stratification according to sex was performed to overcome
differences in airway diameter. Bronchial hyperresponsiveness was assessed by an
indirect bronchial challenge test, />. isocapnic hyperventilation with cold air
(IHCA). We chose to study the effects of an indirect bronchial challenge test with
IHCA, since IHCA provides a more physiological stimulus for airway contraction
and represents a highly specific test for increased airway hyperreactiviry [27]. The
response to IHCA was analysed using both conventional flow-volume recordings
by a pneumotachograph as with the forced oscillation technique (FOT). This
method requires no deep inspiratory manoeuvre, which may influence bronchial
tone and may influence the result of bronchoprovocation testing [28]. We ob-
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served that IHCA induced a significant decrease in FEV, from baseline (18%
pred.) and that characteristic changes occurred in the FOT recordings, />. an in-
crease in resistance at 8 Hz (7?8) and the development of a negative frequency de-
pendence (FD) curve. Changes in reactance resulted in an increase in resonant fre-
quency (/„) and a decrease in reactance at 8 Hz (A8). These results were in line
with previous data [29,30]. Also, responses in FOT parameters correlated with
changes in FEV, (correlation with change in /?8: r=-0.68, p<0.001; with FD:
r=0.67, p<0.001; with A8: r=0.65, p<0.001 and with /„: r=-0.67, p<0.001); the
present data confirm observations from previous studies [30]. Treatment with be-
domethasone dipropionate (BDP) induced statistically significant changes in ef-
fects of IHCA, as assessed with the FOT. BDP treatment resulted in: a diminished
increase in /?8 induced by IHCA; a decrease in the steepness of the slope of the
FD-curve; a decrease in AB changes after IHCA and a decrease in change of/,,, fol-
lowing IHCA. Although a trend towards a decreased change in FEV, after IHCA
was observed, these results did not reach statistical significance. In addition, a high
correlation was observed between IgE levels in patients and the effect of BDP on
IHCA, as assessed by FOT (r=0.88, p<0.001). These observations are in accor-
dance with data from a previous study [31]. No changes were observed in asthma-
symptom scores, peak flow rates and use of P,-agonists. However, it should be no-
ticed that all patients in the study group had very mild asthma. In summary, this
study showed that beclomethasone reduces bronchial hyperresponsiveness in sta-
ble asthmatic patients and the study demonstrated that the forced oscillation tech-
nique was more sensitive to changes in bronchial tone than conventional flow-
volume recordings.
In C/W/J/VJT 7, we studied levels of inflammatory mediators in peripheral blood of
the asthmatic patients, participating in the study, as described in chapter five. We
chose to study levels of soluble adhesion molecules, because expression of adhesion
molecules is increased in the bronchial mucosa in asthmatic patients [32,33] and
increased levels of sICAM-1 and sE-Selectin have been observed in blood of pa-
tients with acute asthma [34,35]. Also, after segmental allergen challenge, in-
creased levels of sICAM-1 have been found in blood [36], suggesting that soluble
adhesion molecule levels in the circulation may reflect inflammatory changes
within the pulmonary compartment. Since TNFcc is very potent in the upregula-
tion of adhesion molecule expression on endothelial and epithelial cells [6,8], we
also measured levels of soluble TNF-receptors, since they reflect the inflammatory
status of patients [37]; in addition, one study has observed increased levels of solu-
ble TNF-receptors in acute asthma [38]. At entry of the study, levels of sICAM-1,
sE-Selectin-1, sTNF-R55 and sTNF-R75 in our group of asthmatic patients were
comparable with levels in a group of healthy volunteers (age 20-40 yrs). These ob-
servations are in line with previous observations [34,35]. Treatment with BDP re-
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suited in a significant, although small decrease in sTNF-R55, already apparent
from 2 weeks of treatment. Furthermore, BDP induced a gradual decrease in
sICAM-1 levels, which reached significance after 6 weeks of treatment. Interest-
ingly, the magnitude of BDP-induced decrease in sICAM-1 (30 ng/ml) was com-
parable to the changes in sICAM-1, observed in peripheral blood after segmental
allergen challenge [36]. In addition, we also observed that BDP induced a decrease
in blood eosinophils, which was already apparent after two weeks treatment with
BDP (in analogy with the trend observed in sTNF-R55). No changes occurred in
levels of sTNF-R75 and sE-Selectin-1. Although effects of BDP on levels of
sTNF-R55 and sICAM-1 were significantly correlated with the initial levels of
these markers at entry of the study, no correlations could be demonstrated be-
tween the effect of BDP on levels of inflammatory mediators and indicators of
asthma-severity (pulmonary function, bronchial hyperresponsiveness and number
of blood eosinophils). We suggest tJiat the observed changes in sTNF-R55 and
sICAM-1 reflect the anti-inflammatory effects of beclomethasone on bronchial
inflammation.
In f/w/>fcr S, we analysed the levels of antioxidant enzymes (superoxide dismutase,
catalase, glutathione peroxidase, glutathione S-transferase) and total cell glu-
tathione in erythrocytes of patients, participating in the study, as described in
chapter five. Besides enhanced production of cytokines, cells involved in the asth-
matic inflammation also produce increased amounts of reactive oxygen species
(ROS) [39,40,41]. ROS are involved in the pathogenesis of asthma, since they in-
duce changes in airway contractility, induce plasma leakage and induce release of
secondary mediators f.£. PAF [42]. Besides increased ROS exposure, antioxidant
defenses in asthma are decreased, resulting in a further disturbed oxidant-
antioxidant balance [43]. Several studies demonstrated decreased levels of glu-
tathione peroxidase [44,45] and catalase [46] in asthmatic patients. In this study,
we analysed the effect of inhaled beclomethasone on antioxidant levels in erythro-
cytes, since several studies have shown that erythrocyte antioxidant levels reflect
chronic changes in exposure to ROS [47,48,49,50]. In this study, we showed that
treatment with BDP induced a gradual increase in erythrocyte catalase levels,
which reached significance after 6 weeks. In contrast, treatment with BDP re-
sulted in a gradual decrease in the total content of erythrocyte glutathione, which
became significant after 6 weeks. We also showed that BDP-induced change in
catalase levels inversely correlated with catalase levels at entry, suggesting that pa-
tients with lower catalase levels represented patients with more serious asthma.
Futhermore, it was shown that patients, who responded to corticosteroid treat-
ment by a rise in catalase levels, had higher blood eosinophil counts than patients,
who did not respond to beclomethasone with a rise in catalase levels. For effects of
BDP on glutathione levels, this distinction was not observed. Also, within the
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present study, we could observe no correlations between erythrocyte antioxidant
enzyme levels and indicators of asthma severity (pulmonary function, bronchial
hyperresponsiveness, IgE), nor did effects of BDP on antioxidant levels correlate
with asthma severity.
We speculate that the observed changes in antioxidant levels in erythrocytes reflect
a decreased exposure to ROS, induced by anti-inflammatory effects of BDP
within the airways.
9.2 GENERAL DISCUSSION
In this thesis, it was demonstrated that TNFa induces BHR by a direct effect on
airway smooth muscle; however, although other cytokines, like IL-5 and IL-4, are
also implicated in the development of BHR, it is not clear yet whether they induce
BHR directly or indirectly [51]. Since TNFa is produced early in the inflamma-
tory response and has been shown to induce cytokine release in cells and enhance
adhesion molecule expression [6], TNFa can be considered to play a central role
in the asthmatic inflammation [52]. We therefore investigated possibilities for
pharmacological immunomodulation of TNFa by drugs, used in the treatment of
asthma. The inhibitory effects of salbutamol and salmeterol on gene-transcription
for TNFa and IL-6 were shown to be comparable with the effects of theophylline;
however, for salbutamol and salmeterol, effects were achieved at concentrations,
which resemble local concentrations within the airways, whereas for theophylline
effects were achieved at relatively high concentrations. The /'« w'/ro studies were
performed in cells, obtained from healthy subjects and may not accurately reflect
the activation status of inflammatory cells, observed in asthmatic patients. In case
of theophylline, studies have shown that theophylline has an increased inhibitory
effect on phosphodiesterase in atopic patients in comparison with healthy subjects
[53], suggesting that theophylline may achieve immunomodulatory effects in
asthma at even lower concentrations. This observation is supported by observa-
tions from clinical studies [22,23]. Specific type IV phosphodiesterase-inhibitors,
which are currently under development, have been shown /'« wVro to possess im-
munomodulatory effects at much lower concentrations than theophylline [54]
and may represent potent drugs in asthma treatment.
Although we observed immunomodulatory effects for the (},-agonists in pharma-
ceutical concentrations, studies in humans have shown differences between the
protective effects of long-acting p,-agonists in acute inflammatory reactions, as
observed after allergen challenge [55,56,57] and effects, observed in chronic
asthma [58,59]. After allergen challenge, salmeterol decreased levels of IL-4,-5 and
ECP [55] and inhibited the development of bronchial hyperresponsiveness [56].
The observed protection of salmeterol on the development of BHR may, at least in
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part, be explained by the inhibitory effect of salmeterol on TNFa release, as ob-
served above (chapter 3 and 5). The discrepancy, observed between effects of sal-
meterol in /'« w'/ro studies and effects on bronchial inflammation /'«two, especially
in chronic asthma, is difficult to explain. For salbutamol, the absence of an effect
/'« two can be explained by its short duration of action, but salmeterol may induce
immunomodulatory effects /'« two, due to its longer duration of action. It is possi-
ble that in chronic asthma, P-receptor activation may result in a decreased cAMP
generation, due to the inflammation. This hypothesis is supported by the observa-
tion that activated alveolar macrophages of asthmatic patients generate less cAMP
than macrophages, obtained from healthy volunteers [60]. In contrast, the bron-
chodilating capacities of salmeterol are preserved, since bronchodilation by p-ag-
onists is reported to occur mainly through maxi-K channels, opened directly by a
subunit of the stimulatory G-protein, suggesting that smooth muscle relaxation
may occur, independent of an increase in cAMP [61]. Since cAMP is an important
secondary mediator in the immunomodulatory effects of p-receptor agonists
[62,63], this may explain why effects of p,-agonists are less obvious in asthmatic
inflammation /'« two. Therefore, the addition of corticosteroids to treatment with
long-acting p,-agonists may result in enhanced anti-inflammatory effects of P-ag-
onists and may result in an improved control of asthma [25,26].
In the second part of the thesis, we evaluated the effect of corticosteroids on airway
hyperresponsiveness in asthmatic patients and we simultaneously monitored
changes in peripheral blood markers.
The study was performed in patients with stable, mild asthma, who, according to
the new guidelines for classification of asthma [64], should be classified in the
group of intermittent asthma, as judged by their FEV,, asthma-symptom score
(mild dyspnea once a day) and peak flow variability (<10%). Several studies have
observed that, even in this group of patients with mild stable asthma, increased
numbers of mast cells, eosinophils, lymphocytes and macrophages are present
within the bronchial mucosa and epithelium [65,66]. In addition, an increased
thicknesss of the basement membrane was observed in these patients [66], suggest-
ing that airway remodelling represents an early event in the pathophysiology of
asthma.
Our patient group demonstrated a considerable bronchial hyperresponsiveness, as
was shown by the response to IHCA, which was substantially increased in com-
parison to healthy subjects [27,67]. Treatment with beclomethasone resulted in
the reduction of BHR as assessed with FOT. The absence of an effect, as assessed
by FEV, measurement, can be explained by a recent study, demonstrating that, es-
pecially in patients with the mildest form of airway obstruction, the performance
of a deep inspiratory manoeuvre, as is required for the measurement of FEV,, re-
sulted in the largest reversal of bronchial obstruction [68].
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The general concept, that BHR and airway inflammation are correlated [69], sug-
gests that airway inflammation is present in our patients. Although we did not per-
form bronchial biopsies in our patients to assess changes in bronchial inflamma-
tion, beclomethasone dipropionate, used in an almost similar treatment protocol,
induced a significant reduction in the number of epithelial and mucosal mast cells,
eosinophils and T-lymphocytes [70]. Also, a significant reduction in T-
lymphocyte activation markers was observed, both in BAL and to a lesser extent in
peripheral blood [71]. In these studies, patient groups were comparable with re-
gard to baseline pulmonary function to our patient group, although PEF variabil-
ity, asthma symptom score and bronchial hyperreactivity were somewhat higher.
In the last two chapters of this thesis, we monitored changes in peripheral blood
markers, which might reflect changes in bronchial inflammation. Since pilot stud-
ies showed that proinflammatory cytokines (TNFot, IL-6 and IL-8) could not be
detected in peripheral blood of our patients, other markers, involved also in the
asthmatic inflammation, were used. The present study observed that, parallel to
the observed decrease in BHR, levels of circulating TNF-R55 and ICAM-1 de-
creased, as did the number of peripheral blood eosinophils. BDP may decrease lev-
els of circulating mediators either by inhibiting synthesis in epithelial [72] or en-
dothelial cells [73], or indirectly, by inhibiting the release of cytokines, that can
regulate the expression of these molecules, like f.£. TNFa or IL-4.
The effect of BDP on the number of circulating eosinophils are in line with data
from previous studies [74]. Studies suggest that colony-stimulating factors re-
leased from cells, within the pulmonary compartment, may influence hematopo-
etic cells. Whether the observed decrease in number of eosinophils is the result of
reduced production of these colony-stimulating factors (<?.£. IL-5) within the lung
[12,75], or that corticosteroids have a direct effect on bone marrow by preventing
the release of maturing eosinophils into the blood stream, is not clear. We specu-
late that the reduction in peripheral blood eosinophils probably reflects reduced
airway inflammation with subsequent decrease in eosinophil colony forming
units.
The observed changes in erythrocyte antioxidant levels may be induced by a de-
creased generation of ROS, induced by effects of BDP on asthmatic inflamma-
tion. The changes in erythrocyte antioxidant levels may reflect the adjustment of
antioxidant levels in erythrocyte progenitor cells, which respond to a decreased ex-
posure to ROS in the circulation. In asthmatic patients, ROS generation is in-
creased [76,77] and, even in patients with stable asthma, the oxidant-antioxidant
balance is disturbed, as was demonstrated in peripheral blood [78]. In order to
treat our patients most efficiently, we need to know whether primary therapy in
asthma should be aimed at controlling ROS production or providing additional
antioxidative defenses. Future studies in asthmatic patients should analyse the oxi-
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dative burden and antioxidant defenses simultaneously in order to answer this
question.
Studies in the second part of the thesis showed that treatment with BDP induced
changes in BHR and levels of inflammatory mediators, whereas judging from their
clinical status, patients were considered not to be candidates for treatment with in-
haled steroids. However, it has been shown that a dissociation may occur between
asthma symptoms and levels of airway inflammation in stable asthmatics [79].
The former study also showed that airway inflammation and BHR correlated
quite well. This might imply that levels of BHR (as indirect indicators of airway
inflammation and airway remodelling) should be added to the current guidelines
for the treatment of asthma, in addition to evaluation of asthma symptoms. This
has recently been suggested by Sont rt*z/., who showed that this policy leads to an
improved control of asthma and, more-over, results in a decrease in the thickness
of the basement membrane [80]. One study also showed that early introduction of
inhaled corticosteroids may reverse airway collagen deposition [81], which may
occur due to actions of inflammatory mediators (like IL-4, TNFa) [82]. This im-
plies that sensitive methods, that can detect even mild inflammatory changes, are
needed in order to prevent chronic airway remodelling.
From our studies, it can be concluded, that the markers, used in this thesis for the
monitoring of asthmatic disease, did not live up to the criteria for "biomarkers";
levels of peripheral blood sICAM-1 and sTNF-R55 did not discriminate between
asthmatics and healthy subjects, whereas sICAM-1, sTNFR-55 and antioxidant
levels in erythrocytes did not correlate with levels of asthma severity nor did they
correlate with BDP-induced changes in BHR. The absence of a clear correlation
between the circulating inflammatory mediators and asthmatic inflammation is
probably explained by the fact that asthma is primarily an inflammation within
the pulmonary compartment and, although leakage of inflammatory mediators
and activated cells occurs into the general circulation, these inflammatory media-
tors in peripheral blood insufficiently reflect the intensity of asthmatic inflamma-
tion. Therefore these markers can not be used as single markers in peripheral
blood, reflecting disease in individual patients with asthma. Determination of the
inflammatory markers, used in this thesis, in combination with newer techniques
(/.*. induced sputum) may provide a solution. Also combining newly developed
techniques may increase their potential usefulness in the monitoring of asthmatic
inflammation; a recent study showed, that the combination of NO measurements
in exhaled air and the number of eosinophils in induced sputum extend the esti-
mation of airway inflammation, although correlation with asthma symptoms was
low [83]. In addition, certain markers may not be useful in patients, treated with
corticosteroids [84], since corticosteroids may have a direct inhibiting effect on
the marker itself, instead of reflecting asthmatic inflammation [85]. Whether the
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combination of peripheral blood markers (f.g. ECP, circulating adhesion mole-
cules, T-lymphocyte-activation markers) and the newer techniques will be more
valuable in die assessment and the monitoring of asthmatic inflammation in the
individual patient needs further investigation.
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Het eerste deel van dit proefschrift beschrijft het effect van TNFa op de ontwikke-
ling van bronchiale hyperreactiviteit /» wVro en onderzoekt effecten van genees-
middelen, gebruikt bij de behandeling van astma, op het immuun-systeem
middels /« w'/ro onderzoek.
Diverse studies hebben aangetoond dat TNFa een rol speelt in de pathofysiologie
van astma. Cellen, betrokken bij de astmatische ontstekingsreactie, zoals epitheel-
cellen, mestcellen, geactiveerde T-lymfocyten en macrofagen, tonen een verhoog-
de afgifte van TNFa en TNFa versterkt op zijn beurt de inflammatoire reactie,
leidend tot een ontstekings-spiraal.
Na blootstelling aan allergenen worden tijdens de late astmatische reactie (LAR)
verhoogde concentraties van TNFa aangetroffen. Aangezien deze LAR gepaard
gaat met een toename van bronchiale hyperreactiviteit, veronderstelden wij dat
TNFa de contractiliteit van glad spierweefsel, gelokaliseerd in de bronchien, door
een direct effect zou kunnen doen toenemen. In /w^tfH/fr 3 onderzochten wij het
effect van TNFa op de isotone contractie van tracheaal glad spierweefsel van de
cavia, opgehangen in een orgaan-bad. Toevoeging van TNFa (10" tot 10"'" M)
gedurende 30 minuten aan dit orgaan-bad, resulteerde in een toename van de ge-
stimuleerde maximale contractie van glad spierweefsel met 70%. Gelijktijdige toe-
voeging van een specifiek TNFa-blokkerende stof (sTNFR-p80) aan dit
orgaan-bad deed de toegenomen contractiliteit volledig verdwijnen; dit bewijst
dat het effect inderdaad specifiek door TNFa veroorzaakt wordt. Aanvullend
blijkt dat een periode van meer dan 30 minuten vereist is alvorens het effect van
TNFa op de contractiliteit van glad spierweefsel bemerkbaar wordt; dit zou erop
kunnen duiden dat er andere mediatoren door TNFa gei'nduceerd worden. Het is
bekend dat TNFa het enzym fosfolipase A, stimuleert, hetgeen ondermeer leidt
tot de vorming van prostaglandines en PAF. Om dit te onderzoeken voerden wij
een experiment uit waarbij, gelijktijdig met TNFa, een specifieke prostaglandi-
ne-synthese remmer (indometacine) of WEB 2086 (een stof, welke PAF-effecten
remt) werd toegevoegd aan het orgaan-bad. Alhoewel indometacine zelf ook de
contractiliteit van het gladde spierweefsel bleek te verhogen, bleek er geen be'in-
vloeding van het TNFa effect aanwezig. Echter, toevoeging van WEB 2086 blok-
keerde het effect van TNFa volledig, er op duidend dat PAF betrokken is in het
effect van TNFa op glad spierweefsel. Gezien het tijdsbeloop in onze experimen-
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ten en de biologische beschikbaarheid van PAF, speculeren wij dat ofwel TNFa de
aanmaak van PAF in gladde spier cellen stimuleert ofwel dat gladde spier cellen
contact maken met cellen, die, ten gevolge van blootstelling aan TNFa, PAF pro-
duceren en via de PAF-receptor van de gladde spiercel de contractiliteit van deze
eel beTnvloeden.
De bevindingen in deze studie vullen observaties in humane studies aan en leiden
tot de hypothese dat blootstelling aan TNFa resulteert in bronchiale hyperreacti-
viteit door een directe beinvloeding van gladde spier contractiliteit door TNFa.
Nadat dit effect van TNFa op de contractiliteit van gladde spieren aangetoond
was, onderzochten wij in /wo/z&ft<£ ^de effecten van theofylline op de uitscheiding
van pro-inflammatoire mediatoren (TNFa, IL-6 en IL-8) en oplosbare TNF-re-
ceptoren, zowel in monocyten als alveolaire macrofagen. Theofylline bleek een
dosis-afhankelijke remming van de uitscheiding van TNFa in lipopolysacchari-
de(LPS)-gestimuleerde monocyten te veroorzaken; bij een theofylline-concentra-
tie van 20 (J.g/ml was er sprake van een gedeeltelijke remming, welke maximaal was
bij een concentratie van 80 |^g/ml; deze concentratie wordt echter klinisch niet ge-
bruikt, omdat deze gepaard gaat met onacceptabele bijwerkingen. Aanvullend on-
derzoek laat zien dat op mRNA-niveau, theofylline (20 |J.g/ml) de ophoping van
LPS-gestimuleerde TNFa-mRNA met 59% remt en de ophoping van LPS-gein-
duceerde IL-6 mRNA met 49% remt. Echter in het geval van IL-6, worden er op
eiwit-niveau nauwelijks veranderingen gevonden, zodat wij vermoeden dat de ver-
minderde IL-6 mRNA synthese gecompenseerd wordt door post-transcriptionele
mechanismen.
Aanvullend bleek dat de door theofylline veroorzaakte remming van de uitschei-
ding van TNFa niet verklaard kan worden door verhoogde concentraties van
IL-10 (IL-10 remt namelijk de synthese van TNFa); integendeel, theofylline leek
eerdereen daling van IL-10 te veroorzaken. Ditzou kunnen berusten op een, door
theofylline veroorzaakte, daling van TNFa, aangezien TNFa de aanmaak van
IL-10 induceert, als onderdeel van een natuurlijk regulatie-mechanisme.
In tegenstelling tot monocyten, bleek theofylline geen invloed te hebben op de
uitscheiding van cytokines door macrofagen, hetgeen verklaard zou kunnen wor-
den door het feit dat macrofagen verder uitgerijpt zijn dan monocyten. Dit laatste
verklaart waarschijnlijk ook de bevinding dat macrofagen meer TNFa uitscheiden
dan monocyten. Zo bleek theofylline ook de afsplitsing van TNF-receptor-75 te
be'i'nvloeden in monocyten, terwijl er geen veranderingen optraden in macrofagen.
Het belang van dit verschil is vooralsnog onduidelijk.
In menselijke bloedvatcellen (endotheel) bleek theofylline (100 (Xg/ml) de expres-
sie van VCAM-1 op de membraan van TNFa-gestimuleerde endotheel-cellen te
rernmen, terwijl er geen effect gezien werd op de LPS-gestimuleerde VCAM-1 ex-
pressie van endotheel-cellen. De expressie van andere adhesie-moleculen
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(ICAM-1 en E-selectin-1) of uitscheiding van proinflammatoire mediatoren (IL-6
en IL-8) werd niet beinvloed door theofylline. Aangezien VCAM-1 betrokken is
in de regulatie van de influx van eosinofielen en lymfocyten in weefsel, zouden be-
vindingen uit ons;» w>ro onderzoek de basis kunnen vormen voor bevindingen in
humaan onderzoek, die laten zien dat theofylline ophoping van eosinofielen en
T-lymfocyten in bronchusweefsel remt en dat staken van theofylline leidt tot een
toename van deze cellen in de bronchiaal mucosa van patienten met astma.
Samenvattend laat het onderzoek, beschreven in dit hoofdstuk, zien dat theofylli-
ne /'« «'m> immuno-modulerende eigenschappen bezit, op basis waarvan een deel
van de gunstige effecten van theofylline in de behandeling van astma verklaard
zouden kunnen worden.
Naast theofylline wordt tegenwoordig bij de behandeling van astma in toenemen-
de mate gebruik gemaakt van zogenaamde langwerkende p,-sympaticomimetica.
De toegevoegde waarde van deze medicatie voor de behandeling van astma zou,
naast luchtweg-verwijding, ook kunnen berusten op immuno-modulerende effec-
ten. In /rao/a!tfw£ 5 werden de effecten van salmeterol en salbutamol op de uitschei-
ding van pro-inflammatoire mediatoren (TNFa, IL-6 en IL-8) onderzocht /'«
w'fro in LPS-gestimuleerde monocyten, afkomstig van bloed van gezonde vrijwilli-
gers. Salmeterol (10®- 1(H' M) en salbutamol (10M0'* M) bleken beide de uit-
scheiding van TNFa te remmen (maximale remming 50%) en voor IL-6 werd er
een trend tot remming gezien. Bij salbutamol bleek er sprake van een dosis-afhan-
kelijke remming van TNFa, terwijl er voor salmeterol al een maximale remming
van TNFa optrad bij de laagste concentraties. Coi'ncubatie met propranolol, een
P-antagonist, bleek het effect van salmeterol en salbutamol volledig teniet te doen,
aantonend dat de (3-receptor betrokken is in dit effect. Aanvullend bleek dat IL-10
hier mogelijk wel betrokken is in de remming van TNFa door salmeterol en sal-
butamol, aangezien in deze experimenten de IL-10 uitscheiding wel bleek toe te
nemen bij de hoogste concentratie van LPS. Aangezien de uitscheiding van TNFa
ook geremd werd in experimenten waar geen verhoogde uitscheiding van IL-10
aanwezig was, werden de effecten van salmeterol en salbutamol op de LPS-geindu-
ceerde ophoping van TNFa- en IL-6 mRNA onderzocht, analoog aan de experi-
menten met theofylline. Zowel salmeterol als salbutamol bleken de ophoping van
TNFa mRNA en in mindere mate IL-6 mRNA te remmen.
Het tweede deel van het proefschrift beschrijft de effecten van behandeling met in-
halatie-steroiden (beclomethasone dipropionate) in patienten met stabiel, mild
astma bronchiale. Gekeken werd naar de effecten op astma-symptomen en bron-
chiale hyperreactiviteit, gemeten met behulp van koude lucht bronchoprovocatie.
Tegelijkertijd werd het effect van de behandeling met inhalatie-steroiden vervolgd
aan de hand van biologische merkstoffen in het bloed van astmatische patienten.
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In /wy£&ft<£ 6"wordt het effect van de behandeling met geinhaJeerd beclomethaso-
ne dipropionate (1000 (Ig/dag gedurende zes weken) vervolgd aan de hand van
astma-symptomen, piek-flow en long-functie-metingen alsmede bepalingen van
de bronchiale hyperreactiviteit. Veertig patienten met stabiel, mild astma (geen in-
halatie-steroiden gebruikend) namen deel aan een dubbel-blind, placebo-gecon-
troleerd onderzoek. Per groep namen evenveel mannen als vrouwen deel om te
corrigeren voor verschillen in luchtwegdiameter. Bronchiale hyperreactiviteit
werd bepaald middels de isocapnische koude lucht bronchoprovocatie techniek,
welke op een natuurlijke wijze een luchtweg-vernauwing induceert en een be-
trouwbare maatstaf voor bronchiale hyperreactiviteit vormt. Het effect van koude
lucht inhalatie werd beoordeeld aan de hand van flow-volume metingen alsmede
middels impedantie-metingen van de luchtwegen met behulp van de geforceerde
oscillatie techniek (FOT). FOT metingen behoeven niet vooraf gegaan te worden
door geforceerde inademingsmanoeuvres, die, doordat zij luchtweg verwijding
kunnen geven, het resultaat van de hyperreactiviteits-metingen kunnen be'i'nvloe-
den. Koude lucht bronchoprovocatie resulteerde bij onze patienten in duidelijke
dalingen van de FEV, (18% van de uitgangswaarde) en karakteristieke veranderin-
gen in de impedantie-curves: een toename van de weerstand bij 8 Hz, de ontwik-
keling van een negatieve frequentie-afhankelijkheid van de weerstands-curve
(dwz. de weerstand daalt bij stijgende frequentie van het opgelegde signaal), een
dating van de reactantie bij 8 Hz en een stijging van de resonantie-frequentie (dwz.
die frequentie, waarbij de reactantie-curve de nuUijn passeert). Observaties in ons
onderzoek bevestigden bevindingen uit eerdere studies. Verder bleken de verande-
ringen in de FOT parameters te correleren met de veranderingen in de FEV,. Be-
handeling van patienten met beclomethasone resulteerde in een afname van de
reactie op de koude lucht bronchoprovocatie, geevalueerd middels de geforceerde
oscillatie techniek. Belangrijkste bevindingen waren een minder sterke weer-
standstijging bij 8 Hz, een minder uitgesproken negatieve frequentie-afhankelijk-
heid, een minder sterke daling van de reactantie bij 8 Hz alsmede een minder
sterke stijging van de resonantie-frequentie. Alhoewel in het conventionele long-
functie onderzoek een tendens tot minder sterke daling van de FEV, na koude
lucht inhalatie aanwezig leek te zijn, waren deze veranderingen niet significant
verschillend van de placebo-groep. Verder bleek het IgE gehalte in bloed te corre-
leren met het effect van beclomethasone op de koude lucht broncho-provocatie.
Astma-symptoom scores, piek-flow metingen alsmede medicatie gebruik veran-
derden niet in de met beclomethasone-behandelde groep; bedacht moet wel wor-
den dat deze patienten al een stabiel, licht astma hadden met relatief weinig
klachten.
Samenvattend tonen wij in dit hoofdstuk aan dat behandeling met beclomethaso-
ne bronchiale hyperreactiviteit vermindert in patienten met stabiel astma en dat de
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geforceerde oscillatie techniek gevoeliger is voor veranderingen in de tonus van de
luchtwegen dan de conventionele flow-volume bepalingen.
7 beschrijft de veranderingen van inflammatoire mediatoren in het
bloed van patienten, welke deelnamen aan het protocol, zoals beschreven in
hoofdstuk 5. Wij bestuurden veranderingen in het niveau van circulerende adhe-
sie-moleculen, enerzijds omdat deze moleculen in toegenomen hoeveeiheid aan-
wezig zijn in de bronchiaal mucosa van astmatici, andererzijds omdat, zowel bij
acuut astma als na allergeen provocatie, in het perifeer bloed verhoogde concentra-
ties van circulerende adhesie-moleculen waargenomen zijn. Dit suggereert dat ver-
anderingen van mediatoren in perifeer bloed in bepaalde mate veranderingen in
het long compartiment kunnen weerspiegelen. Aangezien TNFa de expressie van
adhesiemoleculen, zowel op epitheel - als endotheel-cellen doet toenemen, onder-
zochten wij ook de hoeveeiheid circulerende TNF-receptoren, welke een goede
maat vormen voor de inflammatoire status van een patient. Ook voor circulerende
TNF-receptoren geldt dat zij bij een exacerbatie van astma in verhoogde concen-
traties kunnen voorkomen in perifeer bloed. Bij aanvang van de studie bleken het
niveau van circulerende inflammatoire mediatoren (sICAM-1, sE-selectin-1,
sTNF-R55 en sTNF-R75) in onze groep van astma-patienten vergelijkbaar met
het niveau van deze mediatoren in bloed van gezonde vrijwilligers. Behandeling
met beclomethasone resulteerde in een significante afname van circulerend
TNF-R55 in astmatische patienten, welke reeds bemerkbaar was na 2 weken be-
handeling. Daarnaast trad er een geleidelijke daling op in het niveau van circule-
rend ICAM-1, welke na 6 weken statistisch significant was. Opvallend was dat de
grootte van verandering in sICAM-1 (30 ng/ml) vergelijkbaar was met verande-
ringen van sICAM-1 in perifeer bloed na segmentele allergeen provocatie. Verder
bleek behandeling met beclomethasone vanaf 2 weken te resulteren in een signifi-
cante daling van het aantal eosinofiele cellen in perifeer bloed. Alhoewel verande-
ringen in circulerend ICAM-1 en TNF-R55 significant correleerden met niveaus
ten tijde van het begin van de studie, bleken de veranderingen ten tijde van behan-
deling met beclomethasone niet te correleren met de ernst van astma, gemeten aan
long-functie, bronchiaJe hyperreactiviteit en aantal eosinofiele granulocyten. Wij
veronderstellen dat de veranderingen van sTNF-R55 en sICAM-1 in perifeer
bloed een weerspiegeling zijn van de anti-inflammatoire effecten van beclometha-
sone op de bronchiale mucosa.
Vervolgens beschrijven wij in /w0/S&/w£ S de niveaus van antioxidatieve enzymen
(superoxide dismutase, catalase, glutathion-peroxidase en glutathion S-transfera-
se) en anti-oxidanten (glutathion) in de erythrocyten van de hierboven beschreven
groep patienten en vervolgen het effect van behandeling met beclomethasone op
het anti-oxidatief systeem.
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Cellen, betrokken bij de astmatische reactie, produceren toegenomen hoeveelhe-
den zuurstof radicalen. Deze zuurstof radicalen spelen een rol in de pathofysiolo-
gie van astma, aangezien zij veranderingen in luchtweg-reactiviteit, lekkage van
plasma en productie van inflammatoire mediatoren veroorzaken (bijvoorbeeld
PAF). Daarnaast blijkt er bij patienten met astma ook nog sprake van een verla-
ging van hun anti-oxidatieve enzym-systeem (zoals ondermeer voor catalase en
glutathion-peroxidase). Dit complex van veranderingen leidt er toe dat patienten
met astma een verstoorde oxidant-antioxidant balans hebben. In ons onderzoek
hebben wij met name gekeken naar veranderingen in het antioxidatieve systeem
van de erythrocyt, aangezien diverse studies hebben laten zien dat dit een goede
weerspiegeling vormt voor de mate van chronische blootstelling aan zuurstof-radi-
calen.
Ons onderzoek laat zien dat tijdens behandeling met beclomethasone een geleide-
lijke toename van catalase optreedt, welke na 6 weken therapie significant verschilt
ten opzichte van placebo. Glutathion verandert ook significant na 6 weken behan-
deling met beclomethasone, echter hier treedt een geleidelijke daling in het gluta-
thion-gehalte van de erythrocyt op. De veranderingen in catalase bleken
omgekeerd evenredig te zijn met het begin-niveau van catalase in de erythrocyt; dit
was niet het geval voor glutathion. Verder bleken degenen, die tijdens behandeling
met beclomethasone een stijging van het catalase lieten zien (responders), signifi-
cant hogere aantallen eosinofiele granulocyten in het perifeer bloed te hebben ten
opzichte van de non-responders. In dit onderzoek konden er geen verbanden ge-
vonden worden tussen antioxidant niveaus en en de ernst van astma (longfunctie,
bronchiale hyperreactiviteit, IgE); evenzo bestond er geen correlatie tussen de ef-
fecten van beclomethasone op het antioxidatieve systeem en de ernst van de astma.
Een mogelijke verklaring voor de door ons gevonden veranderingen in de antioxi-
dant niveaus binnen de erythrocyt zou een verminderde blootstelling van erythro-
cyten aan zuurstof radicalen kunnen zijn, secundair optredend aan de
anti-inflammatoire effecten van beclomethasone in de luchtwegen van astmati-
sche patienten.
10.2 DISCUSSIE
In dit proefschrift werd aangetoond dat TNFa bronchiale hyperreactiviteit op-
wekt ten gevolge van een direct effect van TNFa op de contractiliteit van gladde
spiercellen; ook andere cytokines, zoals IL-5 en IL-4, kunnen bronchiale hyperre-
activiteit veroorzaken, echter tot op heden is er nog geen direct effect op gladde
spier cellen aangetoond voor deze cytokines. TNFa wordt vroeg tijdens de inflam-
matoire reactie geproduceerd en kan op zijn beurt deze reactie versterken door toe-
genomen expressie van adhesiemoleculen en bevordering van cytokine
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uitscheiding door cellen. Derhalve wordt aan TNFa een centrale rol toebedeeld in
de astmatische inflammatoire reactie. Wij onderzochten /'« w'rro mogelijke anti-in-
flammatoire efFecten van medicijnen, gebruikt in de behandeling van astma. Sal-
meterol en salbutamol remden de LPS-gestimuleerde ophoping van mRNA voor
TNFa en IL-6 in vergelijkbare mate ten opzichte van theofylline, echter, terwijl de
effecten van salmeterol en salbutamol al optraden bij therapeutische concentraties,
bleken de efFecten van theofylline pas op te treden bij relatief hoge doseringen. Een
bezwaar van onze methode is dat voor ons onderzoek cellen afkomstig van gezon-
de vrijwilligers gebruikt werden, waarbij de activatie-toestand van deze cellen kan
verschillen met die van astmatische patienten. Voor theofylline is aangetoond dat
de remming van fosfodiesterase meer uitgesproken is in atopische patienten dan
gezonden, leidend tot de veronderstelling dat theofylline bij astmatische patienten
al in lagere doseringen werkzaam kan zijn. Klinische studies lijken in deze richting
te wijzen en momenteel worden er specifieke fosfodiesterase-IV remmers ontwik-
kelt, welke /'« wVro een meer uitgesproken anti-inflammatoire werking lijken te
hebben dan theofylline.
Alhoewel wij in onze studies anti-inflammatoire efFecten aantoonden voor P,-ag-
onisten in pharmaceutische concentraties, lijken er /'« w't/o verschillen te zijn be-
trefFende het anti-inflammatoir efFect van lang-werkende p,-agonisten ten tijde
van acute astmatische reacties (zoals bijvoorbeeld optredend na allergeen-bloot-
stelling) en in de meer chronische situatie. Na allergeen blootstelling remt salmete-
rol de ontwikkeling van bronchiale hyperreactiviteit, hetgeen deels verklaard zou
kunnen worden door remmende efFecten van salmeterol op TNFa (zoals beschre-
ven in hooFdstuk 3 en 5). De discrepantie tussen onze bevindingen van anti-in-
flammatoire efFecten van salmeterol (en salbutamol) /» p/Vro en de schijnbaar
afwezige invloed van salmeterol op de bronchiale inflammatie in stabiel astma zijn
niet eenvoudig te verklaren. Zeker voor salmeterol zou men ook /'« f/'w efFect ver-
wachten, mede gezien de lange werkingsduur van salmeterol. Een mogelijke ver-
klaring hiervoor zou een verminderde productie van cAMP kunnen zijn ten
gevolge van de astmatische inflammatie; alveolaire macroFagen van astmatische
patienten produceren inderdaad minder cAMP na stimulatie dan macroFagen, aF-
komstig van gezonde vrijwilligers. Het bronchusverwijdend efFect van p-agonisten
wordt hierdoor niet beinvloed, aangezien dit niet via cAMP gemedieerd wordt.
Daarentegen speelt cAMP wel een rol bij immuun-regulerende efFecten van P-ag-
onisten, zoals salmeterol. Dit zou verklaren waarom de anti-inflammatoire efFec-
ten van p-agonisten minder uitgesproken zijn bij de astmatische patient.
Combinatie van lang-werkende p,-agonisten met (inhalatie) corticosteroiden zou
daarentegen kunnen leiden tot een versterkt anti-inflammatoir efFect van de p,-ag-
onisten, leidend tot een efFectievere behandeling van astma.
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Het tweede deel van het proefschrift beschrijft de effecten van geinhaleerd beclo-
methasone op bronchiale hyperreactiviteit en op biologische merkstoffen in het
perifere bloed van patienten met astma.
Dit deel van het onderzoek werd verricht in patienten met stabiel, licht astma.
Volgens de nieuwe richtlijnen voor de classificatie van astma zouden deze patien-
ten omschreven moeten worden als patienten met intermitterend astma. Onder-
zoek heeft aangetoond dat zelfs intermitterend astma gepaard gaat met bronchiale
inflammatie en dat, zelfs bij deze patienten, er al een verbreding van de basaal
membraan aanwezig is.
De patienten in onze onderzoeks-groep bezaten een uitgesproken bronchiale hy-
perreactiviteit, blijkend uit de omvang van hun reactie op de koude lucht bron-
choprovocatie. Behandeling met beclomethasone verminderde de bronchiale
hyperreactiviteit, mits gemeten met behulp van de geforceerde oscillatie techniek.
Het feit dat er geen duidelijk effect optrad, indien de FEV, werd gebruikt als res-
pons-parameter kan verklaard worden uit de bevindingen van een recente studie,
die liet zien dat, juist in patienten met lichte vormen van astma, de geforceerde
diepe inspiratie, zoals vereist voor de FEV, bepaling, leidt tot een uitgesproken
luchrweg-verwijding en derhalve de door koude lucht opgewekte luchtweg-ver-
nauwing maskeert.
We veronderstellen dat ook in onze patienten-groep een bronchiale inflammatie
aanwezig moet zijn, volgend uit het feit dat bronchiale hyperreactiviteit en lucht-
weg inflammatie aan elkaar gecorreleerd zijn. Alhoewel wij bij onze patienten geen
bronchusbiopten genomen hebben, bleek beclomethasone in een andere studie,
met een vergelijkbare studie-duur en intensiteit van behandeling, een significante
reductie van bronchiale inflammatie te bewerkstelligen. Ook bleek beclomethaso-
ne een verandering in de activatie status van T-lymfocyten te veroorzaken, zowel
in de broncho-alveolaire lavage als in perifeer bloed. Derhalve vervolgden wij ver-
anderingen in merkstoffen in perifeer bloed, die de veranderingen van bronchiale
inflammatie zouden kunnen weerspiegelen, zoals beschreven in de laatste twee
hoofdstukken van dit proefschrift. Aangezien pilot-studies geen pro-inflammatoi-
re cytokines (TNFa, IL-6 en IL-8) konden aantonen in het perifere bloed van
onze patienten, gebruikten wij andere markers van inflammatie in het perifere
bloed. Wij vonden dat ten tijde van behandeling met beclomethasone een daling
van circulerend TNF-R55 en ICAM-1 optrad, parallel met een daling van de
bronchiale hyperreactiviteit. Mogelijke verklaringen voor deze daling van inflam-
matoire mediatoren zou kunnen zijn dat beclomethasone de aanmaak van deze
stoffen in epitheel- of endodieel-cellen remt of dat beclomethasone de produktie
van cytokines zoals IL-4 en TNFa remt, die de expressie van deze mediatoren
mede beinvloeden.
Het effect van beclomethasone op het aantal eosinofiele granulocyten in de circu-
latie onderschrijft bevindingen uit andere studies. Men denkt dat cellen, gelokali-
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seerd in de long, kolonie-stimulerende factoren produceren, die de hemato-
logische stamcellen aanzetten tot productie van ondermeer eosinofiele granulocy-
ten. Corticosteroiden zouden dan effect kunnen uitoefenen op het aantal perifere
eosinofiele granulocyten ofwel door een remmende werking op de synthese van •
deze kolonie-stimulerende factoren of door remming van het vrijkomen van eo-
sinofiele granulocyten vanuit het beenmerg naar de bloedbaan. Wij vermoeden
dat de door ons waargenomen vermindering van het aantal eosinofiele cellen zou
kunnen berusten op een remming van de bronchiale inflammatie met daarop vol-
gend een afname van de productie van kolonie-vormende factoren.
Analoog hieraan zouden de veranderingen in de antioxidanten en antioxidatieve
enzymen, zoals die optraden in erythrocyten, verklaard kunnen worden door een
afname van de productie van zuurstof-radicalen, eveneens veroorzaakt door rem-
ming van de astmatische inflammatie door beclomethasone. De progenitor cellen
in het beenmerg zouden dan hierop kunnen reageren met een verminderde aan-
maak van anti-oxidatieve enzymen. Aangezien astma niet alleen gepaard gaat met
verhoogde zuurstof-radicaal productie, maar ook met verlaging van antioxidatieve
enzymen, is het vanuit therapeutisch oogpunt van belang op welke (primaire)
stoornis wij onze behandeling moeten richten. Om dit adequaat te kunnen onder-
zoeken is gelijktijdige bestudering van zowel de zuurstof radicaal productie als ana-
lyse van de anti-oxidatieve verdedigingsmechanismen van belang.
Beclomethasone bleek in staat een afname van bronchiale hyperreactiviteit en een
daling van inflammatoire mediatoren te induceren in patienten met ogenschijnlijk
stabiel, licht astma. Afgaand op de symptomen van astma in onze patienten, zou er
volgens de vigerende internationale richtlijnen geen reden geweest zijn hen te be-
handelen met corticosteroiden. Er blijkt echter een duidelijke discrepantie te kun-
nen optreden tussen astma-symptomen en mate van bronchiale inflammatie.
Aangezien er een redelijke correlatie bestaat tussen bronchiale hyperreactiviteit en
bronchiale inflammatie, zou dit een reden kunnen zijn om, behoudens astma-
symptomen, ook de ernst van bronchiale hyperreactiviteit mee te wegen in onze
overwegingen betreffende de medicamenteuze behandeling van astma. Sont en
co-auteurs toonden aan dat deze manier van behandeling leidt tot een betere con-
trole van astma en de structurele omvorming van astmatische luchtwegen remt. Er
zijn aanwijzingen dat vroegtijdige introductie van inhalatie-corticostero'iden kan
leiden tot een vermindering van de al aanwezige structurele ombouw van de ast-
matische luchtwegen, waarvan men aanneemt dat deze plaats vindt onder invloed
van inflammatoire mediatoren (bijvoorbeeld IL-4, TNFa). Derhalve lijken tech-
nieken, welke bronchiale inflammatie vroegtijdig kunnen detecteren, van belang
in de klinische praktijk om deze chronische structurele ombouw van astmatische
luchtwegen te voorkomen.
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Uit dit proefschrift blijkt dat de mediatoren, die wij gebruikt hebben in onze stu-
dies om astma te monitoren, niet geschikt zijn als "biomarkers": niveaus van circu-
lerend ICAM-1 en TNF-R55 bleken enerzijds niet te discrimineren tussen
patienten met astma en gezonde personen, anderzijds bleek er onvoldoende sa-
menhang tussen de concentraties van deze stoffen en de ernst van astma. Evenmin
bleken zij te het effect van beclomethasone op de bronchiale hyperreactiviteit te
kunnen voorspellen. De verklaring hiervoor zou kunnen zijn dat astma zich pri-
mair gedraagt als een ontsteking, met name gelokaliseerd in het long-comparti-
ment, en, alhoewel er soms lekkage van deze mediatoren naar de algemene
circulatie kan optreden, weerspiegelt dit onvoldoende de (bronchiale) astmatische
inflammatie. Combinatie van onze "markers" met nieuwere onderzoeks-metho-
den (zoals bijvoorbeeld geinduceerd sputum of bepaling van vluchtige gassen in
uitademings-lucht (bijv.NO)), zou een oplossing kunnen bieden. Recent bleek
dat de combinatie van het aantal eosinofiele granulocyten in geinduceerd sputum
en meting van NO in uitgeademde lucht bij patienten met astma wel meer infor-
matie biedt over de uitgebreidheid van de inflammatie, echter desalniettemin bleef
de samenhang met astma symptomen laag. Van belang is verder dat bepaalde me-
dicijnen, gebruikt ter behandeling van astma, ook rechtstreeks de productie van
deze markers beinvloedt en daarmee de markers als monitor van de ziekte-activi-
teit onbetrouwbaar maakt. Of markers in perifeer bloed (zoals ondermeer ECP,
adhesie-moleculen, T-lymfocytaire activatie markers), gecombineerd met nieuwe-
re technieken een toegevoegde waarde zullen hebben in de karakterisering en mo-
nitoring van de bronchiale inflammatie in de individuele patient met astma zal






Een proefschrift wordt zelden allee"n gemaakt en vormt dan ook de afsluiting van
een (soms langer dan geplande) periode, waarin er met veel mensen meer of min-
der intensief is samen gewerkt. Dit is dan ook bij uitstek de plaats om al die perso-
nen te bedanken, die betrokken waren bij de totstandkoming van dit proefschrift.
Prof. Dr. E.F.M. Wouters, beste Emiel, onze allereerste kennismaking begon met
de vraag of ik toch echt niet eerst onderzoek wilde doen, alvorens aan de opleiding
Longziekten te beginnen. Ondanks mijn ontkennende antwoord, heeft het vol-
gens mij nog geen jaar geduurd alvorens je mij met het eerste onderzoeksvoorstel
confronteerde. Alhoewel het onderwerp zich in een voor mij volstrekt onbekend
onderzoeksveld bevond, ben je er toch in geslaagd mij enthousiast te krijgen voor
onderzoek, zoals beschreven in dit proefschrift. Gaarne wil ik je bedanken voor de
energie en moeite die je hebt gestoken in de correctie van de manuscripten en de
toelichtingen op de materie. Met name je vermogen de materie in een breder per-
spectief te plaatsen en te relateren aan andere onderzoeksresukaten leverde een
duidelijk verdieping van de discussie op, waarvoor ik je zeer erkentelijk ben. Ik
hoop dat wij de onderzoeksrelatie nog vele jaren kunnen continueren.
Dr. W.A. Buurman, beste Wim, zeker in het begin zal ik voor jou een vreemde
(pulmonologische) eend in de (heelkundige) bijt geweest zijn. Jouw overtuiging
dat een promovendus zelf de bepalingen verricht moet hebben om te weten waar-
over hij/zij praat, kan ik van harte ondersteunen, alhoewel ik wel denk dat verdere
automatisering op het lab ook zijn prettige kanten heeft. Ik dank je voor onze be-
sprekingen en de kritische beoordeling van de manuscripten, waarbij je vlot mijn
(soms al te lange betogen) minimaliseerde tot essentiele punten, waardoor de kwa-
liteit van het manuscript met stukken vooruit ging. Je brede belangstelling en ken-
nis waren een belangrijke steun in de totstandkoming van dit proefschrift.
Hierbij wil ik ook de leden van de beoordelingscommissie bedanken voor hun be-
reidheid deze thesis te willen beoordelen. Een speciaal woord van dank geldt voor
Prof. Dr. A. Bast, zowel voor het bekleden van het voorzitterschap van de beoorde-
lingscommissie, als ook voor de betoonde gastvrijheid op het laboratorium aan de
VU, alwaar een deel van het onderzoek in dit proefschrift verricht is.
Uiteraard was mijn start op het laboratorium algemene heelkunde (toen nog in het
BMC) niet zo prettig verlopen zonder de hulp van al die mensen die daar werk-
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zaam waren: Ingeborg, Mark, Maarten, Albert, Jeske, Jessica, Monique, Sandra,
Ivo, Trudy, Gaby en Mieke. Mieke, jij was degene die mij de fijne kneepjes van het
lab-werk heeft bijgebracht en altijd behulpzaam was bij problemen, ook indien ik
's nachts op het BMC weer eens iets niet kon vinden. Gaandeweg is jouw belang-
stelling ook meer richting Pulmonologie verplaatst en hebben wij nog een aantal
studies verricht buiten het leader van dit proefschrift. Dank voor je hulp.
Verder moet ik al mijn ex-collega-assistenten (Marcel, Jean, Harrie, Ellen en
Frank), de collega's in het AZM (Guul, Geertjan, Arne en Marjolein) en mijn hui-
dige collega's (Rob, Jean (alweer) en Joan) bedanken voor hun bereidheid bepaal-
de taken over te nemen, zeker als er weer eens een dag labwerk verricht moest
worden en mijn pieper een goed onderkomen zocht. Zonder jullie hulp was dit al-
les niet gelukt.
Uiteraard hartelijk dank aan het secretariaat Longziekten AZM (Anouk, France,
Gonda, Manon, Nicole en Resy) en ons secretariaat Hornerheide (Annemiek en
Gerrie) voor de geboden ondersteuning.
Ik ben mijn vader en moeder dankbaar dat zij het mij mogelijk gemaakt hebben te
gaan studeren en mij het uithoudingsvermogen hebben meegegeven, dat nodig is
voor het afronden van een proefschrift. Het is alleen jammer dat mijn grootvader
en peetoom H. Follmer de voltooiing van mijn proefschrift niet meer heeft mogen
meemaken.
Beste Justine, aan alles komt een eind: dit geldt voor het dankwoord, maar geluk-
kig ook voor de promotie-periode. Ik dank je voor je geduld en ik hoop dat wij
weer meer tijd aan elkaar en aan de kinderen kunnen besteden.
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